CA2293692C - Methods and reagents for vaccination which generate a cd8 t cell immune response - Google Patents
Methods and reagents for vaccination which generate a cd8 t cell immune response Download PDFInfo
- Publication number
- CA2293692C CA2293692C CA2293692A CA2293692A CA2293692C CA 2293692 C CA2293692 C CA 2293692C CA 2293692 A CA2293692 A CA 2293692A CA 2293692 A CA2293692 A CA 2293692A CA 2293692 C CA2293692 C CA 2293692C
- Authority
- CA
- Canada
- Prior art keywords
- recombinant
- cell
- epitopes
- mva
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title abstract description 21
- 238000002255 vaccination Methods 0.000 title abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 193
- 108091007433 antigens Proteins 0.000 claims abstract description 167
- 102000036639 antigens Human genes 0.000 claims abstract description 167
- 239000000427 antigen Substances 0.000 claims abstract description 166
- 239000000203 mixture Substances 0.000 claims abstract description 92
- 230000037452 priming Effects 0.000 claims abstract description 86
- 239000013598 vector Substances 0.000 claims abstract description 86
- 230000003362 replicative effect Effects 0.000 claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 239000013612 plasmid Substances 0.000 claims description 107
- 201000004792 malaria Diseases 0.000 claims description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 230000001681 protective effect Effects 0.000 claims description 70
- 241000700605 Viruses Species 0.000 claims description 49
- 241000700618 Vaccinia virus Species 0.000 claims description 41
- 230000005867 T cell response Effects 0.000 claims description 38
- 229960005486 vaccine Drugs 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 35
- 241000223960 Plasmodium falciparum Species 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 25
- 244000052769 pathogen Species 0.000 claims description 25
- 230000001717 pathogenic effect Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 230000010076 replication Effects 0.000 claims description 22
- 239000003937 drug carrier Substances 0.000 claims description 21
- 241000701161 unidentified adenovirus Species 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 108020004511 Recombinant DNA Proteins 0.000 claims description 14
- 208000002672 hepatitis B Diseases 0.000 claims description 12
- 208000005176 Hepatitis C Diseases 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 108010036616 P18-I10 peptide Proteins 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 241000288906 Primates Species 0.000 claims description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 7
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 7
- 208000002476 Falciparum Malaria Diseases 0.000 claims description 5
- 241000700662 Fowlpox virus Species 0.000 claims description 5
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 4
- 208000000666 Fowlpox Diseases 0.000 claims description 3
- 108010076039 Polyproteins Proteins 0.000 claims description 3
- 108010059061 tyrosyl-leucyl-asparagyl-lysyl-isoleucyl-glutaminyl-asparagyl-seryl-leucine Proteins 0.000 claims description 3
- 241000700663 Avipoxvirus Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003612 virological effect Effects 0.000 abstract description 7
- 238000002649 immunization Methods 0.000 description 170
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 143
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 112
- 241000699670 Mus sp. Species 0.000 description 73
- 210000003046 sporozoite Anatomy 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 48
- 241000224017 Plasmodium berghei Species 0.000 description 44
- 230000004044 response Effects 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 35
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 32
- 208000015181 infectious disease Diseases 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 30
- 208000007089 vaccinia Diseases 0.000 description 29
- 206010046865 Vaccinia virus infection Diseases 0.000 description 28
- 101710117490 Circumsporozoite protein Proteins 0.000 description 26
- 241000725303 Human immunodeficiency virus Species 0.000 description 26
- 230000005847 immunogenicity Effects 0.000 description 26
- 230000006698 induction Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000011725 BALB/c mouse Methods 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 238000011510 Elispot assay Methods 0.000 description 18
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 18
- 244000045947 parasite Species 0.000 description 17
- 108010041986 DNA Vaccines Proteins 0.000 description 16
- 229940021995 DNA vaccine Drugs 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 241000712461 unidentified influenza virus Species 0.000 description 16
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 15
- 241000282553 Macaca Species 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241000282579 Pan Species 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- 238000007918 intramuscular administration Methods 0.000 description 14
- 206010072219 Mevalonic aciduria Diseases 0.000 description 13
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 102000011931 Nucleoproteins Human genes 0.000 description 12
- 108010061100 Nucleoproteins Proteins 0.000 description 12
- 241000282577 Pan troglodytes Species 0.000 description 12
- 241000282412 Homo Species 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 210000004988 splenocyte Anatomy 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 108010077245 asparaginyl-proline Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- JTXVXGXTRXMOFJ-FXQIFTODSA-N Asn-Pro-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O JTXVXGXTRXMOFJ-FXQIFTODSA-N 0.000 description 6
- 238000011765 DBA/2 mouse Methods 0.000 description 6
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- UVKNEILZSJMKSR-FXQIFTODSA-N Pro-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 UVKNEILZSJMKSR-FXQIFTODSA-N 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108020001019 DNA Primers Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 108010093581 aspartyl-proline Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 229940065638 intron a Drugs 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000037369 susceptibility to malaria Diseases 0.000 description 4
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 3
- ZJLORAAXDAJLDC-CQDKDKBSSA-N Ala-Tyr-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O ZJLORAAXDAJLDC-CQDKDKBSSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 3
- NURJSGZGBVJFAD-ZLUOBGJFSA-N Asp-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O NURJSGZGBVJFAD-ZLUOBGJFSA-N 0.000 description 3
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 3
- 241000178270 Canarypox virus Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- QZQYITIKPAUDGN-GVXVVHGQSA-N Gln-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N QZQYITIKPAUDGN-GVXVVHGQSA-N 0.000 description 3
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 3
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 3
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 3
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 3
- 101900222562 Influenza A virus Nucleoprotein Proteins 0.000 description 3
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 3
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 3
- PPQRKXHCLYCBSP-IHRRRGAJSA-N Leu-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N PPQRKXHCLYCBSP-IHRRRGAJSA-N 0.000 description 3
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 3
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 3
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- DJBCKVNHEIJLQA-GMOBBJLQSA-N Met-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCSC)N DJBCKVNHEIJLQA-GMOBBJLQSA-N 0.000 description 3
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 3
- 241000223830 Plasmodium yoelii Species 0.000 description 3
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 3
- HKYTWJOWZTWBQB-AVGNSLFASA-N Tyr-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HKYTWJOWZTWBQB-AVGNSLFASA-N 0.000 description 3
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 108010018866 cysteinyl-seryl-valyl-threonyl-cysteinyl-glycine Proteins 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 108010054813 diprotin B Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 108010092114 histidylphenylalanine Proteins 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 3
- 108010090894 prolylleucine Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 2
- JJIBHAOBNIFUEL-SRVKXCTJSA-N Arg-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)N JJIBHAOBNIFUEL-SRVKXCTJSA-N 0.000 description 2
- XHFXZQHTLJVZBN-FXQIFTODSA-N Asn-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N XHFXZQHTLJVZBN-FXQIFTODSA-N 0.000 description 2
- ZDOQDYFZNGASEY-BIIVOSGPSA-N Asn-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZDOQDYFZNGASEY-BIIVOSGPSA-N 0.000 description 2
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 2
- JZLFYAAGGYMRIK-BYULHYEWSA-N Asn-Val-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O JZLFYAAGGYMRIK-BYULHYEWSA-N 0.000 description 2
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 2
- HOQGTAIGQSDCHR-SRVKXCTJSA-N Asp-Asn-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HOQGTAIGQSDCHR-SRVKXCTJSA-N 0.000 description 2
- GISFCCXBVJKGEO-QEJZJMRPSA-N Asp-Glu-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GISFCCXBVJKGEO-QEJZJMRPSA-N 0.000 description 2
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 2
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100377706 Escherichia phage T5 A2.2 gene Proteins 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- WHVLABLIJYGVEK-QEWYBTABSA-N Gln-Phe-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WHVLABLIJYGVEK-QEWYBTABSA-N 0.000 description 2
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 2
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 2
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 2
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 2
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101710165610 Heat-stable 19 kDa antigen Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 2
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 2
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 2
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 2
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 2
- 241001084338 Listeria sp. Species 0.000 description 2
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 2
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 2
- OBZHNHBAAVEWKI-DCAQKATOSA-N Lys-Pro-Asn Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O OBZHNHBAAVEWKI-DCAQKATOSA-N 0.000 description 2
- QBHGXFQJFPWJIH-XUXIUFHCSA-N Lys-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN QBHGXFQJFPWJIH-XUXIUFHCSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- IHITVQKJXQQGLJ-LPEHRKFASA-N Met-Asn-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N IHITVQKJXQQGLJ-LPEHRKFASA-N 0.000 description 2
- VZBXCMCHIHEPBL-SRVKXCTJSA-N Met-Glu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN VZBXCMCHIHEPBL-SRVKXCTJSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000009182 Parasitemia Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 description 2
- XQAPEISNMXNKGE-FXQIFTODSA-N Ser-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CS)C(=O)O XQAPEISNMXNKGE-FXQIFTODSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- YGKVNUAKYPGORG-AVGNSLFASA-N Tyr-Asp-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YGKVNUAKYPGORG-AVGNSLFASA-N 0.000 description 2
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 2
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 2
- AAOPYWQQBXHINJ-DZKIICNBSA-N Val-Gln-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N AAOPYWQQBXHINJ-DZKIICNBSA-N 0.000 description 2
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 230000000680 avirulence Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010012058 leucyltyrosine Proteins 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 244000000040 protozoan parasite Species 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TWLQEIBUXHHZPI-UPPQRMANSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]p Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 TWLQEIBUXHHZPI-UPPQRMANSA-N 0.000 description 1
- 108010004200 (asparaginyl-alanyl-asparaginyl-proline)3 Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 description 1
- BVLPIIBTWIYOML-ZKWXMUAHSA-N Ala-Val-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BVLPIIBTWIYOML-ZKWXMUAHSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- BVBKBQRPOJFCQM-DCAQKATOSA-N Arg-Asn-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BVBKBQRPOJFCQM-DCAQKATOSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 1
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 1
- UEONJSPBTSWKOI-CIUDSAMLSA-N Asn-Gln-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O UEONJSPBTSWKOI-CIUDSAMLSA-N 0.000 description 1
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 1
- LJRPYAZQQWHEEV-FXQIFTODSA-N Asp-Gln-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O LJRPYAZQQWHEEV-FXQIFTODSA-N 0.000 description 1
- CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- 101710197318 Asparagine-rich protein Proteins 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 101100228469 Caenorhabditis elegans exp-1 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- FALJZCPMTGJOHX-SRVKXCTJSA-N Gln-Met-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O FALJZCPMTGJOHX-SRVKXCTJSA-N 0.000 description 1
- UGEZSPWLJABDAR-KKUMJFAQSA-N Gln-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)N)N UGEZSPWLJABDAR-KKUMJFAQSA-N 0.000 description 1
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- LJLPOZGRPLORTF-CIUDSAMLSA-N Glu-Asn-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LJLPOZGRPLORTF-CIUDSAMLSA-N 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- NJPQBTJSYCKCNS-HVTMNAMFSA-N Glu-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N NJPQBTJSYCKCNS-HVTMNAMFSA-N 0.000 description 1
- ZHNHJYYFCGUZNQ-KBIXCLLPSA-N Glu-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O ZHNHJYYFCGUZNQ-KBIXCLLPSA-N 0.000 description 1
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 1
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- ZGXGVBYEJGVJMV-HJGDQZAQSA-N Glu-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O ZGXGVBYEJGVJMV-HJGDQZAQSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- STVHDEHTKFXBJQ-LAEOZQHASA-N Gly-Glu-Ile Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STVHDEHTKFXBJQ-LAEOZQHASA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- FLYSHWAAHYNKRT-JYJNAYRXSA-N His-Gln-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FLYSHWAAHYNKRT-JYJNAYRXSA-N 0.000 description 1
- SVVULKPWDBIPCO-BZSNNMDCSA-N His-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SVVULKPWDBIPCO-BZSNNMDCSA-N 0.000 description 1
- GNBHSMFBUNEWCJ-DCAQKATOSA-N His-Pro-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O GNBHSMFBUNEWCJ-DCAQKATOSA-N 0.000 description 1
- BZAQOPHNBFOOJS-DCAQKATOSA-N His-Pro-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O BZAQOPHNBFOOJS-DCAQKATOSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 1
- QIHJTGSVGIPHIW-QSFUFRPTSA-N Ile-Asn-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N QIHJTGSVGIPHIW-QSFUFRPTSA-N 0.000 description 1
- KMBPQYKVZBMRMH-PEFMBERDSA-N Ile-Gln-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O KMBPQYKVZBMRMH-PEFMBERDSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- PDTMWFVVNZYWTR-NHCYSSNCSA-N Ile-Gly-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O PDTMWFVVNZYWTR-NHCYSSNCSA-N 0.000 description 1
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 1
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 1
- XHBYEMIUENPZLY-GMOBBJLQSA-N Ile-Pro-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O XHBYEMIUENPZLY-GMOBBJLQSA-N 0.000 description 1
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 1
- AUIYHFRUOOKTGX-UKJIMTQDSA-N Ile-Val-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N AUIYHFRUOOKTGX-UKJIMTQDSA-N 0.000 description 1
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- GLBNEGIOFRVRHO-JYJNAYRXSA-N Leu-Gln-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLBNEGIOFRVRHO-JYJNAYRXSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 1
- RZXLZBIUTDQHJQ-SRVKXCTJSA-N Leu-Lys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O RZXLZBIUTDQHJQ-SRVKXCTJSA-N 0.000 description 1
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
- ARRIJPQRBWRNLT-DCAQKATOSA-N Leu-Met-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ARRIJPQRBWRNLT-DCAQKATOSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- NLOZZWJNIKKYSC-WDSOQIARSA-N Lys-Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 NLOZZWJNIKKYSC-WDSOQIARSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- IVFUVMSKSFSFBT-NHCYSSNCSA-N Lys-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN IVFUVMSKSFSFBT-NHCYSSNCSA-N 0.000 description 1
- WAIHHELKYSFIQN-XUXIUFHCSA-N Lys-Ile-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O WAIHHELKYSFIQN-XUXIUFHCSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- MIMXMVDLMDMOJD-BZSNNMDCSA-N Lys-Tyr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O MIMXMVDLMDMOJD-BZSNNMDCSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 1
- NSMXRFMGZYTFEX-KJEVXHAQSA-N Met-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCSC)N)O NSMXRFMGZYTFEX-KJEVXHAQSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- AJOKKVTWEMXZHC-DRZSPHRISA-N Phe-Ala-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 AJOKKVTWEMXZHC-DRZSPHRISA-N 0.000 description 1
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 1
- MJQFZGOIVBDIMZ-WHOFXGATSA-N Phe-Ile-Gly Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O MJQFZGOIVBDIMZ-WHOFXGATSA-N 0.000 description 1
- MWQXFDIQXIXPMS-UNQGMJICSA-N Phe-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O MWQXFDIQXIXPMS-UNQGMJICSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000224021 Plasmodium berghei ANKA Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 1
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 1
- SMCHPSMKAFIERP-FXQIFTODSA-N Pro-Asn-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 SMCHPSMKAFIERP-FXQIFTODSA-N 0.000 description 1
- AHXPYZRZRMQOAU-QXEWZRGKSA-N Pro-Asn-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1)C(O)=O AHXPYZRZRMQOAU-QXEWZRGKSA-N 0.000 description 1
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 1
- XYHMFGGWNOFUOU-QXEWZRGKSA-N Pro-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 XYHMFGGWNOFUOU-QXEWZRGKSA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- DWPXHLIBFQLKLK-CYDGBPFRSA-N Pro-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 DWPXHLIBFQLKLK-CYDGBPFRSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- 240000004350 Prunus spinosa Species 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101100439111 Rattus norvegicus Cebpd gene Proteins 0.000 description 1
- SRTCFKGBYBZRHA-ACZMJKKPSA-N Ser-Ala-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SRTCFKGBYBZRHA-ACZMJKKPSA-N 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- XXNYYSXNXCJYKX-DCAQKATOSA-N Ser-Leu-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O XXNYYSXNXCJYKX-DCAQKATOSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- 101000836473 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) Oligopeptide-binding protein AliA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 1
- JAJOFWABAUKAEJ-QTKMDUPCSA-N Thr-Pro-His Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O JAJOFWABAUKAEJ-QTKMDUPCSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- KAJRRNHOVMZYBL-IRIUXVKKSA-N Thr-Tyr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAJRRNHOVMZYBL-IRIUXVKKSA-N 0.000 description 1
- 101710131114 Threonine-rich protein Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 101710104031 Thrombospondin-related anonymous protein Proteins 0.000 description 1
- LDMUNXDDIDAPJH-VMBFOHBNSA-N Trp-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N LDMUNXDDIDAPJH-VMBFOHBNSA-N 0.000 description 1
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 1
- GEGYPBOPIGNZIF-CWRNSKLLSA-N Trp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O GEGYPBOPIGNZIF-CWRNSKLLSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- DANHCMVVXDXOHN-SRVKXCTJSA-N Tyr-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DANHCMVVXDXOHN-SRVKXCTJSA-N 0.000 description 1
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 1
- FJKXUIJOMUWCDD-FHWLQOOXSA-N Tyr-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O FJKXUIJOMUWCDD-FHWLQOOXSA-N 0.000 description 1
- OHOVFPKXPZODHS-SJWGOKEGSA-N Tyr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N OHOVFPKXPZODHS-SJWGOKEGSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 1
- WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 1
- KGSDLCMCDFETHU-YESZJQIVSA-N Tyr-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O KGSDLCMCDFETHU-YESZJQIVSA-N 0.000 description 1
- YKBUNNNRNZZUID-UFYCRDLUSA-N Tyr-Val-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YKBUNNNRNZZUID-UFYCRDLUSA-N 0.000 description 1
- XPYNXORPPVTVQK-SRVKXCTJSA-N Val-Arg-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)O)N XPYNXORPPVTVQK-SRVKXCTJSA-N 0.000 description 1
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 1
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 1
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
- SUGRIIAOLCDLBD-ZOBUZTSGSA-N Val-Trp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SUGRIIAOLCDLBD-ZOBUZTSGSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- ISLJZDYAPAUORR-UHFFFAOYSA-N ethyl n-[2-[(5-nitrothiophene-2-carbonyl)amino]thiophene-3-carbonyl]carbamate Chemical compound C1=CSC(NC(=O)C=2SC(=CC=2)[N+]([O-])=O)=C1C(=O)NC(=O)OCC ISLJZDYAPAUORR-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001492 haemagglutinating effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010020432 prolyl-prolylisoleucine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108700041548 protozoan thrombospondin-related adhesive Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000029302 virus maturation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired poxvirus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
Description
RESPONSE
This invention relates to generation of a protective CD8+ T
cell immune response against target antigens using different primer and booster compositions as sources of CD8+ T cell epitopes.
Introduction A general problem in vaccinology has been an inability to generate high levels of CD8 T cells by immunisation. This has impeded io the development of vaccines against several diseases including malaria.
Plasmodium falciparum malaria causes hundreds of millions of malaria infections each year and is responsible for 1-2 million deaths annually. The development of an effective vaccine against malaria is thus a major priority for global public health. A considerable body of immunological research over the last twenty years had led to the identification both of candidate vaccine antigens from the parasite and immunological mechanisms on the host that are likely to protect against infection and disease. However, despite this progress there is still no means of vaccinating against malaria infection which has been shown to 2o be effective in field trials.
A major problem has been the identification of a means of inducing a sufficiently strong immune response in vaccinated individuals to protect against infection and disease. So, although many malaria antigens are known that might be useful in vaccinating against malaria the problem has been how to deliver such antigens or fragments of them known as epitopes, which are recognised by cells of the immune system, in a way that induces a sufficiently strong immune response of a particular type.
!t has been known for many years that it is possible to protect individuals by immunising them with very large doses of irradiated malaria sporozoites given by bites from infected mosquitoes. Although this is a wholly impractical method of mass vaccination it has provided a model for analysing the immune responses that might be mediating protective immunity against sporozoite infection (Nardin and Nussenzweig 1993).
A considerable amount of research over the last decade or s more has indicated that a major protective immune response against the early pre-erythrocytic stage of P. falciparum malaria is mediated by T
lymphocytes of the CD8+ ve type (CD8+ T cells). Such cells have been shown to mediate protection directly in mouse models of malaria infection (Nardin and Nussenzweig 1993). Such T cells have also been identified in individuals naturally exposed to malaria and in volunteers immunised with irradiated sporozoites (Hill et aJ. 1991; Aidoo et al. 1995; Wizel et al.
1995).
There is much indirect evidence that such CD8+ T cells are protective against malaria infection and disease in humans (Laivani et al. 1994).
CD8+ T cells may function in more than one way. The best known function is the killing or lysis of target cells bearing peptide antigen in the context of an MHC class I molecule. Hence these cells are often termed cytotoxic T lymphocytes (CTL). However, another function, perhaps of greater protective relevance in malaria infections is the ability of CD8+ T
cells to secrete interferon gamma (IFN-y). Thus assays of lytic activity and of IFN-y release are both of value in measuring a CD8+ T cell immune response. In malaria these CD8+ve cells can protect by killing the parasite at the early intrahepatic stage of malaria infection before any symptoms of disease are produced (Seguin et al. 1994).
The agent of fatal human malaria, P. falciparum infects a restricted number of host species: humans, chimpanzees and some species of New World monkey. The best non-human model of malaria is the chimpanzee because this species is closely related to humans and liver-stage infection is observed consistently unlike in the monkey hosts (Thomas et al. 1994). Because of the expense and limited availability of chimpanzees most laboratory studies of malaria are performed in mice, ....-~_..-.._...__.._...._..__._....v...~.~. _... ... . . T .......... .. . .
... . .. ......,..... ..._~ ._ ....... ......... . .. . ... . ....... ......
.. .
This invention relates to generation of a protective CD8+ T
cell immune response against target antigens using different primer and booster compositions as sources of CD8+ T cell epitopes.
Introduction A general problem in vaccinology has been an inability to generate high levels of CD8 T cells by immunisation. This has impeded io the development of vaccines against several diseases including malaria.
Plasmodium falciparum malaria causes hundreds of millions of malaria infections each year and is responsible for 1-2 million deaths annually. The development of an effective vaccine against malaria is thus a major priority for global public health. A considerable body of immunological research over the last twenty years had led to the identification both of candidate vaccine antigens from the parasite and immunological mechanisms on the host that are likely to protect against infection and disease. However, despite this progress there is still no means of vaccinating against malaria infection which has been shown to 2o be effective in field trials.
A major problem has been the identification of a means of inducing a sufficiently strong immune response in vaccinated individuals to protect against infection and disease. So, although many malaria antigens are known that might be useful in vaccinating against malaria the problem has been how to deliver such antigens or fragments of them known as epitopes, which are recognised by cells of the immune system, in a way that induces a sufficiently strong immune response of a particular type.
!t has been known for many years that it is possible to protect individuals by immunising them with very large doses of irradiated malaria sporozoites given by bites from infected mosquitoes. Although this is a wholly impractical method of mass vaccination it has provided a model for analysing the immune responses that might be mediating protective immunity against sporozoite infection (Nardin and Nussenzweig 1993).
A considerable amount of research over the last decade or s more has indicated that a major protective immune response against the early pre-erythrocytic stage of P. falciparum malaria is mediated by T
lymphocytes of the CD8+ ve type (CD8+ T cells). Such cells have been shown to mediate protection directly in mouse models of malaria infection (Nardin and Nussenzweig 1993). Such T cells have also been identified in individuals naturally exposed to malaria and in volunteers immunised with irradiated sporozoites (Hill et aJ. 1991; Aidoo et al. 1995; Wizel et al.
1995).
There is much indirect evidence that such CD8+ T cells are protective against malaria infection and disease in humans (Laivani et al. 1994).
CD8+ T cells may function in more than one way. The best known function is the killing or lysis of target cells bearing peptide antigen in the context of an MHC class I molecule. Hence these cells are often termed cytotoxic T lymphocytes (CTL). However, another function, perhaps of greater protective relevance in malaria infections is the ability of CD8+ T
cells to secrete interferon gamma (IFN-y). Thus assays of lytic activity and of IFN-y release are both of value in measuring a CD8+ T cell immune response. In malaria these CD8+ve cells can protect by killing the parasite at the early intrahepatic stage of malaria infection before any symptoms of disease are produced (Seguin et al. 1994).
The agent of fatal human malaria, P. falciparum infects a restricted number of host species: humans, chimpanzees and some species of New World monkey. The best non-human model of malaria is the chimpanzee because this species is closely related to humans and liver-stage infection is observed consistently unlike in the monkey hosts (Thomas et al. 1994). Because of the expense and limited availability of chimpanzees most laboratory studies of malaria are performed in mice, ....-~_..-.._...__.._...._..__._....v...~.~. _... ... . . T .......... .. . .
... . .. ......,..... ..._~ ._ ....... ......... . .. . ... . ....... ......
.. .
using the rodent malaria species P. berghei or P. yoelii. These latter two models are well studied and it has been shown in both that CD8+ve lymphocytes play a key role in protective immunity against sporozoite challenge.
Previous studies have assessed a large variety of means of inducing CD8+ T cell responses against malaria. Several of these have shown some level of CD8+ T cell response and partial protection against malaria infection in the rodent models (e.g. Li et al. 1993; Sedegah et al 1994; Lanar et al. 1996). However, an effective means of immunising with Io subunit vaccines by the induction of sufficiently high levels of CD8+ T
lymphocytes to protect effectively against malaria sporozoite infection has not previously been demonstrated.
In recent years improved immune responses generated to potential vaccines have been sought by varying the vectors used to deliver the antigen. There is evidence that in some instances antibody responses are improved by using two different vectors administered sequentially as prime and boost. A variety of combinations of prime and boost have been tested in different potential vaccine regimes.
Leong et al. (Vaccines 1995, 327-331) describe immunising mice firstly to DNA expressing the influenza haemagglutinin (HA) antigen and then with a recombinant fowipox vector expressing HA. An enhanced antibody response was obtained following boosting.
Richmond et al. (Virology 1997, 230: 265-274) describe attempts to raise neutralising antibodies against HIV-1 env using DNA
priming and recombinant vaccinia virus boosting. Only low levels of antibody responses were observed with this prime boost regime and the results were considered disappointing.
Fuller et al. (Vaccine 1997, 15:924-926 and Immunol Cell Biol 1997, 75:389-396) describe an enhancement of antibody responses to DNA immunisation of macaques by using a booster immunisation with CA 02293692 1999-12-06 =
Previous studies have assessed a large variety of means of inducing CD8+ T cell responses against malaria. Several of these have shown some level of CD8+ T cell response and partial protection against malaria infection in the rodent models (e.g. Li et al. 1993; Sedegah et al 1994; Lanar et al. 1996). However, an effective means of immunising with Io subunit vaccines by the induction of sufficiently high levels of CD8+ T
lymphocytes to protect effectively against malaria sporozoite infection has not previously been demonstrated.
In recent years improved immune responses generated to potential vaccines have been sought by varying the vectors used to deliver the antigen. There is evidence that in some instances antibody responses are improved by using two different vectors administered sequentially as prime and boost. A variety of combinations of prime and boost have been tested in different potential vaccine regimes.
Leong et al. (Vaccines 1995, 327-331) describe immunising mice firstly to DNA expressing the influenza haemagglutinin (HA) antigen and then with a recombinant fowipox vector expressing HA. An enhanced antibody response was obtained following boosting.
Richmond et al. (Virology 1997, 230: 265-274) describe attempts to raise neutralising antibodies against HIV-1 env using DNA
priming and recombinant vaccinia virus boosting. Only low levels of antibody responses were observed with this prime boost regime and the results were considered disappointing.
Fuller et al. (Vaccine 1997, 15:924-926 and Immunol Cell Biol 1997, 75:389-396) describe an enhancement of antibody responses to DNA immunisation of macaques by using a booster immunisation with CA 02293692 1999-12-06 =
replicating recombinant vaccinia viruses. However, this did not translate into enhanced protective efficacy as a greater reduction in viral burden and attenuation of CD4 T cell loss was seen in the DNA primed and boosted animals.
s Hodge et al (Vaccine 1997, 15: 759-768) describe the induction of lymphoproliferative T cell responses in a mouse model for cancer using human carcinoembryonic antigen (CEA) expressed in a recombinant fowl pox virus (ALVAC). The authors primed an immune response with CEA-recombinant replication competent vaccinia viruses of io the Wyeth or WR strain and boosted the response with CEA-recombinant ALVAC. This led to an increase in T cell proliferation but did not result in enhanced protective efficacy if compared to three wild type recombinant immunisations (100% protection), three recombinant ALVAC-CEA
immunisations (70% protection) or WR prime followed by two ALVAC-CEA
1s immunisations (63% protection).
Thus some studies of heterologous prime-boost combination have found some enhancement of antibody and lymphoproliferative responses but no significant effect on protective efficacy in an animal model. CD8 T cells were not measured in these studies. The limited 20 enhancement of antibody response probably simply reflects the fact that antibodies to the priming immunogen will often reduce the immunogenicity of a second immunisation with the same immunogen, while boosting with a different carrier will in part overcome this problem. This mechanism would not be expected to be significantly affected by the order of immunisation.
25 Evidence that a heterologous prime boost immunisation regime might affect CD8 T cell responses was provided by Li et al. (1993).
They described partial protective efficacy induced in mice against malaria sporozoite challenge by administering two live viral vectors, a recombinant replicating influenza virus followed by a recombinant replicating vaccinia 30 virus encoding a malaria epitope. Reversing the order of immunisation led to loss of all protective efficacy and the authors suggested that this might be related to infection of liver cells by vaccinia, resulting in localisation of CTLs in the liver to protect against the hepatocytic stages of malaria parasites.
s Hodge et al (Vaccine 1997, 15: 759-768) describe the induction of lymphoproliferative T cell responses in a mouse model for cancer using human carcinoembryonic antigen (CEA) expressed in a recombinant fowl pox virus (ALVAC). The authors primed an immune response with CEA-recombinant replication competent vaccinia viruses of io the Wyeth or WR strain and boosted the response with CEA-recombinant ALVAC. This led to an increase in T cell proliferation but did not result in enhanced protective efficacy if compared to three wild type recombinant immunisations (100% protection), three recombinant ALVAC-CEA
immunisations (70% protection) or WR prime followed by two ALVAC-CEA
1s immunisations (63% protection).
Thus some studies of heterologous prime-boost combination have found some enhancement of antibody and lymphoproliferative responses but no significant effect on protective efficacy in an animal model. CD8 T cells were not measured in these studies. The limited 20 enhancement of antibody response probably simply reflects the fact that antibodies to the priming immunogen will often reduce the immunogenicity of a second immunisation with the same immunogen, while boosting with a different carrier will in part overcome this problem. This mechanism would not be expected to be significantly affected by the order of immunisation.
25 Evidence that a heterologous prime boost immunisation regime might affect CD8 T cell responses was provided by Li et al. (1993).
They described partial protective efficacy induced in mice against malaria sporozoite challenge by administering two live viral vectors, a recombinant replicating influenza virus followed by a recombinant replicating vaccinia 30 virus encoding a malaria epitope. Reversing the order of immunisation led to loss of all protective efficacy and the authors suggested that this might be related to infection of liver cells by vaccinia, resulting in localisation of CTLs in the liver to protect against the hepatocytic stages of malaria parasites.
5 Rodrigues et al. (J. Immunol. 1994, 4636-4648) describe immunising mice with repeated doses of a recombinant influenza virus expressing an immunodominant B cell epitope of the maiarial circumsporozoite (CS) protein followed by a recombinant vaccinia virus booster. The use of a wild type vaccinia strain and an attenuated but io replication-competent vaccinia strain in the booster yielded very similar levels of partial protection. However the attenuated but replication competent strain was slightly less immunogenic for priming CD8 T cells than the wild type vaccinia strain.
Murata et al. (Cell. Immunol. 1996, 173: 96-107) reported enhanced CD8 T cell responses after priming with replicating recombinant influenza viruses and boosting with a replicating strain of vaccinia virus and suggested that the partial protection observed in the two earlier studies was attributable to this enhanced CD8 T cell induction.
Thus these three studies together provide evidence that a 2o booster immunisation with a replicating recombinant vaccinia virus may enhance to some degree CD8 T cell induction following priming with a replicating recombinant influenza virus. However, there are two limitations to these findings in terms of their potential usefulness. Firstly, the immunogenicity induced was only sufficient to achieve partial protection against malaria and even this was dependent on a highly immunogenic priming immunisation with an unusual replicating recombinant influenza virus. Secondly, because of the potential and documented side-effects of using these replicating viruses as immunogens these recombinant vectors are not suitable for general human use as vaccines.
CA 02293692 1999-12-06 ^
Murata et al. (Cell. Immunol. 1996, 173: 96-107) reported enhanced CD8 T cell responses after priming with replicating recombinant influenza viruses and boosting with a replicating strain of vaccinia virus and suggested that the partial protection observed in the two earlier studies was attributable to this enhanced CD8 T cell induction.
Thus these three studies together provide evidence that a 2o booster immunisation with a replicating recombinant vaccinia virus may enhance to some degree CD8 T cell induction following priming with a replicating recombinant influenza virus. However, there are two limitations to these findings in terms of their potential usefulness. Firstly, the immunogenicity induced was only sufficient to achieve partial protection against malaria and even this was dependent on a highly immunogenic priming immunisation with an unusual replicating recombinant influenza virus. Secondly, because of the potential and documented side-effects of using these replicating viruses as immunogens these recombinant vectors are not suitable for general human use as vaccines.
CA 02293692 1999-12-06 ^
Modified vaccinia virus Ankara (MVA) is a strain of vaccinia virus which does not replicate in most cell types, including normal human tissues. MVA was derived by serial passage >500 times in chick embryo fibroblasts (CEF) of material derived from a pox lesion on a horse in Ankara, Turkey (Mayr et al. 1975). It was shown to be replication-impaired yet able to induce protective immunity against veterinary poxvirus infections (Mayr 1976). MVA was used as a human vaccine in the final stages of the smallpox eradication campaign, being administered by intracutaneous, subcutaneous and intramuscular routes to >120,000 io subjects in southern Germany. No significant side effects were recorded, despite the deliberate targeting of vaccination to high risk groups such as those with eczema (Mayr et al. 1978; Stickl et al. 1974; Mahnel et al.
1994;). The safety of MVA reflects the avirulence of the virus in animal models, including irradiated mice and following intracranial administration 1s to neonatal mice. The non-replication of MVA has been correlated with the production of proliferative white plaques on chick chorioallantoic membrane, abortive infection of non-avian cells, and the presence of six genomic deletions totalling approximately 30 kb (Meyer et al. 1991). The avirulence of MVA has been ascribed partially to deletions affecting host 2o range genes K1 L and C7L, although limited viral replication still occurs on human TK-143 cells and African Green Monkey CV-1 cells (Altenburger et al. 1989). Restoration of the K1 L gene only partially restores MVA host range (Sutter et al. 1994). The host range restriction appears to occur during viral particle maturation, with only immature virions being observed 25 in human HeLa cells on electron microscopy (Sutter et a!. 1992). The late block in viral replication does not prevent efficient expression of recombinant genes in MVA. Recombinant MVA expressing influenza nucleoprotein, influenza haemagglutinin, and SIV proteins have proved to be immunogenic and provide varying degrees of protection in animal 3o models, although this has never been ascribed to CD8+ T lymphocytes t ._..._..._ .__ :_ _ alone (Sutter et al. 1994, Hirsch et al. 1995; Hirsch et al. 1996).
Recombinant MVA is considered a promising human vaccine candidate because of these properties of safety and immunogenicity (Moss et al.
1995). Recombinant MVA containing DNA which codes for foreign antigens is described in US 5,185,146 (Altenburger).
Poxviruses have evolved strategies for evasion of the host immune response that include the production of secreted proteins that function as soluble receptors for tumour necrosis factor, IL-1 R, interferon (IFN)-a/(3 and IFN-y, which normally have sequence similarity to the io extracellular domain of cellular cytokine receptors (Symons et al. 1995;
Alcami et al. 1995; Alcami et al. 1992). The most recently described receptor of this nature is a chemokine receptor (Graham et al. 1997).
These viral receptors generally inhibit or subvert an appropriate host immune response, and their presence is associated with increased is pathogenicity. The II-1(3 receptor is an exception: its presence diminishes the host febrile response and enhances host survival in the face of infection (Alcami et al. 1996). We have discovered that MVA lacks functional cytokine receptors for interferon y, interferon aR, Tumour Necrosis Factor and CC chemokines, but it does possess the potentially 2o beneficial IL-1 P receptor. MVA is the only known strain of vaccinia to possess this cytokine receptor profile, which theoretically renders it safer and more immunogenic than other poxviruses. Another replication-impaired and safe strain of vaccinia known as NYVAC is fully described in Tartaglia et al.(Virology 1992, 188: 217-232).
25 It has long been recognised that live viruses have some attractive features as recombinant vaccine vectors including a high capacity for foreign antigens and fairly good immunogenicity for cellular immune responses (Ellis 1988 new technologies for making vaccines. In:
Vaccines. Editors: Plotkin S A and Mortimer E A. W B Saunders, 30 Philadelphia, page 568; Woodrow G C 1977. In: New Generation CA 02293692 1999-12-06 ^
1994;). The safety of MVA reflects the avirulence of the virus in animal models, including irradiated mice and following intracranial administration 1s to neonatal mice. The non-replication of MVA has been correlated with the production of proliferative white plaques on chick chorioallantoic membrane, abortive infection of non-avian cells, and the presence of six genomic deletions totalling approximately 30 kb (Meyer et al. 1991). The avirulence of MVA has been ascribed partially to deletions affecting host 2o range genes K1 L and C7L, although limited viral replication still occurs on human TK-143 cells and African Green Monkey CV-1 cells (Altenburger et al. 1989). Restoration of the K1 L gene only partially restores MVA host range (Sutter et al. 1994). The host range restriction appears to occur during viral particle maturation, with only immature virions being observed 25 in human HeLa cells on electron microscopy (Sutter et a!. 1992). The late block in viral replication does not prevent efficient expression of recombinant genes in MVA. Recombinant MVA expressing influenza nucleoprotein, influenza haemagglutinin, and SIV proteins have proved to be immunogenic and provide varying degrees of protection in animal 3o models, although this has never been ascribed to CD8+ T lymphocytes t ._..._..._ .__ :_ _ alone (Sutter et al. 1994, Hirsch et al. 1995; Hirsch et al. 1996).
Recombinant MVA is considered a promising human vaccine candidate because of these properties of safety and immunogenicity (Moss et al.
1995). Recombinant MVA containing DNA which codes for foreign antigens is described in US 5,185,146 (Altenburger).
Poxviruses have evolved strategies for evasion of the host immune response that include the production of secreted proteins that function as soluble receptors for tumour necrosis factor, IL-1 R, interferon (IFN)-a/(3 and IFN-y, which normally have sequence similarity to the io extracellular domain of cellular cytokine receptors (Symons et al. 1995;
Alcami et al. 1995; Alcami et al. 1992). The most recently described receptor of this nature is a chemokine receptor (Graham et al. 1997).
These viral receptors generally inhibit or subvert an appropriate host immune response, and their presence is associated with increased is pathogenicity. The II-1(3 receptor is an exception: its presence diminishes the host febrile response and enhances host survival in the face of infection (Alcami et al. 1996). We have discovered that MVA lacks functional cytokine receptors for interferon y, interferon aR, Tumour Necrosis Factor and CC chemokines, but it does possess the potentially 2o beneficial IL-1 P receptor. MVA is the only known strain of vaccinia to possess this cytokine receptor profile, which theoretically renders it safer and more immunogenic than other poxviruses. Another replication-impaired and safe strain of vaccinia known as NYVAC is fully described in Tartaglia et al.(Virology 1992, 188: 217-232).
25 It has long been recognised that live viruses have some attractive features as recombinant vaccine vectors including a high capacity for foreign antigens and fairly good immunogenicity for cellular immune responses (Ellis 1988 new technologies for making vaccines. In:
Vaccines. Editors: Plotkin S A and Mortimer E A. W B Saunders, 30 Philadelphia, page 568; Woodrow G C 1977. In: New Generation CA 02293692 1999-12-06 ^
Vacciness 2"d Edition. Editors: Levine M M, Woodrow G C, Kaper J B, Cobon G, page 33). This has led to attempts to attenuate the virulence of such live vectors in various ways including reducing their replication capacity (Tartaglia J et al. 1992 Virology 188: 217-232). However such a reduction in replication reduces the amount of antigen produced by the virus and thereby would be expected to reduce vaccine immunogenicity.
Indeed attenuation of replicating vaccinia strains has previously been shown to lead to some substantial reductions in antibody responses (Lee M S et al, 1992 J Virology 66: 2617-2630). Similarly the non-replicating io fowipox vector was found to be less immunogenic for antibody production and less protective than a replicating wild-type vaccinia strain in a rabies study (Taylor J et al. 1991 Vaccine 9: 190-193).
It has now been discovered that non-replicating and replication-impaired strains of poxvirus provide vectors which give an extremely good boosting effect to a primed CTL response. Remarkably, this effect is significantly stronger than a boosting effect by wild type poxviruses. The effect is observed with malarial and other antigens such as viral and tumour antigens, and is protective as shown in mice and non-human primate challenge experiments. Complete rather than partial protection from sporozoite challenge has been observed with the novel immunisation regime.
It is an aim of this invention to identify an effective means of immunising against malaria. It is a further aim of this invention to identify means of immunising against other diseases in which CD8+ T cell responses play a protective role. Such diseases include but are not limited to infection and disease caused by the viruses HIV, herpes simplex, herpes zoster, hepatitis C, hepatitis B, influenza, Epstein-Barr virus, measles, dengue and HTLV-1; by the bacteria Mycobacterium tuberculosis and Listeria sp.; and by the protozoan parasites Toxoplasma and _ r. . __._____.._._......._.._...._._ . . . ~
Indeed attenuation of replicating vaccinia strains has previously been shown to lead to some substantial reductions in antibody responses (Lee M S et al, 1992 J Virology 66: 2617-2630). Similarly the non-replicating io fowipox vector was found to be less immunogenic for antibody production and less protective than a replicating wild-type vaccinia strain in a rabies study (Taylor J et al. 1991 Vaccine 9: 190-193).
It has now been discovered that non-replicating and replication-impaired strains of poxvirus provide vectors which give an extremely good boosting effect to a primed CTL response. Remarkably, this effect is significantly stronger than a boosting effect by wild type poxviruses. The effect is observed with malarial and other antigens such as viral and tumour antigens, and is protective as shown in mice and non-human primate challenge experiments. Complete rather than partial protection from sporozoite challenge has been observed with the novel immunisation regime.
It is an aim of this invention to identify an effective means of immunising against malaria. It is a further aim of this invention to identify means of immunising against other diseases in which CD8+ T cell responses play a protective role. Such diseases include but are not limited to infection and disease caused by the viruses HIV, herpes simplex, herpes zoster, hepatitis C, hepatitis B, influenza, Epstein-Barr virus, measles, dengue and HTLV-1; by the bacteria Mycobacterium tuberculosis and Listeria sp.; and by the protozoan parasites Toxoplasma and _ r. . __._____.._._......._.._...._._ . . . ~
Trypanosoma; and certain forms of cancer e.g. melanoma, cancer of the breast and cancer of the colon.
We describe here a novel method of immunising that generated very high levels of CD8+ T cells and was found to be capable of inducing unprecedented complete protection against P. berghei sporozoite challenge. The same approach was tested in higher primates and found to be highly immunogenic in this species also, and was found to induce partial protection against P. falciparum challenge. Induction of protective immune responses has also been demonstrated in two additional mouse I o models of viral infection and cancer.
We show further than the novel immunisation regime that is described here is also effective in generating strong CD8+ T cell responses against HIV epitopes. Considerable evidence indicates that the generation of such CD8+ T cell responses can be expected to be of value in 1s prophylactic or therapeutic immunisation against this viral infection and disease (Gallimore et al 1995; Ada 1996). We demonstrate that strong CD8+T cell responses may be generated against epitopes from both HIV
and malaria using an epitope string with sequences from both of these micro-organisms. The success in generating enhanced immunogenicity 20 against both HIV and malaria epitopes, and also against influenza and tumour epitopes, indicates that this novel immunisation regime can be effective generally against many infectious pathogens and also in non-infectious diseases where the generation of a strong CD8+ T cell response may be of value.
25 A surprising feature of the current invention is the finding of the very high efficacy of non-replicating agents in both priming and particularly in boosting a CD8+ T cell response. In general the immunogenicity of CD8+ T cell induction by live replicating viral vectors has previously been found to be higher than for non-replicating agents or 30 replication-impaired vectors. This is as would be expected from the greater amount of antigen produced by agents that can replicate in the host. Here however we find that the greatest immunogenicity and protective efficacy is surprisingly observed with non-replicating vectors. The latter have an added advantage for vaccination in that they are in general safer for use in humans 5 than replicating vectors.
The present invention provides in one aspect a kit for generating a protective CD8+ T cell immune response against at least one target antigen, which kit comprises:
(i) a priming composition comprising a source of one or more CD8+ T
We describe here a novel method of immunising that generated very high levels of CD8+ T cells and was found to be capable of inducing unprecedented complete protection against P. berghei sporozoite challenge. The same approach was tested in higher primates and found to be highly immunogenic in this species also, and was found to induce partial protection against P. falciparum challenge. Induction of protective immune responses has also been demonstrated in two additional mouse I o models of viral infection and cancer.
We show further than the novel immunisation regime that is described here is also effective in generating strong CD8+ T cell responses against HIV epitopes. Considerable evidence indicates that the generation of such CD8+ T cell responses can be expected to be of value in 1s prophylactic or therapeutic immunisation against this viral infection and disease (Gallimore et al 1995; Ada 1996). We demonstrate that strong CD8+T cell responses may be generated against epitopes from both HIV
and malaria using an epitope string with sequences from both of these micro-organisms. The success in generating enhanced immunogenicity 20 against both HIV and malaria epitopes, and also against influenza and tumour epitopes, indicates that this novel immunisation regime can be effective generally against many infectious pathogens and also in non-infectious diseases where the generation of a strong CD8+ T cell response may be of value.
25 A surprising feature of the current invention is the finding of the very high efficacy of non-replicating agents in both priming and particularly in boosting a CD8+ T cell response. In general the immunogenicity of CD8+ T cell induction by live replicating viral vectors has previously been found to be higher than for non-replicating agents or 30 replication-impaired vectors. This is as would be expected from the greater amount of antigen produced by agents that can replicate in the host. Here however we find that the greatest immunogenicity and protective efficacy is surprisingly observed with non-replicating vectors. The latter have an added advantage for vaccination in that they are in general safer for use in humans 5 than replicating vectors.
The present invention provides in one aspect a kit for generating a protective CD8+ T cell immune response against at least one target antigen, which kit comprises:
(i) a priming composition comprising a source of one or more CD8+ T
10 cell epitopes of the target antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T
cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier;
with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
In another aspect the invention provides a method for generating a protective CD8+ T cell immune response against at least one target antigen, which method comprises administering at least one dose of component (i), followed by at least one dose of component (ii) of the kit according to the invention.
In accordance with one aspect of the present invention there is provided a kit for generating a protective CD8+ T cell immune response against at least one target antigen, which kit comprises: (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes in (i) is a non-viral vector or a non-replicating or replication-impaired viral vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition l0a comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+
T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier; with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
In accordance with another aspect of the present invention there is provided use of at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant DNA plasmid.
In accordance with yet another aspect of the present invention there is provided use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or tumour, and at least one dose of a recombinant MVA vector encoding the same epitope or antigen in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant protein or particle.
In accordance with still yet another aspect of the present invention there is provided a medicament for boosting a primed CD8+ T cell response against at least one target antigen, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+
T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
10b In accordance with still yet another aspect of the present invention there is provided use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector as a source of one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided use of at least one dose of a recombinant DNA
plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the a recombinant non-replicating or replication-impaired poxvirus is administered following the recombinant DNA plasmid.
In accordance with still yet another aspect of the present invention there is provided the use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or tumour, and at least one dose of a recombinant MVA vector encoding the same epitope or antigen for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is administered following the recombinant protein or particle.
In accordance with still yet another aspect of the present invention there is provided the use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
10c In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector as a source of one or more CD8+ T cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is DNA, a Ty-virus-like particle comprising two or more CD8+ T cell epitopes present in a recombinant string of CD8+ T cell epitopes, or a non-replicating recombinant adenovirus vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is the vaccinia virus strain Modified Virus Ankara (MVA), or a strain derived therefrom; for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising a DNA plasmid encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a Modified Virus Ankara (MVA) vector encoding a source of CDB+ T cell epitopes from the target hepatitis B or hepatitis C antigen, including at least one CD8+ T
cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen in the 10d manufacture of a medicament for boosting a differently primed CD8+ T cell immune response against the hepatitis B or hepatitis C antigen.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising as a source of CD8+ T cell epitopes, DNA encoding a recombinant string of CD8+ T cell epitopes from a target melanoma antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising as a source of CD8+ T cell epitopes a Modified Virus Ankara (MVA) vector encoding a recombinant string of CD8+ T cell epitopes from the target melanoma antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided a medicament for boosting a naturally primed CD8+ T cell response against at least one target antigen in an individual naturally exposed to the target antigen, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA encoding one or more CD8+ T
cell epitopes of a target antigen in the manufacture of a medicament for boosting a naturally primed CD8+ T cell immune response against the target antigen.
Preferably, the source of CD8+ T cell epitopes in (i) in the method according to the invention is a non-viral vector or a non-replicating or replication-impaired viral vector, although replicating viral vectors may be used.
cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier;
with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
In another aspect the invention provides a method for generating a protective CD8+ T cell immune response against at least one target antigen, which method comprises administering at least one dose of component (i), followed by at least one dose of component (ii) of the kit according to the invention.
In accordance with one aspect of the present invention there is provided a kit for generating a protective CD8+ T cell immune response against at least one target antigen, which kit comprises: (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes in (i) is a non-viral vector or a non-replicating or replication-impaired viral vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition l0a comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+
T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier; with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
In accordance with another aspect of the present invention there is provided use of at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant DNA plasmid.
In accordance with yet another aspect of the present invention there is provided use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or tumour, and at least one dose of a recombinant MVA vector encoding the same epitope or antigen in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant protein or particle.
In accordance with still yet another aspect of the present invention there is provided a medicament for boosting a primed CD8+ T cell response against at least one target antigen, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+
T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
10b In accordance with still yet another aspect of the present invention there is provided use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector as a source of one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided use of at least one dose of a recombinant DNA
plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the a recombinant non-replicating or replication-impaired poxvirus is administered following the recombinant DNA plasmid.
In accordance with still yet another aspect of the present invention there is provided the use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or tumour, and at least one dose of a recombinant MVA vector encoding the same epitope or antigen for generation of a protective CD8+ T cell immune response against the pathogen or tumour, wherein the recombinant non-replicating or replication-impaired poxvirus is administered following the recombinant protein or particle.
In accordance with still yet another aspect of the present invention there is provided the use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
10c In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector as a source of one or more CD8+ T cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is DNA, a Ty-virus-like particle comprising two or more CD8+ T cell epitopes present in a recombinant string of CD8+ T cell epitopes, or a non-replicating recombinant adenovirus vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is the vaccinia virus strain Modified Virus Ankara (MVA), or a strain derived therefrom; for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising a DNA plasmid encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a Modified Virus Ankara (MVA) vector encoding a source of CDB+ T cell epitopes from the target hepatitis B or hepatitis C antigen, including at least one CD8+ T
cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA vector encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen in the 10d manufacture of a medicament for boosting a differently primed CD8+ T cell immune response against the hepatitis B or hepatitis C antigen.
In accordance with still yet another aspect of the present invention there is provided a kit comprising: (i) a priming composition comprising as a source of CD8+ T cell epitopes, DNA encoding a recombinant string of CD8+ T cell epitopes from a target melanoma antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising as a source of CD8+ T cell epitopes a Modified Virus Ankara (MVA) vector encoding a recombinant string of CD8+ T cell epitopes from the target melanoma antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
In accordance with still yet another aspect of the present invention there is provided a medicament for boosting a naturally primed CD8+ T cell response against at least one target antigen in an individual naturally exposed to the target antigen, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
In accordance with still yet another aspect of the present invention there is provided the use of an MVA encoding one or more CD8+ T
cell epitopes of a target antigen in the manufacture of a medicament for boosting a naturally primed CD8+ T cell immune response against the target antigen.
Preferably, the source of CD8+ T cell epitopes in (i) in the method according to the invention is a non-viral vector or a non-replicating or replication-impaired viral vector, although replicating viral vectors may be used.
Preferably, the source of CD8+ T cell epitopes in (i) is not a poxvirus vector, so that there is minimal cross-reactivity between the primer and the booster.
In one preferred embodiment of the invention, the source of s CD8+ T cell epitopes in the priming composition is a nucleic acid, which may be DNA or RNA, in particular a recombinant DNA plasmid. The DNA
or RNA may be packaged, for example in a lysosome, or it may be in free form.
In another preferred embodiment of the invention, the source to of CD8+ T cell epitopes in the priming composition is a peptide, polypeptide, protein, polyprotein or particle comprising two or more CD8+ T
cell epitopes, present in a recombinant string of CD8+ T cell epitopes or in a target antigen. Polyproteins include two or more proteins which may be the same, or preferably different, linked together. Particularly preferred in 15 this embodiment is a recombinant proteinaceous particle such as a Ty virus-like particle (VLP) (Burns et al. Molec. Biotechnol. 1994, 1: 137-145).
Preferably, the source of CD8+ T cell epitopes in the boosting composition is a vaccinia virus vector such as MVA or NYVAC. Most preferred is the vaccinia strain modified virus ankara (MVA) or a strain 2o derived therefrom. Alternatives to vaccinia vectors include avipox vectors such as fowlpox or canarypox vectors. Particularly suitable as an avipox vector is a strain of canarypox known as ALVAC (commercially available as Kanapox), and strains derived therefrom.
Poxvirus genomes can carry a large amount of heterologous 2s genetic information. Other requirements for viral vectors for use in vaccines include good immunogenicity and safety. MVA is a replication-impaired vaccinia strain with a good safety record. In most cell types and normal human tissues, MVA does not replicate; limited replication of MVA
is observed in a few transformed cell types such as BHK21 cells. It has 30 now been shown, by the results described herein, that recombinant MVA
CA 02293692 1999-12-06 ^
In one preferred embodiment of the invention, the source of s CD8+ T cell epitopes in the priming composition is a nucleic acid, which may be DNA or RNA, in particular a recombinant DNA plasmid. The DNA
or RNA may be packaged, for example in a lysosome, or it may be in free form.
In another preferred embodiment of the invention, the source to of CD8+ T cell epitopes in the priming composition is a peptide, polypeptide, protein, polyprotein or particle comprising two or more CD8+ T
cell epitopes, present in a recombinant string of CD8+ T cell epitopes or in a target antigen. Polyproteins include two or more proteins which may be the same, or preferably different, linked together. Particularly preferred in 15 this embodiment is a recombinant proteinaceous particle such as a Ty virus-like particle (VLP) (Burns et al. Molec. Biotechnol. 1994, 1: 137-145).
Preferably, the source of CD8+ T cell epitopes in the boosting composition is a vaccinia virus vector such as MVA or NYVAC. Most preferred is the vaccinia strain modified virus ankara (MVA) or a strain 2o derived therefrom. Alternatives to vaccinia vectors include avipox vectors such as fowlpox or canarypox vectors. Particularly suitable as an avipox vector is a strain of canarypox known as ALVAC (commercially available as Kanapox), and strains derived therefrom.
Poxvirus genomes can carry a large amount of heterologous 2s genetic information. Other requirements for viral vectors for use in vaccines include good immunogenicity and safety. MVA is a replication-impaired vaccinia strain with a good safety record. In most cell types and normal human tissues, MVA does not replicate; limited replication of MVA
is observed in a few transformed cell types such as BHK21 cells. It has 30 now been shown, by the results described herein, that recombinant MVA
CA 02293692 1999-12-06 ^
and other non-replicating or replication-impaired strains are surprisingly and significantly better than conventional recombinant vaccinia vectors at generating a protective CD8+ T cell response, when administered in a boosting composition following priming with a DNA plasmid, a recombinant Ty-VLP or a recombinant adenovirus.
It will be evident that vaccinia virus strains derived from MVA, or independently developed strains having the features of MVA which make MVA particularly suitable for use in a vaccine, will also be suitable for use in the invention.
MVA containing an inserted string of epitopes (MVA-HM, which is described in the Examples) has been deposited at the European Collection of Animal Cell Cultures, CAMR, Salisbury, Wiltshire SP4 OJG, UK under accession no. V97060511 on 5 June 1997.
The term "non-replicating" or "replication-impaired" as used 1s herein means not capable of replication to any significant extent in the majority of normal mammalian cells or normal human cells. Viruses which are non-replicating or replication-impaired may have become so naturally (i.e. they may be isolated as such from nature) or artificially e.g. by breeding in vitro or by genetic manipulation, for example deletion of a gene which is critical for replication. There will generally be one or a few cell types in which the viruses can be grown, such as CEF cells for MVA.
Replication of a virus is generally measured in two ways:
1) DNA synthesis and 2) viral titre. More precisely, the term "non-replicating or replication-impaired" as used herein and as it applies to poxviruses means viruses which satisfy either or both of the following criteria:
1) exhibit a 1 log (10 fold) reduction in DNA synthesis compared to the Copenhagen strain of vaccinia virus in MRC-5 cells (a human cell line);
* T
It will be evident that vaccinia virus strains derived from MVA, or independently developed strains having the features of MVA which make MVA particularly suitable for use in a vaccine, will also be suitable for use in the invention.
MVA containing an inserted string of epitopes (MVA-HM, which is described in the Examples) has been deposited at the European Collection of Animal Cell Cultures, CAMR, Salisbury, Wiltshire SP4 OJG, UK under accession no. V97060511 on 5 June 1997.
The term "non-replicating" or "replication-impaired" as used 1s herein means not capable of replication to any significant extent in the majority of normal mammalian cells or normal human cells. Viruses which are non-replicating or replication-impaired may have become so naturally (i.e. they may be isolated as such from nature) or artificially e.g. by breeding in vitro or by genetic manipulation, for example deletion of a gene which is critical for replication. There will generally be one or a few cell types in which the viruses can be grown, such as CEF cells for MVA.
Replication of a virus is generally measured in two ways:
1) DNA synthesis and 2) viral titre. More precisely, the term "non-replicating or replication-impaired" as used herein and as it applies to poxviruses means viruses which satisfy either or both of the following criteria:
1) exhibit a 1 log (10 fold) reduction in DNA synthesis compared to the Copenhagen strain of vaccinia virus in MRC-5 cells (a human cell line);
* T
2) exhibit a 2 log reduction in viral titre in HELA cells (a human cell line) compared to the Copenhagen strain of vaccinia virus.
Examples of poxviruses which fall within this definition are s MVA, NYVAC and avipox viruses, while a virus which falls outside the definition is the attenuated vaccinia strain M7.
Alternative preferred viral vectors for use in the priming composition according to the invention include a variety of different viruses, genetically disabled so as to be non-replicating or replication-impaired.
Such viruses include for example non-replicating adenoviruses such as El deletion mutants. Genetic disabling of viruses to produce non-replicating or replication-impaired vectors has been widely described in the literature (e.g. McLean et al. 1994).
Other suitable viral vectors for use in the priming composition are vectors based on herpes virus and Venezuelan equine encephalitis virus (VEE) (Davies et al. 1996). Suitable bacterial vectors for priming include recombinant BCG and recombinant Salmonella and Salmonella transformed with plasmid DNA (Darji A et al. 1997 Cell 91: 765-775).
Alternative suitable non-viral vectors for use in the priming composition include lipid-tailed peptides known as lipopeptides, peptides fused to carrier proteins such as KLH either as fusion proteins or by chemical linkage, whole antigens with adjuvant, and other similar systems.
Adjuvants such as QS21 or SBAS2 (Stoute J A et al. 1997 N Engi J
Medicine 226: 86-91) may be used with proteins, peptides or nucleic acids to enhance the induction of T cell responses. These systems are sometimes referred to as "immunogens" rather than "vectors", but they are vectors herein in the sense that they carry the relevant CD8+ T cell epitopes.
There is no reason why the priming and boosting compositions should not be identical in that they may both contain the = CA 02293692 1999-12-06 ^
Examples of poxviruses which fall within this definition are s MVA, NYVAC and avipox viruses, while a virus which falls outside the definition is the attenuated vaccinia strain M7.
Alternative preferred viral vectors for use in the priming composition according to the invention include a variety of different viruses, genetically disabled so as to be non-replicating or replication-impaired.
Such viruses include for example non-replicating adenoviruses such as El deletion mutants. Genetic disabling of viruses to produce non-replicating or replication-impaired vectors has been widely described in the literature (e.g. McLean et al. 1994).
Other suitable viral vectors for use in the priming composition are vectors based on herpes virus and Venezuelan equine encephalitis virus (VEE) (Davies et al. 1996). Suitable bacterial vectors for priming include recombinant BCG and recombinant Salmonella and Salmonella transformed with plasmid DNA (Darji A et al. 1997 Cell 91: 765-775).
Alternative suitable non-viral vectors for use in the priming composition include lipid-tailed peptides known as lipopeptides, peptides fused to carrier proteins such as KLH either as fusion proteins or by chemical linkage, whole antigens with adjuvant, and other similar systems.
Adjuvants such as QS21 or SBAS2 (Stoute J A et al. 1997 N Engi J
Medicine 226: 86-91) may be used with proteins, peptides or nucleic acids to enhance the induction of T cell responses. These systems are sometimes referred to as "immunogens" rather than "vectors", but they are vectors herein in the sense that they carry the relevant CD8+ T cell epitopes.
There is no reason why the priming and boosting compositions should not be identical in that they may both contain the = CA 02293692 1999-12-06 ^
priming source of CD8+ T cell epitopes as defined in (i) above and the boosting source of CD8+ T cell epitopes as defined in (ii) above. A single formulation which can be used as a primer and as a booster will simplify administration. The important thing is that the primer contains at least the s priming source of epitopes as defined in (i) above and the booster contains at least the boosting source of epitopes as defined in (ii) above.
The CD8+ T cell epitopes either present in, or encoded by the priming and boosting compositions, may be provided in a variety of different forms', such as a recombinant string of one or two or more epitopes, or in the context of the native target antigen, or a combination of both of these. CD8+ T cell epitopes have been identified and can be found in the literature, for many different diseases. It is possible to design epitope strings to generate a CD8+ T cell response against any chosen antigen that contains such epitopes. Advantageously, the epitopes in a string of multiple epitopes are linked together without intervening sequences so that unnecessary nucleic acid and/or amino acid material is avoided. In addition to the CD8+ T cell epitopes, it may be preferable to include one or more epitopes recognised by T helper cells, to augment the immune response generated by the epitope string. Particularly suitable T
helper cell epitopes are ones which are active in individuals of different HLA types, for example T helper epitopes from tetanus (against which most individuals will already be primed). A useful combination of three T
helper epitopes is employed in the examples described herein. It may also be useful to include B cell epitopes for stimulating B cell responses and antibody production.
The priming and boosting compositions described may advantageously comprise an adjuvant. In particular, a priming composition comprising a DNA plasmid vector may also comprise granulocyte macrophage-colony stimulating factor (GM-CSF), or a plasmid encoding it, to act as an adjuvant; beneficial effects are seen using GM-CSF in polypeptide form.
The compositions described herein may be employed as therapeutic or prophylactic vaccines. Whether prophylactic or therapeutic 5 immunisation is the more appropriate will usually depend upon the nature of the disease. For example, it is anticipated that cancer will be immunised against therapeutically rather than before it has been diagnosed, while anti-malaria vaccines will preferabiy, though not necessarily be used as a prophylactic.
10 The compositions according to the invention may be administered via a variety of different routes. Certain routes may be favoured for certain compositions, as resulting in the generation of a more effective response, or as being less likely to induce side effects, or as being easier for administration. The present invention has been shown to 15 be effective with gene gun delivery, either on gold beads or as a powder.
In further aspects, the invention provides:
- a method for generating a protective CD8+ T cell immune response against a pathogen or tumour, which method comprises administering at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of the pathogen or cancer, followed by at least one dose of a non-replicating or replication-impaired recombinant pox virus encoding the same epitope or antigen;
- a method for generating a protective CD8+ T cell immune response against a pathogen or tumour, which method comprises 2> administering at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of the pathogen or cancer, followed by at least one dose of a recombinant MVA vector encoding the same epitope or antigen;
CA 02293692 1999-12-06 ^
The CD8+ T cell epitopes either present in, or encoded by the priming and boosting compositions, may be provided in a variety of different forms', such as a recombinant string of one or two or more epitopes, or in the context of the native target antigen, or a combination of both of these. CD8+ T cell epitopes have been identified and can be found in the literature, for many different diseases. It is possible to design epitope strings to generate a CD8+ T cell response against any chosen antigen that contains such epitopes. Advantageously, the epitopes in a string of multiple epitopes are linked together without intervening sequences so that unnecessary nucleic acid and/or amino acid material is avoided. In addition to the CD8+ T cell epitopes, it may be preferable to include one or more epitopes recognised by T helper cells, to augment the immune response generated by the epitope string. Particularly suitable T
helper cell epitopes are ones which are active in individuals of different HLA types, for example T helper epitopes from tetanus (against which most individuals will already be primed). A useful combination of three T
helper epitopes is employed in the examples described herein. It may also be useful to include B cell epitopes for stimulating B cell responses and antibody production.
The priming and boosting compositions described may advantageously comprise an adjuvant. In particular, a priming composition comprising a DNA plasmid vector may also comprise granulocyte macrophage-colony stimulating factor (GM-CSF), or a plasmid encoding it, to act as an adjuvant; beneficial effects are seen using GM-CSF in polypeptide form.
The compositions described herein may be employed as therapeutic or prophylactic vaccines. Whether prophylactic or therapeutic 5 immunisation is the more appropriate will usually depend upon the nature of the disease. For example, it is anticipated that cancer will be immunised against therapeutically rather than before it has been diagnosed, while anti-malaria vaccines will preferabiy, though not necessarily be used as a prophylactic.
10 The compositions according to the invention may be administered via a variety of different routes. Certain routes may be favoured for certain compositions, as resulting in the generation of a more effective response, or as being less likely to induce side effects, or as being easier for administration. The present invention has been shown to 15 be effective with gene gun delivery, either on gold beads or as a powder.
In further aspects, the invention provides:
- a method for generating a protective CD8+ T cell immune response against a pathogen or tumour, which method comprises administering at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of the pathogen or cancer, followed by at least one dose of a non-replicating or replication-impaired recombinant pox virus encoding the same epitope or antigen;
- a method for generating a protective CD8+ T cell immune response against a pathogen or tumour, which method comprises 2> administering at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of the pathogen or cancer, followed by at least one dose of a recombinant MVA vector encoding the same epitope or antigen;
CA 02293692 1999-12-06 ^
- the use of a recombinant non-replicating or replication-impaired pox virus vector in the manufacture of a medicament for boosting a CD8+ T cell immune response;
- the use of an MVA vector in the manufacture of a medicament for boosting a CD8+ T cell immune response;
- a medicament for boosting a primed CD8+ T cell response against at least one target antigen or epitope, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired it} recombinant poxvirus vector, together with a pharmaceutically acceptable carrier; and - the priming and/or boosting compositions described herein, in particulate form suitable for delivery by a gene gun; and methods of immunisation comprising delivering the compositions by means of a gene gun.
Also provided by the invention are: the epitope strings described herein, including epitope strings comprising the amino acid sequences listed in table 1 and table 2; recombinant DNA plasmids encoding the epitope strings; recombinant Ty-VLPs comprising the epitope strings; a recombinant DNA plasmid or non-replicating or replication impaired recombinant pox virus encoding the P. falciparum antigen TRAP;
and a recombinant polypeptide comprising a whole or substantially whole protein antigen such as TRAP and a string of two or more epitopes in sequence such as CTL epitopes from malaria.
Example Formulations and Immunisation Protocols Formulation I
Priming Composition: DNA plasmid 1 mg/ml in PBS
Boosting Composition: Recombinant MVA, 108 ffu in PBS
r =
- the use of an MVA vector in the manufacture of a medicament for boosting a CD8+ T cell immune response;
- a medicament for boosting a primed CD8+ T cell response against at least one target antigen or epitope, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired it} recombinant poxvirus vector, together with a pharmaceutically acceptable carrier; and - the priming and/or boosting compositions described herein, in particulate form suitable for delivery by a gene gun; and methods of immunisation comprising delivering the compositions by means of a gene gun.
Also provided by the invention are: the epitope strings described herein, including epitope strings comprising the amino acid sequences listed in table 1 and table 2; recombinant DNA plasmids encoding the epitope strings; recombinant Ty-VLPs comprising the epitope strings; a recombinant DNA plasmid or non-replicating or replication impaired recombinant pox virus encoding the P. falciparum antigen TRAP;
and a recombinant polypeptide comprising a whole or substantially whole protein antigen such as TRAP and a string of two or more epitopes in sequence such as CTL epitopes from malaria.
Example Formulations and Immunisation Protocols Formulation I
Priming Composition: DNA plasmid 1 mg/ml in PBS
Boosting Composition: Recombinant MVA, 108 ffu in PBS
r =
Protocol: Administer two doses of 1 mg of priming composition, i.m., at 0 and 3 weeks followed by two doses of booster intradermally at 6 and 9 weeks.
Formulation 2 Priming Composition: Ty-VLP 500 g in PBS
Boosting Composition: MVA, 108 ffu in PBS
Protocol: Administer two doses of priming composition, i.m., at 0 and 3 io weeks, then 2 doses of booster at 6 and 9 weeks. For tumour treatment, MVA is given i.v. as one of most effective routes.
Formulation 3 Priming Composition: Protein 500 g + adjuvant (QS-21) Boosting Composition: Recombinant MVA, 10g ffu in PBS
Protocol: Administer two doses of priming composition at 0 and 3 weeks and 2 doses of booster i.d. at 6 and 9 weeks.
Formulation 4 Priming Composition: Adenovirus vector, 109 pfu in PBS
Boosting Composition: Recombinant MVA, 10g ffu in PBS
Protocol: Administer one or two doses of priming composition intradermally at 0 and 3 weeks and two doses of booster i.d. at 6 and 9 weeks.
The above doses and protocols may be varied to optimise protection.
Doses may be given between for example, 1 to 8 weeks apart rather than 3o 2 weeks apart.
is The invention will now be further described in the examples which follow.
EXAMPLES
Materials and Methods Generation of the epitope strings.
The malaria epitope string was made up of a series of cassettes each encoding three epitopes as shown in Table 1, with to restriction enzyme sites at each end of the cassette. Each cassette was constructed from four synthetic oligonucleotides which were annealed together, ligated into a cloning vector and then sequenced to check that no errors had been introduced. Individual cassettes were then joined together as required. The BamHl site at the 3' end of cassette C was fused to the i s Bgl/1 site at the 5' end of cassette A, destroying both restriction enzyme sites and encoding a two amino acid spacer (GS) between the two cassettes. Cassettes B, D and H were then joined to the string in the same manner. A longer string containing CABDHFE was also constructed in the same way.
Table 1. CTL epitopes of the malaria (M) string Cassette Epitope Amino acid DNA sequence Type HLA
Sequence restrictio n A Ls8 KPNDKSLY AAGCCGAACGACAAGTCCTTGTAT CTL 835 Cp26 KPKDELDY AAACCTAAGGACGAATTGGACTAC CTL B35 Ls6 KPIVQYDNF AAGCCAATCGTTCAATACGAQAACTTC CTL 853 8 Tr42/43 ASKNKEKAU( GCCTCCAAGAACAAGGAAAAGGCTTTGATCAT CTL B8 c Tr39 GIAGGLALL GGTATCGCTGGTGGTTTGGCCTTGTTG CTL A2.1 Cp6 MNPNDPNRN ATGAACCCTAATGACCCAAACAGAAACGTC CTL 87 v C St8 MINAYLDKL ATGATCAACGCCTACTTGGACAAGTTG CTL A2.2 Ls50 ISKYEDEI ATCTCCAAGTACGAAGACGAAATC CTL B17 Pb9 SYIPSAEKI TCCTACATCCCATCTGCCGAAAAGATC CTL mouse H2-Kd D Tr26 HLGNVKYLV CACTTGGGTAACGTTAAGTACTTGGTT CTL A2.1 Ls53 KSLYDEHI AAGTCTTTGTACGATGAACACATC CTL B58 Tr29 LLMDCSGSI TTATTGATGGACTGTTCTGGTTCTATT CTL A2.2 E NANP NANPNANPN AACGCTAATCCAAACGCAAATCCGAACGCCA Bcell ANPNANP ATCCTAACGCGAATCCC
TRAP DEWSPCSVT GACGAATGGTCTCCATGTTCTGTCACTTGTG Heparin AM CGKGTRSRK GTAAGGGTACTCGCTCTAGAAAGAGAGAA binding RE motif F Cp39 YLNKIQNSL TACTTGAACAAAATTCAAAACTCTTTG CTL A2.1 La72 MEKLKELEK ATGGAAAAGTTGAAAGAATTGGAAAAG CTL B8 ex23 ATSVLAGL GCTACTTCTGTCTTGGCTGGTTTG CTL 658 H CSP DPNANPNVD GACCCAAACGCTAACCCAAACGTTGACCCA T helper Universal PNANPNV AACGCCAACCCAAACGTC
BCG QVHFQPLPP CAAGTTCACTTCCAACCATTGCCTCCGGCCG T helper epitopes AWKL TTGTCAAGTTG
TT QFIKANSKFI CAATTCATCAAGGCCAACTCTAAGTTCATCG T helper GITE GTATCACCGAA
Table 1 Sequences included in the malaria epitope string. Each cassette consists of the epitopes shown above, in the order shown, with no > additional sequence between epitopes within a cassette. A Bglll site was added at the 5' end and a BamHl site at the 3' end, such that between cassettes in an epitope string the BamHl/Bgl/l junction encodes GS. All epitopes are from P. falciparum antigens except for pb9 (P. berghei), BCG
(M. tuberculosis) and TT (Tetanus). The amino acid and DNA sequences lo shown in the table have SEQ ID NOS. 1 to 40 in the order in which they appear.
Figure 1 shows the construct used to express Ty-VLP with the malaria epitope cassette CABDHFE. CTL epitopes are from P.
falciparum STARP (sporozoite threonine- and asparagine-rich protein) (st), 15 LSA-1 (liver stage antigen 1) (1s), CSP (circumsporozoite protein) (cp), CA 02293692 1999-12-06 ^
TRAP (thrombospondin-related adhesive protein) (tr), LSA-3 (liver stage antigen 3) (Ia) and Exp-1 (exported protein 1) (ex). Helper epitopes are from the P. falciparum CS protein, the M. tuberculosis 38Kd antigen and Tetanus Toxoid. NANP is the antibody epitope from CS and AM is the 5 adhesion motif from P. falciparum TRAP (Muller et al 1993). The length of the complete string is 229 amino acids as shown in the table 1 legend, with the amino acid sequence:-MINAYLDKLISKYEDEISYIPSAEKIGSKPNDKSLYKPKDELDYKPIVQYDN
FGSASKNKEKALIIGIAGGLALLMNPNDPNRNVGSHLGNVKYLVKSLYDE
io HILLMDCSGSIGSDPNANPNVDPNANPNVQVHFQPLPPAWKLQFIKANS
KFIGITEGSYLNKIQNSLMEKLKELEKATSVLAGLGSNANPNANPNANPNA
NPDEWSPCSVTCGKGTRSRKREGSGK [SEQ ID NO: 41].
The HIV epitope string was also synthesised by annealing oligonucleotides. Finally the HIV and malaria epitope strings were fused 1s by joining the BamHl site at the 3' end of the HIV epitopes to the Bglll site at the 5' end of cassettes CAB to form the HM string (Table 2) Table 2 CTL epitopes of the HIV/SIV epitope string Epitope Restriction Origin YLKDQQLL A24, B8 HIV-1 gp4l ERYLKDQQL B14 HIV-1 gp4l EITPIGLAP Mamu-B'01 SIV env PPIPVGEIY B35 HIV-1 p24 GEIYKRWII B8 HIV-1 p24 KRWIILGLNK B*2705 HIV-1 p24 IILGLNKIVR A33 HIV-1 p24 LGLNKIVRMY Bw62 HIV-1 p24 YNLTMKCR Mamu-A"`02 SIV env RGPGRAFVTI A2, H-2Dd HIV-1 gp120 GRAFVTIGK B*2705 HIV-1 gp120 TPYDINQML B53 HIV-2 gag CTPYDINQM Mamu-A`01 SIV gag *
RPQVPLRPMTY B51 HIV-1 nef QVPLRPMTYK A"0301, All HIV-1 nef VPLRPMTY 835 HIV-1 nef AVDLSHFLK All HIV-1 nef DLSHFLKEK A*0301 HIV-1 nef FLKEKGGL B8 HIV-1 nef ILKEPVHGV A*0201 HIV-1 pol ILKEPVHGVY Bw62 HIV-1 pol HPDIVIYQY B35 HIV-1 pol VIYQYMDDL A"0201 HIV-1 pol Table 2 Sequences of epitopes from HIV or SIV contained in the H
epitope string and assembled as shown in figure 2. The amino acids in the table have SEQ ID NOS: 42 to 64 in the order in which they appear.
Figure 2 shows a schematic outline of the H, M and HM
proteins. The bar patterns on the schematic representations of the polyepitope proteins indicate the origin of the sequences (see tables 1 and 2). The positions of individual epitopes and their MHC restrictions are depicted above and below the proteins. Pb is the only epitope derived from the protein of P. berghei. All other epitopes in the M protein originate from proteins of P. falciparum: cs - circumsporozoite protein, st - STARP, Is -LSA-1 and tr - TRAP. BCG - 38 kDa protein of M. tuberculosis; TT -tetanus toxin.
For the anti-tumour vaccine an epitope string containing CTL
epitopes was generated, similar to the malaria and HIV epitope string. In this tumour epitope string published murine CTL epitopes were fused together to create the tumour epitope string with the amino acid sequence:
MLPYLGWLVF-AQHPNAELL-KHYLFRNL-SPSYVYHQF-IPNPLLGLD
[SEQ ID NO: 65]. CTL epitopes shown here were fused together. The first amino acid methionine was introduced to initiate translation.
CA 02293692 1999-12-06 ^
Ty virus-like particles (VLPs).
The epitope string containing cassette CABDH was introduced into a yeast expression vector to make a C-terminal in-frame fusion to the TyA protein. When TyA or TyA fusion proteins are expressed in yeast from this vector, the protein spontaneously forms virus like particles which can be purified from the cytoplasm of the yeast by sucrose gradient centrifugation. Recombinant Ty-VLPs were prepared in this manner and dialysed against PBS to remove the sucrose before injection (c.f. Layton et al. 1996).
Adenoviruses Replication-defective recombinant Adenovirus with a deletion of the El genes was used in this study (McGrory et al, 1988). The Adenovirus expressed E. coli P-galactosidase under the control of a CMV
IE promoter. For immunisations, 10' pfu of virus were administered intradermally into the ear lobe.
Peptides Peptides were purchased from Research Genetics (USA), 2o dissolved at 10 mg/ml in DMSO (Sigma) and further diluted in PBS to 1 mg/mi. Peptides comprising CTL epitopes that were used in the experiments described herein are listed in table 3 Table 3 Sequence of CTL peptide epitopes sequence Antigen MHC
restriction LPYLGWLVF P1A tumour antigen Ld SYIPSAEKI P. berghei CSP Kd RGPGRAFVTI HIV gag Dd . ......T....... . .._..._.. . .W...-..._._,.._ .... ... . ~._.
TPHPARIGL E. coli 0-galactosidase L
TYQRTRALV Influenza A virus NP K
SDYEGRLI Influenza A virus NP Kk ASNENMETM Influenza A virus NP Db INVAFNRFL P. falciparum TRAP Kb The amino acid sequences in Table 3 have SEQ ID NOS: 66 to 73, in the order in which they appear in the Table.
> Plasmid DNA constructs A number of different vectors were used for constructing DNA
vaccines. Plasmid pTH contains the CMV IE promoter with intron A, followed by a polylinker to allow the introduction of antigen coding sequences and the bovine growth hormone transcription termination I o sequence. The plasmid carries the ampicillin resistance gene and is capable of replication in E. coli but not mammalian cells. This was used to make DNA vaccines expressing each of the following antigens: P. berghei TRAP, P. berghei CS, P. falciparum TRAP, P. falciparum LSA-1 (278 amino acids of the C terminus only), the epitope string containing cassettes is CABDH and the HM epitope string (HIV epitopes followed by cassettes CAB). Plasmid pSG2 is similar to pTH except for the antibiotic resistance gene. In pSG2 the ampicillin resistance gene of pTH has been replaced by a kanamycin resistance gene. pSG2 was used to to make DNA vaccines expressing the following antigens: P. berghei PbCSP, a mouse tumour 2o epitope string, the epitope string containing cassettes CABDH and the HM
epitope string. Plasmid V1J-NP expresses influenza nucleoprotein under the control of a CMV IE promoter. Plasmids CMV-TRAP and CMV-LSA-1 are similar to pTH.TRAP and pTH. LSA-1 but do not contain intron A of the CMV promoter. Plasmids RSV.TRAP and RSV.LSA-1 contain the RSV
25 promoter, SV40 transcription termination sequence and are tetracycline CA 02293692 1999-12-06 ^
resistant. For induction of 0-galactosidase-specific CTL plasmid pcDNA3/His/LacZ (Invitrogen) was used. AII DNA vaccines were prepared from E. coli strain DH5cx using Qiagen plasmid purification columns.
; Generation of recombinant vaccinia viruses Recombinant MVAs were made by first cloning the antigen sequence into a shuttle vector with a viral promoter such as the plasmid pSC11 (Chakrabarti et al. 1985; Morrison et al. 1989). P. berghei CS and P. falciparum TRAP, influenza nucleoprotein and the HM and mouse io tumour epitope polyepitope string were each expressed using the P7.5 promoter (Mackett et al. 1984), and P. berghei TRAP was expressed using the strong synthetic promoter (SSP; Carroll et al. 1995). The shuttle vectors, pSC1 1 or pMCO3 were then used to transform cells infected with wild-type MVA so that viral sequences flanking the promoter, antigen i> coding sequence and marker gene could recombine with the MVA and produce recombinants. Recombinant viruses express the marker gene ((~
glucuronidase or P galactosidase) allowing identification of plaques containing recombinant virus. Recombinants were repeatedly plaque purified before use in immunisations. The recombinant NYVAC-PbCSP
20 vaccinia was previously described (Lanar et aI. 1996). The wild type or Western Reserve (WR) strain of recombinant vaccinia encoding PbCSP
was described previously (Satchidanandam et al. 1991).
Cells and culture medium 2s Murine cells and Epstein-Barr virus transformed chimpanzee and macaque B cells (BCL) were cultured in RPMI supplemented with 10%
heat inactivated fetal calf serum (FCS). Splenocytes were restimulated with the peptides indicated (final concentration 1 g/ml) in MEM medium with 10% FCS, 2mM glutarnine, 50U/ml penicillin, 50 M 2-30 mercaptoethanol and 10mM Hepes pH7.2 (Gibco, UK).
Animals Mice of the strains indicated, 6-8 weeks old were purchased from Harlan Olac (Shaws Farm, Blackthorn, UK). Chimpanzees H1 and 5 H2 were studied at the Biomedical Primate Research Centre at Rijswick, The Netherlands. Macaques were studied at the University of Oxford.
Immunisations Plasmid DNA immunisations of mice were performed by 10 intramuscular immunisation of the DNA into the musculus tibialis under anaesthesia. Mouse muscle was sometimes pre-treated with 50 l of 1 mM
cardiotoxin (Latoxan, France) 5-9 days prior to immunisation as described by Davis et al (1993), but the presence or absence of such pre-treatment was not found to have any significant effect on immunogenicity or 15 protective efficacy. MVA immunisation of mice was performed by either intramuscular (i.m.), intravenous (into the lateral tail vein) (i.v.), intradermal (i.d.), intraperitoneal (i.p.) or subcutaneous (s.c.) immunisation.
Plasmid DNA and MVA immunisation of the chimpanzees H1 and H2 was performed under anaesthesia by intramuscular immunisation of leg 20 muscles. For these chimpanzee immunisations the plasmid DNA was co-administered with 15 micrograms of human GM-CSF as an adjuvant.
Recombinant MVA administration to the chimpanzees was by intramuscular immunisation under veterinary supervision. Recombinant human GM-CSF was purchased from Sandoz (Camberley, UK). For 2-5 plasmid DNA immunisations using a gene gun, DNA was precipitated onto gold particles. For intradermal delivery, two different types of gene guns were used, the Acell and the Oxford Bioscience device (PowderJect Pharmaceuticals, Oxford, UK).
CA 02293692 1999-12-06 ^
ELISPOT assays CD8+ T cells were quantified in the spleens of immunised mice without in vitro restimulation using the peptide epitopes indicated and the ELISPOT assay as described by Miyahara et al (1993). Briefly, 96-well nitrocellulose plates (Miliscreen MAHA, Millipore, Bedford UK) were coated with 15 g/ml of the anti-mouse interferon-y monoclonal antibody R4 (EACC) in 50 [LI of phosphate-buffered saline (PBS). After overnight incubation at 4 C the wells were washed once with PBS and blocked for 1 hour at room temperature with 100 l RPMI with 10% FCS. Splenocytes i o from immunised mice were resuspended to 1 x 10' cells/ml and placed in duplicate in the antibody coated wells and serially diluted. Peptide was added to each well to a final concentration of 1 g/ml. Additional wells without peptide were used as a control for peptide-dependence of interferon-y secretion. After incubation at 37 C in 5%CO2 for 12-18 hours the plates were washed 6 times with PBS and water. The wells were then incubated for 3 hours at room temperature with a solution of 1 g/mI of biotinylated anti-mouse interferon-y monoclonai antibody XMG1.2 (Pharmingen, CA, USA) in PBS. After further washes with PBS, 50 l of a 1 g/mI solution of streptavidin-aikaline-phosphatase polymer (Sigma) was added for 2 hours at room temperature. The spots were developed by adding 50 i of an alkaline phosphatase conjugate substrate solution (Biorad, Hercules, CA, USA). After the appearance of spots the reaction was stopped by washing with water. The number of spots was determined with the aid of a stereomicroscope.
ELISPOT assays on the chimpanzee peripheral blood lymphocytes were performed using a very similar method employing the assay and reagents developed to detect human CD8 T cells (Mabtech, Stockholm).
.
CTL assays CTL assays were performed using chromium labelled target cells as indicated and cultured mouse spleen cells as effector cells as described by Allsopp et al. (1996). CTL assays using chimpanzee or s macaque cells were performed as described for the detection of human CTL by Hill et al. (1992) using EBV-transformed autologous chimpanzee chimpanzee or macaque B cell lines as target cells.
P. berghei challenge to Mice were challenged with 2000 (BALB/c) or 200 (C57BL/6) sporozoites of the P. bergheiANKA strain in 200 l RPMI by intravenous inoculation as described (Lanar et al. 1996). These sporozoites were dissected from the salivary glands of Anopheles stephensi mosquitoes maintained at 18 C for 20-25 days after feeding on infected mice. Blood-1-5 stage malaria infection, indicating a failure of the immunisation, was detected by observing the appearance of ring forms of P. berghei in Giemsa-stained blood smears taken at 5-12 days post-challenge.
P. falciparum challenge 20 The chimpanzees were challenged with 20,000 P. falciparum sporozoites of the NF54 strain dissected from the salivary glands of Ariopheles gambiae mosquitoes, by intravenous inoculation under anaesthesia. Blood samples from these chimpanzees were examined daily from day 5 after challenge by microscopy and parasite culture, in 25 order to detect the appearance of low levels of P. falciparum parasites in the peripheral blood.
P815 tumour challenges Mice were challenged with 1 x 105 P815 cells in 200 l of 30 PBS by intravenous inoculation. Animals were monitored for survival.
CA 02293692 1999-12-06 =
Influenza virus challenges Mice were challenged with 100 haemagglutinating units (HA) of influenza virus A/PR/8/34 by intranasal inoculation. Following challenge the animals were weighed daily and monitored for survival.
Determining peptide specific CTL using tetramers Tetrameric complexes consisting of Mamu-A*01-heavy chain and [32-microglobulin were made as described by Ogg et al (1998). DNA
coding for the leaderless extracellular portion of the Mamu-A*01 MHC
class I heavy chain was PCR-amplified from cDNA using 5'primer MamuNdel: 5'-CCT GAC TCA GAC CAT ATG GGC TCT CAC TCC ATG
[SEQ ID NO: 74] and 3' primer: 5'-GTG ATA AGC TTA ACG ATG ATT
CCA CAC CAT TTT CTG TGC ATC CAG AAT ATG ATG CAG GGA TCC
~5 CTC CCA TCT CAG GGT GAG GGG C [SEQ ID NO: 75]. The former primer contained a Nde/ restriction site, the latter included a Hind/// site and encoded for the bioinylation enzyme BirA substrate peptide. PCR
products were digested with Nde/ and Hindlll and ligated into the same sites of the polylinker of bacterial expression vector pGMT7. The rhesus monkey gene encoding a leaderless [32-microglobulin was PCR amplifed from a cDNA clone using primers B2MBACK: 5'-TCA GAC CAT ATG TCT
CGC TCC GTG GCC [SEQ ID NO: 76] and B2MFOR: 5'-TCA GAC AAG
CTT TTA CAT GTC TCG ATC CCA C [SEQ ID NO: 77] and likewise cloned into the Nde/ and Hindlll sites of pGMT7. Both chains were expressed in E. coli strain BL-21, purified from inclusion bodies, refolded in the presence of peptide CTPYDINQM [SEQ ID NO: 54], biotinylated using the BirA enzyme (Avidity) and purified with FPLC and monoQ ion exchange columns. The amount of biotinylated refolded MHC-peptide complexes was estimated in an ELISA assay, whereby monomeric complexes were first captured by conformation sensitive monoclonal . .. .. T. ... ..... . ...... ._.._..._,.._ _..... . . .... . ... . . . . ...
. . . T..
antibody W6/32 and detected by alkaline phosphatase (AP) -conjugated streptavidin (Sigma) followed by colorimetric substrate for AP. The formation of tetrameric complexes was induced by addition of phycoerythrin (PE)-conjugated streptavidin (ExtrAvidin; Sigma) to the refolded biotinylated monomers at a molar ratio of MHC-peptide : PE-streptavidin of 4: 1. The complexes were stored in the dark at 4 C. These tetramers were used to analyse the frequency of Mamu-A*01/gag-specific CD8+ T cells in peripherial blood lymphocytes (PBL) of immunised macaques.
ImmunogenicitYStudies in Mice Previous studies of the induction of CTL against epitopes in the circumsporozoite (CS) protein of Plasmodium berghei and Plasmodium yoelii have shown variable levels of CTL induction with different delivery systems. Partial protection has been reported with plasmid DNA (Sedegah et al. 1994), influenza virus boosted by replicating vaccinia virus (Li et al.
1991), adenovirus (Rodrigues et al 1997) and particle delivery systems (Schodel et al. 1994). Immunisation of mice intramuscularly with 50 micrograms of a plasmid encoding the CS protein produced moderate levels of CD8+ cells and CTL activity in the spleens of these mice after a single injection (Figures 3, 4).
For comparison groups of BALB/c mice (n = 5) were injected intravenously with 106 ffu/pfu of recombinant vaccinia viruses of different strains (WR, NYVAC and MVA) all expressing P. berghei CSP. The frequencies of peptide-specific CD8+ T cells were measured 10 days later in an ELISPOT assay. MVA.PbCSP induced 181 +/- 48, NYVAC 221+/- 27 and WR 94+/- 19 (mean +/- standard deviation) peptide-specific CD8+ T
cells per million spienocytes. These results show that surprisingly replication-impaired vaccinia viruses are superior to replicating strains in CA 02293692 1999-12-06 ^
priming a CD8+ T cell response. We then attempted to boost these moderate CD8+ T cell responses induced by priming with either plasmid DNA or MVA using homologous or heterologous vectors. A low level of CD8+ T cells was observed after two immunisations with CS recombinant s DNA vaccine alone, the recombinant MVA vaccine alone or the recombinant MVA followed by recombinant DNA (Figure 3). A very much higher level of CD8+ T cells was observed by boosting the DNA-primed immune response with recombinant MVA. In a second experiment using ten mice per group the enhanced immunogenicity of the DNA/MVA
10 sequence was confirmed: DNA/MVA 856 +/- 201; MVA/DNA 168 +/- 72;
MVA/MVA 345+/- 90; DNA/DNA 92 +/- 46. Therefore the sequence of a first immunisation with a recombinant plasmid encoding the CS protein followed by a second immunisation with the recombinant MVA virus yielded the highest levels of CD8+ T lymphocyte response after immunisation.
15 Figure 3 shows malaria CD8 T cell ELISPOT data following different immunisation regimes. Results are shown as the number of peptide-specific T cells per million splenocytes. Mice were immunised either with the PbCSP-plasmid DNA or the PbCSP-MVA virus or combinations of the two as shown on the X axis, at two week intervals and 20 the number of splenocytes specific for the pb9 malaria epitope assayed two weeks after the last immunisation. Each point represents the number of spot-forming cells (SFCs) measured in an individual mouse. The highest level of CD8+ T cells was induced by priming with the plasmid DNA
and boosting with the recombinant MVA virus. This was more 25 immunogenic than the reverse order of immunisation (MVA/DNA), two DNA immunisations (DNA/DNA) or two MVA immunisations (MVA/MVA). It was also more immunogenic than the DNA and MVA immunisations given simultaneously (DNA + MVA 2w), than one DNA immunisation (DNA 4w) or one MVA immunisation given at the earlier or later time point (MVA 2w and 30 MVA 4w).
Figure 4 shows that malaria CD8 T cell ELISPOT and CTL
levels are substantially boosted by a recombinant MVA immunisation following priming with a plasmid DNA encoding the same antigen. A and C. CD8+ T cell responses were measured in BALB/c mice using the y-s interferon ELISPOT assay on fresh splenocytes incubated for 18 h with the Kd restricted peptide SYIPSAEKI [SEQ ID NO: 67] from P. berghei CSP
and the Ld restricted peptide TPHPARIGL [SEQ ID NO: 69] from E. coli R-galactosidase. Note that the ELISPOT counts are presented on a logarithmic scale. B and D. Splenocytes from the same mice were also assayed in conventional StCr-release assays at an effector: target ration of 100:1 after 6 days of in vitro restimulation with the same peptides (1 g/ml).
The mice were immunised with plasmid DNA expressing either P. berghei CSP and TRAP, PbCSP alone, the malaria epitope cassette including the P. berghei CTL epitope (labelled pTH.M), or R-galactosidase. ELISPOT and CTL levels measured in mice 23 days after one DNA immunisation are shown in A and B respectively. The same assays were performed with animals that received additionally lx 10' ffu of recombinant MVA expressing the same antigen(s) two weeks after the primary immunisation. The ELISPOT and CTL levels in these animals are shown in C and D respectively. Each bar represents data from an individual animal.
Studies were also undertaken of the immunogenicity of the epitope string HM comprising both HIV and malaria epitopes in tandem.
Using this epitope string again the highest levels of CD8+ T cells and CTL
were generated in the spleen when using an immunisation with DNA
vaccine followed by an immunisation with a recombinant MVA vaccine (Table 4, Figure 5).
CA 02293692 1999-12-06 ^
Table 4 Immunogenicity of various DNA/MVA combinations as determined by ELISPOT assays Immunisation 1 lmmunisation 2 HIV epitope Malaria epitope None DNA-HM 70 60 100 10 None MVA-HM 422 128 212 94 Table 4 shows the results of ELISPOT assays performed to measure the levels of specific CD8+ T cells to HIV and malaria epitopes following different immunisation regimes of plasmid DNA and MVA as indicated. The numbers are spot-forming cells per million splenocytes. The HM epitope string is illustrated in figure 2. BALB/c mice were used in all cases. The malaria epitope was pb9 as in figures 2 and 3. The HIV
epitope was RGPGRAFVTI [SEQ ID NO: 51]. The immunisation doses were 50 g of plasmid DNA or 10' focus-forming units (ffu) of recombinant MVA. All immunisations were intramuscular. The interval between immunisations 1 and 2 was from 14-21 days in all cases.
Figure 5 shows the CTL responses induced in BALB/c mice to malaria and H1V epitopes by various immunisation regimes employing plasmid DNA and recombinant MVA. Mice were immunised intramuscularly as described in the legend to table 3 and in methods. High levels of CTL (>30% specific lysis at effector/target ration of 25:1) were observed to both the malaria and HIV epitopes only after priming with r _ _ _ ~
plasmid DNA and boosting with the recombinant MVA. The antigen used in this experiment is the HIV-malaria epitope string. The recombinant MVA
is denoted MVA.HM and the plasmid DNA expressing this epitope string is denoted pTH.HM. Levels of specific lysis at various effector to target ratios are shown. These were determined after 5 days in vitro restimulation of spienocytes with the two peptides pb9 and RGPGRAFVTI [SEQ ID NO:
51].
Comparison of numerous delivery systems for the induction of CTL was reported by Allsopp et al. (1996). Recombinant Ty-virus like i o particles (Ty-VLPs) and lipid-tailed malaria peptides both gave good CTL
induction but Ty-VLPs were better in that they required only a single immunising dose for good CTL induction. However, as shown here even two doses of Ty particles fail to induce significant protection against sporozoite challenge (Table 7, line 1). lmmunisation with a recombinant modified vaccinia Ankara virus encoding the circumsporozoite protein of P.
berghei also generates good levels of CTL. However, a much higher level of CD8+ T cell response is achieved by a first immunisation with the Ty-VI-P followed by a second immunisation with the MVA CS vaccine (Table 5).
Table 5 lmmunogenicity of various Ty-VLP/MVA combinations as determined by ELISPOT and CTL assays Immunisation I Immunisation 2 ELISPOT No %Specific Lysis Ty-CABDH Ty- CABDH 75 15 MVA.PbCSP MVA.PbCSP 38 35 Ty-CABDH MVA.PbCSP 225 42 Ty- CABDH MVA.HM 1930 nd CA 02293692 1999-12-06 ^
Table 5 Results of ELISPOT and CTL assays performed to measure the levels of specific CD8+ T cells to the malaria epitope pb9 following different immunisation regimes of Ty-VLPs and recombinant MVA virus as indicated. The CTL and ELISPOT data are from different experiments.
The ELISPOT levels (spots per million splenocytes) are measured on un-restimulated cells and the CTL activity, indicated as specific lysis at an effector to target ratio of 40:1, on cells restimulated with pb9 peptide in vitro for 5-7 days. Both represent mean levels of three mice. BALB/c mice were used in all cases. The immunisation doses were 50 g of Ty-VLP or 10' ffu (foci forming units) of recombinant MVA. All immunisations were intramuscular. The interval between immunisations 1 and 2 was from 14-21 days. MVA.HM includes cassettes CAB.
Priming of an immune response with DNA delivered by a gene gun and boosting with recombinant MVA
Immunogenicity and challenge.
The use of a gene gun to deliver plasmid DNA intradermally and thereby prime an immune response that could be boosted with recombinant MVA was investigated. Groups of BALB/c mice were immunised with the following regimen:
I) Three gene gun immunisations with pTH.PbCSP (4 mg per immunisation) at two week intervals II) Two gene gun immunisations followed by MVA i.v. two weeks later III) One intramuscular DNA immunisation followed by MVA i.v. two weeks later.
The immunogenicity of the three immunisation regimens was analysed using ELISPOT assays. The highest frequency of specific T cells was observed with two gene gun immunisations followed by an MVA i.v.
T =
boost and the intramuscular DNA injection followed an MVA i.v. boost (Figure 6).
Figure 6 shows the results of ELISPOT assays performed to measure the levels of specific CD8+ T cells to the malaria epitope pb9 s following different immunisation regimes. Groups of BALB/c mice (n= 3) were immunised as indicated (g.g. = gene gun). The time between all immunisations was 14 days. ELISPOT assays were done two weeks after the last immunisation.
10 CTL induction to the same antigen in different mouse strains To address the question whether the boosting effect described above in BALB/c mice with two CTL epitopes SYIPSAEKI [SEQ ID NO: 67]
derived from P. berghei CSP and RGPGRAFVTI [SEQ ID NO: 68] derived from HIV) is a universal phenomenon, two sets of experiments were is carried out. CTL responses to the influenza nucleoprotein were studied in five inbred mouse strains. In a first experiment three published murine CTL
epitopes derived from the influenza nucleoprotein were studied (see Table 3). Mice of three different H-2 haplotypes, BALB/c and DBA/2 (H-2d), C57BL/6 and 129 (H-2b); CBA/J (H-2k), were used. One set of animals was 20 immunised twice at two week intervals with the plasmid V1 J-NP encoding the influenza nucleoprotein. Another set of identical animals was primed with V1J-NP and two weeks later boosted intravenously with 106 ffu of MVA.NP, expressing influenza virus NP. The levels of CTL in individual mice were determined in a 51Cr-release assay with peptide re-stimulated 25 spienocytes. As shown in Figure 7, the DNA priming/MVA boosting immunisation regimen induced higher levels of lysis in all the mouse strains analysed and is superior to two DNA injections.
Figure 7 shows the CTL responses against influenza NP in different mouse strains. Mice of different strains were immunised twice two 30 weeks apart with a DNA vaccine V1 J-NP encoding for the influenza CA 02293692 1999-12-06 ^
nucleoprotein (open circles) or primed with the same DNA vaccine and two weeks later boosted with recombinant MVA expressing influenza virus nucleoprotein (closed circles). Two weeks after the last immunisation spienocytes were restimulated in vitro with the respective peptides (Table 3). The CTL activity was determined in a standard 51Cr-release assay with MHC class I-matched target cells.
CTL induction to different antigens in different mouse strains The effect of MVA boosting on plasmid DNA-primed immune to responses was further investigated using different antigens and different inbred mouse strains. Mice of different strains were immunised with different antigens using two DNA immunisations and compared with DNA/MVA immunisations. The antigens used were E. coli -galactosidase, the malaria/HIV epitope string, a murine tumour epitope string and P.
1s falciparum TRAP. Compared with two DNA immunisations the DNA-priming/MVA-boosting regimen induced higher levels of CTL in all the different mouse strains and antigen combinations tested (Figure 8).
Figure 8 shows CTL responses against different antigens induced in different inbred mouse strains. Mice were immunised with two 20 DNA vaccine immunisations two weeks apart (open circies) or primed with a DNA vaccine and two weeks later boosted with a recombinant MVA
expressing the same antigen (closed circles). The strains and antigens were: C57BL/6; P. falciparum TRAP in A. DBA/2; E.coli (3-galactosidase in B. BALB/c; HM epitope string CTL activity against malaria peptide (pb9) in C. DBA/2; HM epitope string CTL activity against pb9 in D. BALB/c; HM
epitope string CTL activity against HIV peptide in E. DBA/2; HM epitope string CTL activity against HIV peptide in F. BALB/c; tumour epitope string CTL activity against P1A-derived peptide in G. DBA/2; tumour epitope string CTL activity against P1A-derived peptide in H. Sequences of peptide 30 epitopes are shown in table 3. Each curve shows the data for an individual mouse.
T
Sporozoites can efficiently prime an immune response that is boostable by MVA
Humans living in malaria endemic areas are continuously exposed to sporozoite inoculations. Malaria-specific CTL are found in these naturally exposed individuals at low levels. To address the question whether low levels of sporozoite induced CTL responses can be boosted by MVA, BALB/c mice were immunised with irradiated (to prevent malaria infection) P. berghei sporozoites and boosted with MVA. Two weeks after the last immunisation splenocytes were re-stimulated and tested for lytic activity. Two injections with 50 or 300 + 500 sporozoites induced very low or undetectable levels of lysis. Boosting with MVA induced high levels of peptide specific CTL. MVA alone induced only moderate levels of lysis (Figure 9).
Figure 9 shows sporozoite-primed CTL responses are substantially boosted by MVA. Mice were immunised with two low doses (50 + 50) of irradiated sporozoites in A. two high doses (300 +500) of sporozoites in B; mice were boosted with MVA.PbCSP following low-dose sporozoite priming in D; high dose sporozoite priming in E. CTL responses following immunisation with MVA.PbCSP are shown in C.
Recombinant adenoviruses as priming agent The prime-boost immunisation regimen has been exemplified using plasmid DNA and recombinant Ty-VLP as priming agent. Here an example using non-replicating adenoviruses as the priming agent is provided. Replication-deficient recombinant Adenovirus expressing E. coli (3-galactosidase (Adeno-GAL) was used. Groups of BALB/c mice were immunised with plasmid DNA followed by MVA or with Adenovirus followed by MVA. All antigen delivery systems used encoded E. coli R-galactosidase. Priming a CTL response with plasmid DNA or Adenovirus and boosting with MVA induces similar levels of CTL (Figure 10).
CA 02293692 1999-12-06 ^
Figure 10 shows CTL responses primed by plasmid DNA or recombinant Adenovirus and boosted with MVA . Groups of BALB/c mice (n=3) were primed with plasmid DNA A or recombinant Adenovirus expressing R-galactosidase B. Plasmid DNA was administered intramuscularly, MVA intravenously and Adenovirus intradermally.
Spienocytes were restimulated with peptide TPHPARIGL [SEQ ID NO: 69]
two weeks after the last immunisation. CTL activity was tested with peptide-pulsed P815 cells.
Immunogenicity of the DNA prime vaccinia boost regimen depends on the replication competence of the strain of vaccinia virus used The prime boosting strategy was tested using different strains of recombinant vaccina viruses to determine whether the different strains with strains differing in their replication competence may differ in their is ability to boost a DNA-primed CTL response. Boosting with replication-defective recombinant vaccinia viruses such as MVA and NYVAC resulted in the induction of stronger CTL responses compared to CTL responses following boosting with the same dose of replication competent WR
vaccinia virus (Figure 11).
Figure 11 shows CTL responses in BALB/c mice primed with plasmid DNA followed by boosting with different recombinant vaccinia viruses. Animals were primed with pTH.PbCSP 50 g/mouse i.m. and two weeks later boosted with different strains of recombinant vaccina viruses (106 pfu per mouse i.v.) expressing PbCSP. The different recombinant 2-5 vaccinia virus strains were MVA in A; NYVAC in B and WR in C. The superiority of replication-impaired vaccinia strains over replicating strains was found in a further experiment. Groups of BALB/c mice (n = 6) were primed with 50 g/animal of pSG2.PbCSP (i.m.) and 10 days later boosted i.v. with 106 ffu/pfu of recombinant MVA, NYVAC and WR expressing PbCSP. The frequencies of peptide-specific CD8+ T cells were determined using the ELISPOT assay. The frequencies were: MVA 1103 .__..._. ..T. _ +/- 438, NYVAC 826 +/- 249 and WR 468 +/- 135. Thus using both CTL
assays and ELISPOT assays as a measure of CD8 T celf immunogenicity a surprising substantially greater immunogenicity of the replication-impaired vaccinia strains was observed compared to the replication competent strain.
The use of recombinant canary or fowl pox viruses for boosting CD8+
T ce11 responses Recombinant canary pox virus (rCPV) or fowl pox virus (rFVP) are made using shuttle vectors described previously (Taylor et al.
Virology 1992, 187: 321-328 and Taylor et al. Vaccine 1988, 6: 504-508).
The strategy for these shuttle vectors is to insert the gene encoding the protein of interest preceded by a vaccinia-specific promoter between two flanking regions comprised of sequences derived from the CPV or FPV
is genome. These flanking sequences are chosen to avoid insertion into essential viral genes. Recombinant CPV or FPV are generated by in vivo recombination in permissive avian cell lines i.e. primary chicken embryo fibroblasts. Any protein sequence of antigens or epitope strings can be expressed using fowl pox or canary pox virus. Recombinant CPV or FPV
is characterised for expression of the protein of interest using antigen-specific antibodies or including an antibody epitope into the recombinant gene. Recombinant viruses are grown on primary CEF. An immune response is primed using plasmid DNA as described in Materials and Methods. This plasmid DNA primed immune response is boosted using 10' ffu/pfu of rCPV or rFPV inoculated intravenously, intradermally or intramuscularly. CD8+ T cell responses are monitored and challenges are performed as described herein.
CA 02293692 1999-12-06 ^
Malaria Challenge Studies in Mice To assess the protective efficacy of the induced levels of CD8+ T cell response immunised BALB/c or C57BL/6 mice were 5 challenged by intravenous injection with 2000 or 200 P. berghei sporozoites. This leads to infection of liver cells by the sporozoites.
However, in the presence of a sufficiently strong T lymphocyte response against the intrahepatic parasite no viable parasite will leave the liver and no blood-stage parasites will be detectable. Blood films from challenged 10 mice were therefore assessed for parasites by microscopy 5-12 days following challenge.
BALB/c mice immunised twice with a mixture of two plasmid DNAs encoding the CS protein and the TRAP antigen, respectively, of P.
berghei were not protected against sporozoite challenge. Mice immunised 15 twice with a mixture of recombinant MVA viruses encoding the same two antigens were not protected against sporozoite challenge. Mice immunised first with the two recombinant MVAs and secondly with the two recombinant plasmids were also not protected against sporozoite challenge. However, all 15 mice immunised first with the two plasmid 2o DNAs and secondly with the two recombinant MVA viruses were completely resistant to sporozoite challenge (Table 6 A and B).
To assess whether the observed protection was due to an immune response to the CS antigen or to TRAP or to both, groups of mice were then immunised with each antigen separately (Table 6 B). All 10 25 mice immunised first with the CS plasmid DNA and secondly with the CS
MVA virus were completely protected against sporozoite challenge.
Fourteen out of 16 mice immunised first with the TRAP plasmid DNA
vaccine and secondly with the TRAP MVA virus were protected against sporozoite challenge. Therefore the CS antigen alone is fully protective when the above immunisation regime is employed and the TRAP antigen is substantially protective with the same regime.
The good correlation between the induced level of CD8+ T
lymphocyte response and the degree of protection observed strongly > suggests that the CD8+ response is responsible for the observed protection. In previous adoptive transfer experiments it has been demonstrated that CD8+ T lymphocyte clones against the major CD8+ T
cell epitope in the P. berghei CS protein can protect against sporozoite challenge. To determine whether the induced protection was indeed mediated by CDB+ T cells to this epitope we then employed a plasmid DNA and a recombinant MVA encoding only this nine amino acid sequence from P. berghei as a part of a string of epitopes (Table 6 B). (All the other epitopes were from micro-organisms other than P. berghei).
Immunisation of 10 mice first with a plasmid encoding such an epitope t~ string and secondly with a recombinant MVA also encoding an epitope string with the P. berghei CTL epitope led to complete protection from sporozoite challenge (Table 6 B). Hence the induced protective immune response must be the CTL response that targets this nonamer peptide sequence.
CA 02293692 1999-12-06 =
Table 6 Results of mouse challenge experiments using different combinations of DNA and MVA vaccine Immunisation 1 Immunisation 2 No. Infected/ %Protection No. challenged A. Antigens used: PbCSP + PbTRAP
DNA DNA 5/5 0%
MVA MVA 9/10 10%
DNA MVA 0/5 100%
MVA DNA 5/5 0%
Control mice immunised with p-galactosidase DNA DNA 5/5 0%
MVA MVA 5/5 0%
DNA MVA 5/5 0%
MVA DNA 5/5 0%
B.
DNA (CSP +TRAP) MVA (CSP +TRAP) 0/10 100%
DNA (CSP) MVA (CSP) 0/10 100%
DNA (TRAP) MVA (TRAP) 2/16 88%
DNA (epitope) MVA (epitope) 0/11 100%
DNA (beta-gal) MVA (beta-gal) 6/7 14%
none none 9/10 10%
Table 6 Results of two challenge experiments (A and B) using different immunisation regimes of plasmid DNA and MVA as indicated.
BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 ffu of recombinant MVA. The interval between 3o immunisations 1 and 2 was from 14-21 days in all cases. Challenges were performed at 18-29 days after the last immunisation by i.v. injection of 2000 P. berghei sporozoites and blood films assessed at 5, 8 and 10 days post challenge. CSP and TRAP indicate the entire P. berghei antigen and epitope' indicates the cassettes of epitopes shown in table 1 containing T
only a single P. berghei K~-restricted nonamer CTL epitope. Note that in experiment B immunisation with the epitope string alone yields 100%
protection Mice immunised twice with recombinant Ty-VLPs encoding pb9 were fully susceptible to infection. Similarly mice immunised twice with the recombinant MVA encoding the full CS protein were fully susceptible to infection. However, the mice immunised once with the Ty-VLP and subsequently once with the recombinant MVA showed an 85% reduction in malaria incidence when boosted with MVA expressing the full length CS
protein, and 95% when MVA expressing the HM epitope string which includes pb9 was used to boost (Table 7).
Table 7 Results of challenge experiments using different immunisation regimes of Ty-VLPs and MVA
Imrnunisation I Immunisation 2 No. Infected/No.challenged %Protection Ty-CABDHFE Ty- CABDHFE 7/8 13%
Ty-CABDH MVA.PbCSP 2/13 85%
Ty- CABDHFE MVA-NP 5/5 0%
MVA.PbCSP MVA.PbCSP 6/6 0%
MVA.HM Ty- CABDHFE 14/14 0%
Ty=- CABDHFE MVA.HM 1/21 95%
none MVA.HM 8/8 0%
none none 11/12 9%
Table 7 Results of challenge experiments using different immunisation regimes of Ty-VLPs and MVA as indicated. BALB/c mice were used in all cases. Immunisations were of 50 g of Ty-VLP or 10' ffu of recombinant MVA administered intravenously. The interval between immunisations 1 and 2 was from 14-21 days in all cases. Challenges were performed at 18-29 days after the last immunisation by i.v. injection of CA 02293692 1999-12-06 ^
2000 P. berghei sporozoites and blood films assessed at 5, 8 and 10 days post challenge. CSP indicates the entire P. berghei antigen. Ty-VLPs carried epitope cassettes CABDH or CABDHFE as described in table 1.
MVA.HM includes cassettes CAB.
s To determine whether the enhanced immunogenicity and protective efficacy observed by boosting with a recombinant MVA is unique to this particular vaccinia virus strain or is shared by other recombinant vaccinias the following experiment was performed. Mice were immunised with the DNA vaccine encoding P. berghei CS protein and boosted with either (i) recombinant MVA encoding this antigen; (ii) recombinant wild-type vaccinia virus (Western Reserve strain) encoding the same antigen (Satchidanandam et al. 1991), or (iii) recombinant NYVAC (COPAK) virus (Lanar et al. 1996) encoding the same malaria antigen. The highest degree of protection was observed with boosting by the MVA recombinant, 1s 80% (Table 8). A very low level of protection (10%) was observed by boosting with the wild-type recombinant vaccinia virus and a significant level of protection, 60%, by boosting with the NYVAC recombinant. Hence the prime-boost regime we describe induces protective efficacy with any non-replicating vaccinia virus strain. Both the MVA recombinant and 2o NYVAC were significantly (P <0.05 for each) better than the WR strain recombinant.
Table 8 Challenge data results for DNA boosted with various vaccinia strain recombinants.
Immunisation 1 Immunisation 2 No. Infected/No. challenged %Protection DNA-beta gal. MVA.NP 8/8 0%
DNA-CSP MVA-CSP 2/10 80%
DNA-CSP WR-CSP 9/10 10%
DNA-CSP NYVAC-CSP 4/10 60%
7_ lff' Table 8 Results of a challenge experiment using different immunisation regimes of plasmid DNA and various vaccinia recombinants as indicated. BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 ffu/pfu of recombinant MVA or s 10 ffu/pfu of recombinant wild type (WR) vaccinia or 106 ffu/pfu of recombinant NYVAC. Because the WR strain will replicate in the host and the other strains will not, in this experiment a lower dose of WR was used.
The interval between immunisations 1 and 2 was 23 days. Challenges were performed at 28 days after the last immunisation by i.v. injection of t o 2000 P. berghei sporozoites and blood films assessed at 7, 9 and 11 days post challenge. pbCSP indicates the entire P. berghei antigen and NP the nucleoprotein antigen of influenza virus (used as a control antigen). The first immunisation of group A mice was with the plasmid DNA vector expressing beta galactosidase but no malaria antigen.
>> In a further experiment shown in Table 8, mice were immunised with the DNA vaccine encoding P. berghei CS protein and boosted with either (i) recombinant MVA encoding this antigen; (ii) recombinant WR vaccinia virus encoding the same antigen or (iii) recombinant NYVAC (COPAK) virus encoding the same malaria antigen, 2o all at 106 ffu/pfu. A high and statistically significant degree of protection was observed with boosting with recombinant NYVAC (80%) or recombinant MVA (66%). A low and non-significant level of protection (26%) was observed by boosting with the WR recombinant vaccinia virus (Table 9). MVA and NYVAC boosting each gave significantly more 2> protection than WR boosting (P = 0.03 and P = 0.001 respectively). These data re-emphasise that non-replicating pox virus strains are better boosting agents for inducing high levels of protection.
CA 02293692 1999-12-06 =
Table 9 Influence of different recombinant vaccinia strains on protection.
Immunisation 1 Immunisation No. inf./ o DNA 2 No. chall. protection CSP MVA.PbCSP 5/15 66 CSP NYVAC.PbCSP 2/15 80 CSP WR.PbCSP 11/15 26 galactosidase MVA.NP 8/8 0 Table 9 Results of challenge experiments using different immunisation regimes of plasmid DNA and replication incompetent vaccinia recombinants as boosting immunisation. BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 -o ffu/pfu of recombinant MVA or recombinant wild type (WR) vaccinia or recombinant NYVAC. The interval between immunisations 1 and 2 was 23 days. Challenges were performed at 28 days after the last immunisation by i.v. injection of 2000 P. berghei sporozoites and blood films assessed at 7, 9 and 11 days post challenge. PbCSP indicates the entire P. berghei antigen and NP the nucleoprotein antigen of influenza virus (used as a control antigen). The control immunisation was with a plasmid DNA vector expressing P-gatactosidase followed by MVA.NP.
Alternative routes for boosting immune responses with recombinant MVA
Intravenous injection of recombinant MVA is not a preferred route for immunising humans and not feasible in mass immunisations.
T _ T
Therefore different routes of MVA boosting were tested for their immunogenicity and protective efficacy.
Mice were primed with plasmid DNA i.m. Two weeks later they were boosted with MVA administered via the following routes: intravenous (i.v.), s subcutaneous (s.c.), intraperitoneal (i.p.), intramuscular (i.p.) and intradermal (i.d.). Two weeks after this boost peptide-specific CD8+ T cells were determined in an ELISPOT assay. The most effective route which induced the highest levels were i.v. and i.d inoculation of MVA. The other routes gave moderate to poor responses (Figure 12).
io Figure 12 shows frequencies of peptide-specific CD8+ T cells following different routes of MVA boosting. Results are shown as the number of spot-forming cells (SFC) per one million splenocytes. Mice were primed with plasmid DNA and two weeks later boosted with MVA via the indicated routes. The number of splenocytes specific for the SYIPSAEKI
15 [SEQ ID NO: 671 peptide was determined in INF-y ELISPOT assays two weeks after the last immunisation. Each bar represents the mean number of SFCs from three mice assayed individually.
Boosting via the i.v. route was compared with the i.d. and i.m route in a challenge experiment. The i.d route gave high levels of 20 protection (80% protection). In the group of animals that were boosted via the i.m. route, 50% of the animals were protected. Complete protection was achieved with MVA boost administered i.v. (Table 10) Table 10 Influence of the route of MVA administration on protective 25 efficacy Irnmunisation Immunisation No. infected/ %
1 2 No. protection DNA MVA challenged CSP CSP i.v. *0/20 100 CSP CSP i.d 2/10 80 CSP CSP i.m. 5/10 50 CA 02293692 1999-12-06 ^
Epitope epitope i.v. 1/10 90 NP NP i.v. 10/10 0 ' culminative data from two independent experiments Table 10 Results from challenge experiments using different routes of MVA boosting immunisation. Animals were primed by intramuscular plasmid DNA injection and two weeks later boosted with the indicated recombinant MVA (106 ffu/mouse) administered via the routes indicated.
The mice were challenged 16 days after the last immunisation with 2000 P.
berghei sporozoites and screened for blood stage parasitemia at day 8 and post challenge. Epitope indicates the polypeptide string HM.
Alternative routes of DNA priming: The use of a gene gun to prime peptide specific CD8+ T cells Gene gun deiivery is described in detail in for example in Eisenbraun et al. DNA Cell Biol. 1993, 12: 791-797 and Degano et al.
1-5 Vaccine 1998, 16: 394-398.
The mouse malaria challenge experiments described so far using plasmid DNA to prime an immune response used intramuscular injection of plasmid DNA. Intradermal delivery of plasmid DNA using a biolistic device is another route to prime specific CTL responses. Plasmid DNA is coated onto gold particles and delivered intradermally with a gene gun. Groups of mice (n=10) were immunised three times at two weeks intervals with the gene gun alone (4 g/immunisation), immunised two times with the gene gun followed by an intravenous MVA.PbCSP boost or immunised intramuscularly with 50 g of pTH.PbCSP and two weeks later boosted with MVA.PbCSP intravenously. Two weeks after the last immunisation the animals were challenged with 2000 sporozoites to assess protective efficacy of each immunisation regimen. In the group that received the intravenous MVA boost following two gene gun immunisations T =
one out of ten animals developed blood stage parasitemia (90%
protection). Complete protection was observed with intramuscular DNA
priming followed by MVA i.v boosting. Seven out of 10 animals that were immunised three times with the gene gun were infected. (30% protection) (Table 11).
lnununisation I lmmunisation 2 Immunisation 3 No. inf./ %
DNA No. protection chall.
gene gun DNA ~ene gun DNA gene gtni DNA 7/10 30 gene gun DNA gene gun DNA MVA.PbCSP 1/10 90 DNA i.m MVA.PbCSP 0/10 100 Na'ive 10/10 0 Table 11 Results of challenge experiments comparing different routes io of DNA priming (intradermally by gene gun versus intramuscular needle injection). Groups of BALB/c mice (n=10) were immunised as indicated.
Each gene gun immunisation delivered 4 g of plasmid DNA
intraepidermally. For i.m. immunisations 50 g of plasmid DNA were injected. Twenty days after the last immunisation mice were challenged as described previously.
Highly susceptible C57BU6 mice are protected C57BL/6 mice are very susceptible to P. berghei sporozoite challenge.
C57BL/6 mice were immunised using the DNA-MVA prime boost regime with both pre-erythrocytic antigens PbCSP and PbTRAP, and challenged with either 200 or 1000 infectious sporozoites per mouse. (Two hundred sporozoites corresponds to more than twice the dose required to induce infection in this strain). All ten mice challenged with 200 sporozoites showed sterile immunity. Even the group challenged with 1000 CA 02293692 1999-12-06 ^
sporozoites, 60% of the mice were protected (Table 12). All the naive C57BL/6 mice were infected after challenge.
Table 12 Protection of C57BL/6 mice from sporozoite challenge 5 No. animals inf./ %
No. challenged protection 1000 sporozoites DNA followed by MVA 4/10 60 Naive 5/5 0 io 200 sporozoites DNA followed by MVA 0/10 100 Na'ive 5/5 0 15 Table 12 Results of a challenge experiment using C57BL/6 mice.
Animals were immunised with PbCSP and PbTRAP using the DNA
followed by MVA prime boost regime. Fourteen days later the mice were challenged with P. berghei sporozoites as indicated.
2o EXAMPLE 4 Protective efficacy of the DNA-priming/MVA-boosting regimen in two further disease models in mice Following immunogenicity studies, the protective efficacy of the DNA-priming MVA-boosting regimen was tested in two additional murine 25 challenge models. The two challenge models were the P815 tumour model and the influenza A virus challenge model. In both model systems CTL
have been shown to mediate protection.
P815 tumour challenges:
3o Groups (n = 10) of DBA/2 mice were immunised with a combination of DNA
followed by MVA expressing a tumour epitope string or the HM epitope r _ string. Two weeks after the last immunisation the mice were challenged intravenously with 105 P815 cells. Following this challenge the mice were monitored regularly for the development of tumour-related signs and survival.
Figure 13 shows the survival rate of the two groups of mice.
Sixty days after challenge eight out of ten mice were alive in the group immunised with the tumour epitopes string. In the group immunised with the HM epitope string only 2 animals survived. This result is statistically significant: 2/10 vs 8/10 chi-squared = 7.2. P = 0.007. The onset of death in the groups of animals immunised with the tumour epitope string is delayed compared to the groups immunised with the HM epitope string.
Influenza virus challenges:
Groups of BALB/c mice were immunised with three gene gun immunisations with plasmid DNA, two intramuscular plasmid DNA
injections, one i.m. DNA injection followed by one MVA.NP boost i.v. or two gene gun immunisations followed by one MVA.NP boost i.v. Plasmid DNA
and recombinant MVA expressed the influenza virus nucleoprotein. Two weeks after the last immunisation the mice were challenged intranasally with 100 HA of influenza A/PRI8/34 virus. The animals were monitored for survival daily after challenge.
Complete protection was observed in the following groups of animals = two DNA gene gun immunisations followed by one MVA.NP boost i.v., = one i.m. DNA injection followed by one MVA.NP boost i.v.
= two i.m. DNA injections.
In the group of animals immunised three times with the gene gun 71 % of the animals survived (5/7) and this difference from the control group was not significant statistically (P > 0.05). In the naive group 25% of the animals survived (Figure 14) and this group differed significantly (P <
0.05) for the two completely protected groups.
CA 02293692 1999-12-06 =
Figure 14 shows results of an influenza virus challenge experiment. BALB/c mice were immunised as indicated. GG = gene gun immunisations, im = intramuscular injection, iv = intravenous injection.
Survival of the animals was monitored daily after challenge.
In a second experiment groups of 10 BALB/c mice were immunised with MVA.NP i.v. alone, three times with the gene gun, two times with the gene gun followed by one MVA.NP boost i.v. and two i.m injections of V1J-NP followed by one MVA.NP boost. Two weeks after the last immunisation the mice were challenged with 100 HA units of influenza A/PR/8/34 virus.
Complete and statistically significant protection was observed in the following groups of animals:
= two gene gun immunisations followed by one MVA.NP boost, = two i.m injections of V1J-NP followed by one MVA.NP boost.
25 In the group receiving one MVA.NP i.v., 30% (3 out of 10) of animals survived. In the group immunised with a DNA vaccine delivered by the gene gun three times, 70% of the animals were protected but this protection was not significantly different from the na'ive controls. In this challenge experiment 40% (4 out of 10) of the naive animals survived the challenge.
Immunogenicity studies in non-human primates 2> lmmunogenicity and protective efficacy of the prime boost regimen in non-human primates.
In order to show that the strong immunogenicity of the DNA
priming/MVA boosting regime observed in mice translates into strong immunogenicity in primates, the regimen was tested in macaques. The vaccine consisted of a string of CTL epitopes derived from HIV and SIV
sequences (Figure 2), in plasmid DNA or MVA, denoted DNA.H and MVA.H respectively. The use of defined CTL epitopes in a polyepitope string allows testing for SIV specific CTL in macaques. Due to the MHC
class I restriction of the antigenic peptides, macaques were screened for their MHC class I haplotype and Mamu-A*01-positive animals were selected for the experiments described.
Three animals (CYD, Di and DORIS) were immunised following this immunisation regimen:
week 0 DNA (8 g, i.d., gene gun) io week 8 DNA (8 g, i.d., gene gun) week 17 MVA (5 x 10$ pfu, i.d.) week 22 MVA (5 x 108 pfu, i.d.) Blood from each animal was drawn at weeks 0, 2, 5, 8, 10, 11, 17, 18, 19, 21, 22, 23, 24 and 25 of the experiment. The animals were monitored for induction of CTL using two different methods. PBMC isolated from each bleed were re-stimulated in vitro with a peptide encoded in the epitope string and tested for their ability to recognise autologous peptide-loaded target cells in a chromium release cytotoxicity assay. Additionally, freshly isolated PBMC were stained for antigen specific CD8+ T cells using tetramers.
Following two gene gun immunisations very low levels of CTL
were detected using tetramer staining (Figure 15). Two weeks after the first MVA boosting, all three animals developed peptide specific CTL as 2~ detected by tetramer staining (Figure 15). This was reflected by the detection of moderate CTL responses following in vitro restimulation (Figure 16, week 19). The second boost with MVA.H induced very high levels of CD8+, antigen specific T cells (Figure 15) and also very high levels of peptide specific cytotoxic T cells (Figure 16, week 23).
Figure 15 shows detection of SIV-specific MHC class I-restricted CD8+ T cells using tetramers. Three Mamu-A"`A01-positive CA 02293692 1999-12-06 ^
macaques were immunised with plasmid DNA (gene gun) followed by MVA
boosting as indicated. Frequencies of Mamu-A*A01/CD8 double-positive T
cells were identified following FACS analysis. Each bar represents the percentage of CD8+ T cells specific for the Mamu-A*01/gag epitope at the s indicated time point. One percent of CD8 T cells corresponds to about 5000/106 peripheral blood lymphocytes. Thus the levels of epitope-specific CD8 T cells in the peripheral blood of these macaques are at least as high as the levels obvserved in the spleens of immunised and protected mice in the malaria studies.
Figure 16 shows CTL induction in macaques following DNA/MVA immunisation. PBMC from three different macaques (CYD, DI
and DORIS) were isolated at week 18, 19 and 23 and were restimulated with peptide CTPYDINQM [SEQ ID NO: 54] in vitro. After two restimulations with peptide CTPYDINQM [SEQ ID NO: 54] the cultures were tested for their lytic activity on peptide-pulsed autologous target cells.
Strong CTL activity was observed.
lmmunogenicity and Challenge Studies in Chimpanzees To show that a similar regime of initial immunisation with plasmid DNA and subsequent immunisation with recombinant MVA can be effective against Plasmodium falciparum malaria in higher primates an immunisation and challenge study was performed with two chimpanzees.
Chimp H1 received an initial immunisation with 500 g of a plasmid expressing Plasmodium faiciparum TRAP from the CMV promoter without intron A, CMV-TRAP. Chimp H2 received the same dose of CMV-LSA-1, which expresses the C-terminal portion of the LSA-1 gene of P. falciparum.
Both chimps received three more immunisations over the next 2 months, but with three plasmids at each immunisation. H1 received CMV-TRAP as before, plus pTH-TRAP, which expresses TRAP using the CMV promoter T _,._... _....._...__. _ _ with intron A, leading to a higher expression level. H1 also received RSV-LSA-1, which expresses the C-terminal portion of LSA-1 from the RSV
promoter. H2 received CMV-LSA-1, pTH-LSA-1 and RSV-TRAP at the second, third and fourth immunisations. The dose was always 500 FLg of 5 each plasmid.
It was subsequently discovered that the RSV plasmids did not express the antigens contained within them, so H1 was only immunised with plasmids expressing TRAP, and H2 with plasmids expressing LSA-1.
10 Between and following these DNA immunisations assays of cellular immune responses were performed at several time points, the last assay being performed at three months following the fourth DNA
immunisation, but no malaria-specific T cells were detectable in either ELISPOT assays or CTL assays for CD8+ T cells.
15 Both animals were subsequently immunised with three doses of 108 ffu of a recombinant MVA virus encoding the P. falciparum TRAP
antigen over a 6 week period. Just before and also following the third recombinant MVA immunisation T cell responses to the TRAP antigen were detectable in both chimpanzees using an ELISPOT assay to whole 2o TRAP protein bound to latex beads. This assay detects both CD4+ and CD8+ T cell responses. Specific CD8+ T responses were searched for with a series of short 8-11 amino acid peptides in both immunised chimpanzees. Such analysis for CD8+ T cell responses indicated that CD8+ T cells were detectabie only in the chimpanzee H1. The target 25 epitope of these CD8+ T lymphocytes was an 11 amino acid peptide from TRAP, tr57, of sequence KTASCGVWDEW [SEQ ID NO: 781. These CD8+ T cells from H1 had lytic activity against autologous target cells pulsed with the tr57 peptide and against autologous target cells infected with the recombinant PfTRAP-MVA virus. A high precursor frequency of 30 these specific CD8+ T cells of about 1 per 500 lymphocytes was detected CA 02293692 1999-12-06 ^
in the peripheral blood of this chimpanzee H1 using an ELISPOT assay two months following the final MVA immunisation. No specific CD8+ T cell response was clearly detected in the chimpanzee H2, which was not primed with a plasmid DNA expressing TRAP.
Two months after the third PfTRAP-MVA immunisation challenge of H1 and H2 was performed with 20,000 sporozoites, a number that has previously been found to yield reliably detectable blood stage infection in chimpanzees 7 days after challenge (Thomas et al. 1994 and unpublished data). The challenge was performed with the NF54 strain of Plasmodium falciparum. This is of importance because the TRAP
sequence in the plasmid DNA and in the recombinant MVA is from the T9/96 strain of P. falciparum which has numerous amino acid differences to the NF54 TRAP allele (Robson et al. 1990). Thus, this sporozoite challenge was performed with a heterologous rather than homologous strain of parasite. In the chimpanzee H2 parasites were detectable in peripheral blood as expected 7 days after sporozoite challenge using in v i t r o parasite culture detection. However, in H 1 the appearance of blood stage parasites in culture from the day 7 blood samples was delayed by three days consistent with some immune protective effect against the liver-stage infection. In studies of previous candidate malaria vaccines in humans a delay in the appearance of parasites in the peripheral blood has been estimated to correspond to a substantial reduction in parasite density in the liver (Davis et al. 1989). Thus the chimpanzee HI, immunised first with P. falciparum TRAP plasmid DNA and subsequently with the same antigen expressed by a recombinant MVA virus showed a strong CD8+ T
lymphocyte response and evidence of some protection from heterologous sporozoite challenge.
i DISCUSSION
These examples demonstrate a novel regime for immunisation against malaria which induces high levels of protective CD8+
T cells in rodent models of human malaria infection. Also demonstrated is ~ an unprecedented complete protection against sporozoite challenge using subunit vaccines (36 out of 36 mice protected in Table 6 using DNA
priming and MVA boosting with the CS epitope containing vaccines).
Induction of protective immune responses using the DNA priming/MVA
boosting regimen was demonstrated in two additional mouse models of io viral infection influenza A model and cancer (P815 tumour model). More importantly for vaccines for use in humans this immunisation regimen is also highly immunogenic for CD8+ T cells in primates. Strong SIV-gag-specific CTL were induced in 3 out of 3 macaques with plasmid DNA and MVA expressing epitope strings. The levels induced are comparable to t 5 those found in SIV-infected animals. The data from the chimpanzee studies indicate that the same immunisation regime can induce a strong CD8+ T lymphocyte response against P. falciparum in higher primates with some evidence of protection against P. falciparum sporozoite challenge.
Ty-VLPs have previously been reported to induce good levels 20 of CD8+ T cell responses against the P. berghei rodent malaria (Allsopp et al. 1995) but alone this construct is not protective. It has now been found that subsequent immunisation with recombinant MVA boosts the CD8+ T
cell response very substantially and generates a high level of protection (Table 7).
25 Recombinant MVA viruses have not been assessed for efficacy as malaria vaccines previously. Recombinant MVA alone was not significantly protective, nor was priming with recombinant MVA followed by a second immunisation with recombinant plasmid DNA. However, a second immunisation with the recombinant MVA following an initial 30 immunisation with either Ty-VLPs or plasmid DNA yielded impressive CA 02293692 1999-12-06 =
levels of protection. Non-recombinant MVA virus has been safely used to vaccinate thousands of human against smallpox and appears to have an excellent safety profile. The molecular basis of the increased safety and immunogenicity of this strain of vaccinia virus is being elucidated by detailed molecular studies (Meyer et al. 1991; Sutter at al. 1994).
Plasmid DNA has previously been tested as a malaria vaccine for the P. yoelii rodent malaria. High levels of, but not complete, protection is seen in some strains but in other strains of mice little or no protection was observed even after multiple immunisations (Doolan et al.
1996). Although plasmid DNA has been proposed as a method of immunisation against P. falciparum, success has not previously been achieved. The evidence provided here is the first evidence to show that plasmid DNA may be used in an immunisation regime to induce protective immunity against the human malaria parasite P. falciparum.
A similar regime of immunisation to the regime demonstrated herein can be expected to induce useful protective immunity against P.
falciparum in humans. It should be noted that five of the vaccine constructs employed in these studies to induce protective immunity in rodents or chimpanzees contain P. falciparum sequences and could therefore be used for human immunisation against P. falciparum. These are: 1. The P. falciparum TRAP plasmid DNA vaccine. 2. The P.
falciparum TRAP recombinant MVA virus. 3. The Ty-VLP encoding an epitope string of numerous P falciparum epitopes, as well as the single P.
berghei CTL epitope. 4. The plasmid DNA encoding the same epitope string as 3. 5. The recombinant MVA encoding the longer HM epitope string including many of the malaria epitopes in 3 and 4. Similarly the plasmid DNAs and MVA encoding HIV epitopes for human class I
molecules could be used in either prophylactic or therapeutic immunisation against HIV infection.
T ._..._. .. .... _._.._.._~-...._a_....----..... ... ... ....... .. r These studies have provided clear evidence that a novel sequential immunisation regime employing a non-replicating or replication-impaired pox virus as a boost is capable of inducing a strong protective CD8+ T cell response against the malaria parasite. The examples demonstrate clearly a surprising and substantial enhancement of CD8+ T
cell responses and protection compared to replicating strains of pox viruses. Because there is no reason to believe that the immunogenicity of CD8+ T cell epitopes from the malaria parasite should differ substantially from CD8+ T cell epitopes in other antigens it is expected that the immunisation regime described herein will prove effective at generating CD8+ T cell responses of value against other diseases. The critical step in this immunisation regimen is the use of non-replicating or replication-impaired recombinant poxviruses to boost a pre-existing CTL response.
We have shown that CTL responses can be primed using different antigen delivery systems such as a DNA vaccine i.d. and i.m, a recombinant Ty-VLP, a recombinant adenovirus and irradiated sporozoites. This is supported by the data presented on the generation of a CD8+ T cell response against HIV, influenza virus and tumours. Amongst several known examples of other diseases against which a CD8+ T cell immune response is important are the following: infection and disease caused by the viruses HIV, herpes simplex, herpes zoster, hepatitis C, hepatitis B, influenza, Epstein-Barr virus, measles, dengue and HTLV-1; by the bacteria Mycobacterium tuberculosis and Listeria sp.; and by the protozoan parasites Toxoplasma and Trypanosoma. Induction of protective CTL
responses against influenza A virus has been demonstrated in Figure 14.
Furthermore, the immunisation regime described herein is expected to be of value in immunising against forms of cancer where CD8+ T cell responses plays a protective role. The induction of protective CTL
responses using the DNA prime MVA boost regime against tumours is CA 02293692 1999-12-06 ^
shown in Figure 13. Specific examples in humans include melanoma, cancer of the breast and cancer of the colon.
References s 1. Nardin EH & Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annual Review of Immunology (1993) 11: 687-727.
io 2. Hill AVS, Allsopp, CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM. (1991) Common West African HLA antigens are associated with protection from severe malaria. Nature 352: 595-600 3. Aidoo M, Lafvani A, Allsopp CEM, et al. Identification of conserved 1s antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. The Lancet. (1995) 345: 1003-1007.
4. Wizel B, Houghten RA, Parker KC, Coligan JE, Church P, Gordon DM, Ballou WR, Hoffman SL. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two 20 overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J. Exp Med. (1995) 182: 1435-45.
5. Lalvani A, Aidoo M, Allsopp CE, Plebanski M, Whittle HC, Hill AV. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Research in Immunology (1994) 25 145: 461-8.
6. Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and 30 CD8+ T cells. J. Exp. Med. (1994) 180: 353-8.
T i 7. Thomas AW, Slierendregt B, Mons B, Druilhe P. Chimpanzees and supporting models in the study of malaria pre-erythrocytic stages.
Mem. Inst. Oswaldo Cruz. (1994) 89 Suppl 2: 111-4.
8. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci USA. (1994) 91:
9. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. Priming with recombinant influenza io virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.
Proc. Natl. Acad. Sci. USA. (1993) 90: 5214-8.
10. Lanar DE, Tine JA, de-Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and Immunity (1996) 64: 1666-71.
11.Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo et al.
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 279: 2103-6 12. Ada G. Do cytotoxic T lymphocytes clear some HIV/SIV infections?
Journal of Medical Primatology (1996) 25: 158-62.
13. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, 2 5 Silvera P, Dennis M, Corcoran T, Stott J et-al Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine (1995) 1: 1167-73.
14. Mayr A, Hochstein-Mintzel V, Sticki H. Infection (1975) 33: 6-14.
15. Mayr A, Zentralbl Veterinarmed B (1976) 23: 417-30.
CA 02293692 1999-12-06 =
16. Mayr A, Stickl H., Muller HK, Danner K, Singer H. Zentralbl Bakteriol B.
(1978) 167: 375- 90.
17. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. Dtsch Med Wochenschr. (1974) 99: 23866-922.
> 18. Mahnel H, Mayr A. Berl Munch Tierarztl Wochenschr (1994) 107: 253-6.
19. Meyer H, Sutter G, Mayr A. J Gen Virol. (1991) 72: 1031-8.
20. Altenburger W, Suter CP, Altenburger J. Arch Virol. (1989) 105: 15-27.
21. Sutter G, Ramsey-Ewing A, Rosales R, Moss B. J. Virol. (1994) 68:
4109-16.
22. Sutter G, Moss B. Proc Natl Acad Sci U S A (1992) 89: 10847-51.
23. Sutter GW, Wyatt LS, Foley PL, Bennink JR, Moss B. Vaccine (1994).
12: 1032-40.
24. Hirsch VM, Goldstein S, Channock R, et al. Channock R. ed Vaccines 95. Cold Spring Harbor Laboratory Press, (1995) 195-200.
25. Hirsch VM, Fuerst TR, Sutter G, et al. J. Virol. (1996) 70: 3741-52.
26. Moss B, Carroll MW, Wyatt L, et al. In: Anonymous, ed. Vaccines:
Novel strategies in design and production. Plenum Pres (1995).
27. Symons JA, Alcami A, Smith GL. Cell. (1995) 81: 551-60.
28. Alcami A, Smith GL. J. Virol. (1995) 69: 4633-9.
29. Alcami A, Smith GL. Cell. (1992) 71: 153-67.
30. Graham KA et al. Virology (1997) 229: 12-24.
31. Alcami A, Smith GL. Proc. Natl. Acad. Sci. USA (1996) 93:11029-34.
32. Blanchard TJ, Rowland-Jones S, Gotch F, McMichael AJ, Smith GL.
Lancet (1997) 348: 1741 33. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC. J. Infect. Dis. (1994) 170(5): 1100-9.
34. Davis NL, Brown KW, Johnston RE, J. Virol, (1996) 70(6): 3781-7.
35. Layton GT, Harris SJ, Myhan J, West D, Gotch F, Hill-Perkins M, Cole JS, Meyers N, Woodrow S, French TJ, Adams SE, Kingsman AJ.
. .. .. T.. ._......_ ___.._.___._ ...._ . .. . .... .. .... . . . i Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology (1996) 87: 171-8.
36. McGrory-WJ; Bautista-DS; Graham-FL A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology (1988) 163: 614-7 37. Rodrigues EG, Zavala F, Eichinger D, Wifson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. Journal io of Immunology (1997) 158: 1268-74.
38. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Molecular Genetics (1993) 2: 1847-51.
39. Miyahira Y, Murata K, Rodriguez D et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J lmmunol Methods (1995) 18: 45-54.
40. Allsopp CEM, Plebanski M, Gilbert S et al. (1996) Comparison of numerous delivery systems for the induction of cytotoxic T
lymphocytes. European Journal of Immunology (1996) 26:1951-1959.
41. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+
T cell-mediated protective immunity against malaria. J. Immunol.
(1997) 158: 1268-74.
42. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, Milich D.
immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. (1994) 180:
1037-46.
CA 02293692 1999-12-06 =
43. Satchidanandam V, Zavala F, Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol. Biochem. Parasitol. (1991) 48: 89-99.
44. Davis JR; Murphy JR; Baqar S; Clyde DF; Herrington DA; Levine MM.
s Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Transactions of the Royal Society for Tropical Medicine and Hygiene. (1989) 83: 748-50.
45. Meyer, H., Sutter, G. and Mayr, A. (1991). Mapping of deletions in the io genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-38.
46. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice 1s to influenza virus. Vaccine (1994) 12: 1032-40.
47. Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman, SL Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med. (1996) 20 183:1739-46.
48. Muller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for 25 this molecule in sporozoite invasion of hepatocytes. EMBO-J. (1993) 12: 2881-9.
49. Chakrabarti S et al. Mol. Cell. Biol. (1995) 5: 3403-9.
50. Morrison HG, Bauer SP, Lange JV, Esposito JJ, McCormick JB, Auperin DD Protection of guinea pigs from Lassa fever by vaccinia r i virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology. (1989) 171: 179-88.
51. Mackett M et al. J. Virol. (1984) 49: 857-864.
52. Carroll MW and Moss BE, Biotechnology (1995) 19: 352-4.
----- - -- -- -- --INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis) A. 'ilte indications made below relate to the microorganism referred to in the description on page 12 , line 1 0 - 13 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet 0 Name of depositary institution European Collection of Animal Cell Cultures (CAMR) Address of depositary institution (including postal code and country) Salisbury Wiltshire United Kingdom Date of deposit Accession Number June 1997 V97060511 C. ADDTTIONAL INDICATIONS (leave blank ijnot applicable) This information is continued on an additional sheet Q
In respect of all designated States to which such action is possibl and to the extent that it is legally permissible under the law of the designated State, it is requested that a sample of the deposited microorganism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. EPC Rule 28(4), UK Patent Rules 1995, Schedule 2, Paragraph 3, Australian Regulation 3.25(3), Danish D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not jor all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) TheindieationslistedbelowwillbesubmittedtotheInternationalBureaulater(specifyt/
tegeneralnatureoftheindicationse.g., Accession Number ofDeposit) For receiving Office use only For Intemational Bureau use only ~ This sheet was received with the international application This sheet was received by the International Bureau on:
0? SEP'iQO
Authorized officer Authorized ofCicer Form PC'T/RO/134 (July 1992) ~', INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
C. ADDITIONAL INDICATIONS (continued) Patents Act Sections 22 and 33(3), Icelandic Patents Act Sections 22 and 33(3), Norwegian Patents Act Sections 22 and 33(3) and generally similar provisions mutatis mutandis for any other designated State.
SEQUENCE LISTING
GENERAL INFORMATION
APPLICANT: OXXON PHARMACCINES LIMITED
TITLE: METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A
NUMBER OF SEQUENCES: 78 CORRESPONDENCE ADDRESS: KIRBY EADES GALE BAKER
OTTAWA, ON
CANADA, K1P 6N9 COMPUTER-READABLE FORM
MEDIUM TYPE: Floppy disk COMPUTER: IBM TYPE PC
OPERATING SYSTEM: WINDOWS 95 SOFTWARE: PATENTIN V. 2.1 CURRENT APPLICATION DATA
APPLICATION NUMBER: 2,293,692 FILING DATE: 1988-06-09 CLASSIFICATION:
PRIOR APPLICATION DATA
APPLICATION NUMBER: GB 9711957.2 FILING DATE: 1997-06-09 CLASSIFICATION:
PATENT AGENT INFORMATION
NAME: EDWIN J. GALE
REFERENCE NUMBER: 44072-NP
INFORMATION FOR SEQ ID NO: 1 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 1 aag ccg aac gac aag tcc ttg tat 24 Lys Pro Asn Asp Lys Ser Leu Tyr INFORMATION FOR SEQ ID NO: 2 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 2 Lys Pro Asn Asp Lys Ser Leu Tyr INFORMATION FOR SEQ ID NO: 3 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 3 aaa cct aag gac gaa ttg gac tac 24 Lys Pro Lys Asp Glu Leu Asp Tyr INFORMATION FOR SEQ ID NO: 4 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 4 Lys Pro Lys Asp Glu Leu Asp Tyr INFORMATION FOR SEQ ID NO: 5 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 5 aag cca atc gtt caa tac gac aac ttc 27 Lys Pro Ile Val Gln Tyr Asp Asn Phe INFORMATION FOR SEQ ID NO: 6 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 6 Lys Pro Ile Val Gln Tyr Asp Asn Phe INFORMATION FOR SEQ ID NO: 7 SEQUENCE CHARACTERISTICS
LENGTH: 33 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(33) SEQUENCE DESCRIPTION: SEQ ID NO: 7 gcc tcc aag aac aag gaa aag gct ttg atc atc 33 Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile INFORMATION FOR SEQ ID NO: 8 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 8 Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile INFORMATION FOR SEQ ID NO: 9 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 9 ggt atc gct ggt ggt ttg gcc ttg ttg 27 Gly Ile Ala Gly Gly Leu Ala Leu Leu INFORMATION FOR SEQ ID NO: 10 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 10 Gly Ile Ala Gly Gly Leu Ala Leu Leu INFORMATION FOR SEQ ID NO: 11 SEQUENCE CHARACTERISTICS
LENGTH: 30 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(30) SEQUENCE DESCRIPTION: SEQ ID NO: 11 atg aac cct aat gac cca aac aga aac gtc 30 Met Asn Pro Asn Asp Pro Asn Arg Asn Val INFORMATION FOR SEQ ID NO: 12 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 12 Met Asn Pro Asn Asp Pro Asn Arg Asn Val INFORMATION FOR SEQ ID NO: 13 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 13 atg atc aac gcc tac ttg gac aag ttg 27 Met Ile Asn Ala Tyr Leu Asp Lys Leu INFORMATION FOR SEQ ID NO: 14 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 14 Met Ile Asn Ala Tyr Leu Asp Lys Leu INFORMATION FOR SEQ ID NO: 15 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 15 atc tcc aag tac gaa gac gaa atc 24 Ile Ser Lys Tyr Glu Asp Glu Ile INFORMATION FOR SEQ ID NO: 16 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 16 Ile Ser Lys Tyr Glu Asp Glu Ile INFORMATION FOR SEQ ID NO: 17 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 17 tcc tac atc cca tct gcc gaa aag atc 27 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 18 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 18 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 19 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 19 cac ttg ggt aac gtt aag tac ttg gtt 27 His Leu Gly Asn Val Lys Tyr Leu Val INFORMATION FOR SEQ ID NO: 20 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 20 His Leu Gly Asn Val Lys Tyr Leu Val INFORMATION FOR SEQ ID NO: 21 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 21 aag tct ttg tac gat gaa cac atc 24 Lys Ser Leu Tyr Asp Glu His Ile INFORMATION FOR SEQ ID NO: 22 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 22 Lys Ser Leu Tyr Asp Glu His Ile INFORMATION FOR SEQ ID NO: 23 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 23 tta ttg atg gac tgt tct ggt tct att 27 Leu Leu Met Asp Cys Ser Gly Ser Ile INFORMATION FOR SEQ ID NO: 24 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 24 Leu Leu Met Asp Cys Ser Gly Ser Ile INFORMATION FOR SEQ ID NO: 25 SEQUENCE CHARACTERISTICS
LENGTH: 48 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(48) SEQUENCE DESCRIPTION: SEQ ID NO: 25 aac gct aat cca aac gca aat ccg aac gcc aat cct aac gcg aat ccc 48 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro INFORMATION FOR SEQ ID NO: 26 SEQUENCE CHARACTERISTICS
LENGTH: 16 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 26 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro INFORMATION FOR SEQ ID NO: 27 SEQUENCE CHARACTERISTICS
LENGTH: 60 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(60) SEQUENCE DESCRIPTION: SEQ ID NO: 27 gac gaa tgg tct cca tgt tct gtc act tgt ggt aag ggt act cgc tct 48 Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser aga aag aga gaa 60 Arg Lys Arg Glu INFORMATION FOR SEQ ID NO: 28 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 28 Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser Arg Lys Arg Glu INFORMATION FOR SEQ ID NO: 29 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 29 tac ttg aac aaa att caa aac tct ttg 27 Tyr Leu Asn Lys Ile Gln Asn Ser Leu INFORMATION FOR SEQ ID NO: 30 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 30 Tyr Leu Asn Lys Ile Gln Asn Ser Leu INFORMATION FOR SEQ ID NO: 31 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 31 atg gaa aag ttg aaa gaa ttg gaa aag 27 Met Glu Lys Leu Lys Glu Leu Glu Lys INFORMATION FOR SEQ ID NO: 32 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 32 Met Glu Lys Leu Lys Glu Leu Glu Lys INFORMATION FOR SEQ ID NO: 33 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 33 gct act tct gtc ttg gct ggt ttg 24 Ala Thr Ser Val Leu Ala Gly Leu INFORMATION FOR SEQ ID NO: 34 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 34 Ala Thr Ser Val Leu Ala Gly Leu INFORMATION FOR SEQ ID NO: 35 SEQUENCE CHARACTERISTICS
LENGTH: 48 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(48) SEQUENCE DESCRIPTION: SEQ ID NO: 35 gac cca aac gct aac cca aac gtt gac cca aac gcc aac cca aac gtc 48 Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val INFORMATION FOR SEQ ID NO: 36 SEQUENCE CHARACTERISTICS
LENGTH: 16 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 36 Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val INFORMATION FOR SEQ ID NO: 37 SEQUENCE CHARACTERISTICS
LENGTH: 42 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(42) SEQUENCE DESCRIPTION: SEQ ID NO: 37 caa gtt cac ttc caa cca ttg cct ccg gcc gtt gtc aag ttg 42 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu INFORMATION FOR SEQ ID NO: 38 SEQUENCE CHARACTERISTICS
LENGTH: 14 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 38 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu INFORMATION FOR SEQ ID NO: 39 SEQUENCE CHARACTERISTICS
LENGTH: 42 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(42) SEQUENCE DESCRIPTION: SEQ ID NO: 39 caa ttc atc aag gcc aac tct aag ttc atc ggt atc acc gaa 42 Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu INFORMATION FOR SEQ ID NO: 40 SEQUENCE CHARACTERISTICS
LENGTH: 14 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 40 Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu INFORMATION FOR SEQ ID NO: 41 SEQUENCE CHARACTERISTICS
LENGTH: 229 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 41 Met Ile Asn Ala Tyr Leu Asp Lys Leu Ile Ser Lys Tyr Glu Asp Glu Ile Ser Tyr Ile Pro Ser Ala Glu Lys Ile Gly Ser Lys Pro Asn Asp Lys Ser Leu Tyr Lys Pro Lys Asp Glu Leu Asp Tyr Lys Pro Ile Val Gln Tyr Asp Asn Phe Gly Ser Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile Gly Ile Ala Gly Gly Leu Ala Leu Leu Met Asn Pro Asn Asp Pro Asn Arg Asn Val Gly Ser His Leu Gly Asn Val Lys Tyr Leu Val Lys Ser Leu Tyr Asp Glu His Ile Leu Leu Met Asp Cys Ser Gly Ser Ile Gly Ser Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Gly Ser Tyr Leu Asn Lys Ile Gln Asn Ser Leu Met Glu Lys Leu Lys Glu Leu Glu Lys Ala Thr Ser Val Leu Ala Gly Leu Gly Ser Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser Arg Lys Arg Glu Gly Ser Gly Lys INFORMATION FOR SEQ ID NO: 42 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 42 Tyr Leu Lys Asp Gln Gln Leu Leu INFORMATION FOR SEQ ID NO: 43 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 43 Glu Arg Tyr Leu Lys Asp Gln Gln Leu INFORMATION FOR SEQ ID NO: 44 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 44 Glu Ile Thr Pro Ile Gly Leu Ala Pro INFORMATION FOR SEQ ID NO: 45 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 45 Pro Pro Ile Pro Val Gly Glu Ile Tyr INFORMATION FOR SEQ ID NO: 46 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 46 Gly Glu Ile Tyr Lys Arg Trp Ile Ile INFORMATION FOR SEQ ID NO: 47 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 47 Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys INFORMATION FOR SEQ ID NO: 48 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 48 Ile Ile Leu Gly Leu Asn Lys Ile Val Arg INFORMATION FOR SEQ ID NO: 49 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 49 Leu Gly Leu Asn Lys Ile Val Arg Met Tyr INFORMATION FOR SEQ ID NO: 50 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 50 Tyr Asn Leu Thr Met Lys Cys Arg INFORMATION FOR SEQ ID NO: 51 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 51 Arg Gly Pro Gly Arg Ala Phe Val Thr Ile INFORMATION FOR SEQ ID NO: 52 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 52 Gly Arg Ala Phe Val Thr Ile Gly Lys INFORMATION FOR SEQ ID NO: 53 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 53 Thr Pro Tyr Asp Ile Asn Gln Met Leu Pro INFORMATION FOR SEQ ID NO: 54 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 54 Cys Thr Pro Tyr Asp Ile Asn Gln Met INFORMATION FOR SEQ ID NO: 55 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 55 Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr INFORMATION FOR SEQ ID NO: 56 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 56 Gln Val Pro Leu Arg Pro Met Thr Tyr Lys INFORMATION FOR SEQ ID NO: 57 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 57 Val Pro Leu Arg Pro Met Thr Tyr INFORMATION FOR SEQ ID NO: 58 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 58 Ala Val Asp Leu Ser His Phe Leu Lys INFORMATION FOR SEQ ID NO: 59 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 59 Asp Leu Ser His Phe Leu Lys Glu Lys INFORMATION FOR SEQ ID NO: 60 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 60 Phe Leu Lys Glu Lys Gly Gly Leu INFORMATION FOR SEQ ID NO: 61 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 61 Ile Leu Lys Glu Pro Val His Gly Val INFORMATION FOR SEQ ID NO: 62 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 62 Ile Leu Lys Glu Pro Val His Gly Val Tyr INFORMATION FOR SEQ ID NO: 63 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 63 His Pro Asp Ile Val Ile Tyr Gln Tyr INFORMATION FOR SEQ ID NO: 64 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 64 Val Ile Tyr Gln Tyr Met Asp Asp Leu INFORMATION FOR SEQ ID NO: 65 SEQUENCE CHARACTERISTICS
LENGTH: 45 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 65 Met Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Gln His Pro Asn Ala Glu Leu Leu Lys His Tyr Leu Phe Arg Asn Leu Ser Pro Ser Tyr Val Tyr His Gln Phe Ile Pro Asn Pro Leu Leu Gly Leu Asp INFORMATION FOR SEQ ID NO: 66 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 66 Leu Pro Tyr Leu Gly Trp Leu Val Phe INFORMATION FOR SEQ ID NO: 67 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 67 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 68 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 68 Arg Gly Pro Gly Arg Ala Phe Val Thr Ile INFORMATION FOR SEQ ID NO: 69 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 69 Thr Pro His Pro Ala Arg Ile Gly Leu INFORMATION FOR SEQ ID NO: 70 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 70 Thr Tyr Gln Arg Thr Arg Ala Leu Val INFORMATION FOR SEQ ID NO: 71 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 71 Ser Asp Tyr Glu Gly Arg Leu Ile INFORMATION FOR SEQ ID NO: 72 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 72 Ala Ser Asn Glu Asn Met Glu Thr Met INFORMATION FOR SEQ ID NO: 73 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 73 Ile Asn Val Ala Phe Asn Arg Phe Leu INFORMATION FOR SEQ ID NO: 74 SEQUENCE CHARACTERISTICS
LENGTH: 33 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 74 cctgactcag accatatggg ctctcactcc atg 33 INFORMATION FOR SEQ ID NO: 75 SEQUENCE CHARACTERISTICS
LENGTH: 85 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 75 gtgataagct taacgatgat tccacaccat tttctgtgca tccagaatat gatgcaggga 60 tccctcccat ctcagggtga ggggc 85 INFORMATION FOR SEQ ID NO: 76 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 76 tcagaccata tgtctcgctc cgtggcc 27 INFORMATION FOR SEQ ID NO: 77 SEQUENCE CHARACTERISTICS
LENGTH: 31 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 77 tcagacaagc ttttacatgt ctcgatccca c 31 INFORMATION FOR SEQ ID NO: 78 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: peptide SEQUENCE DESCRIPTION: SEQ ID NO: 78 Lys Thr Ala Ser Cys Gly Val Trp Asp Glu Trp
Formulation 2 Priming Composition: Ty-VLP 500 g in PBS
Boosting Composition: MVA, 108 ffu in PBS
Protocol: Administer two doses of priming composition, i.m., at 0 and 3 io weeks, then 2 doses of booster at 6 and 9 weeks. For tumour treatment, MVA is given i.v. as one of most effective routes.
Formulation 3 Priming Composition: Protein 500 g + adjuvant (QS-21) Boosting Composition: Recombinant MVA, 10g ffu in PBS
Protocol: Administer two doses of priming composition at 0 and 3 weeks and 2 doses of booster i.d. at 6 and 9 weeks.
Formulation 4 Priming Composition: Adenovirus vector, 109 pfu in PBS
Boosting Composition: Recombinant MVA, 10g ffu in PBS
Protocol: Administer one or two doses of priming composition intradermally at 0 and 3 weeks and two doses of booster i.d. at 6 and 9 weeks.
The above doses and protocols may be varied to optimise protection.
Doses may be given between for example, 1 to 8 weeks apart rather than 3o 2 weeks apart.
is The invention will now be further described in the examples which follow.
EXAMPLES
Materials and Methods Generation of the epitope strings.
The malaria epitope string was made up of a series of cassettes each encoding three epitopes as shown in Table 1, with to restriction enzyme sites at each end of the cassette. Each cassette was constructed from four synthetic oligonucleotides which were annealed together, ligated into a cloning vector and then sequenced to check that no errors had been introduced. Individual cassettes were then joined together as required. The BamHl site at the 3' end of cassette C was fused to the i s Bgl/1 site at the 5' end of cassette A, destroying both restriction enzyme sites and encoding a two amino acid spacer (GS) between the two cassettes. Cassettes B, D and H were then joined to the string in the same manner. A longer string containing CABDHFE was also constructed in the same way.
Table 1. CTL epitopes of the malaria (M) string Cassette Epitope Amino acid DNA sequence Type HLA
Sequence restrictio n A Ls8 KPNDKSLY AAGCCGAACGACAAGTCCTTGTAT CTL 835 Cp26 KPKDELDY AAACCTAAGGACGAATTGGACTAC CTL B35 Ls6 KPIVQYDNF AAGCCAATCGTTCAATACGAQAACTTC CTL 853 8 Tr42/43 ASKNKEKAU( GCCTCCAAGAACAAGGAAAAGGCTTTGATCAT CTL B8 c Tr39 GIAGGLALL GGTATCGCTGGTGGTTTGGCCTTGTTG CTL A2.1 Cp6 MNPNDPNRN ATGAACCCTAATGACCCAAACAGAAACGTC CTL 87 v C St8 MINAYLDKL ATGATCAACGCCTACTTGGACAAGTTG CTL A2.2 Ls50 ISKYEDEI ATCTCCAAGTACGAAGACGAAATC CTL B17 Pb9 SYIPSAEKI TCCTACATCCCATCTGCCGAAAAGATC CTL mouse H2-Kd D Tr26 HLGNVKYLV CACTTGGGTAACGTTAAGTACTTGGTT CTL A2.1 Ls53 KSLYDEHI AAGTCTTTGTACGATGAACACATC CTL B58 Tr29 LLMDCSGSI TTATTGATGGACTGTTCTGGTTCTATT CTL A2.2 E NANP NANPNANPN AACGCTAATCCAAACGCAAATCCGAACGCCA Bcell ANPNANP ATCCTAACGCGAATCCC
TRAP DEWSPCSVT GACGAATGGTCTCCATGTTCTGTCACTTGTG Heparin AM CGKGTRSRK GTAAGGGTACTCGCTCTAGAAAGAGAGAA binding RE motif F Cp39 YLNKIQNSL TACTTGAACAAAATTCAAAACTCTTTG CTL A2.1 La72 MEKLKELEK ATGGAAAAGTTGAAAGAATTGGAAAAG CTL B8 ex23 ATSVLAGL GCTACTTCTGTCTTGGCTGGTTTG CTL 658 H CSP DPNANPNVD GACCCAAACGCTAACCCAAACGTTGACCCA T helper Universal PNANPNV AACGCCAACCCAAACGTC
BCG QVHFQPLPP CAAGTTCACTTCCAACCATTGCCTCCGGCCG T helper epitopes AWKL TTGTCAAGTTG
TT QFIKANSKFI CAATTCATCAAGGCCAACTCTAAGTTCATCG T helper GITE GTATCACCGAA
Table 1 Sequences included in the malaria epitope string. Each cassette consists of the epitopes shown above, in the order shown, with no > additional sequence between epitopes within a cassette. A Bglll site was added at the 5' end and a BamHl site at the 3' end, such that between cassettes in an epitope string the BamHl/Bgl/l junction encodes GS. All epitopes are from P. falciparum antigens except for pb9 (P. berghei), BCG
(M. tuberculosis) and TT (Tetanus). The amino acid and DNA sequences lo shown in the table have SEQ ID NOS. 1 to 40 in the order in which they appear.
Figure 1 shows the construct used to express Ty-VLP with the malaria epitope cassette CABDHFE. CTL epitopes are from P.
falciparum STARP (sporozoite threonine- and asparagine-rich protein) (st), 15 LSA-1 (liver stage antigen 1) (1s), CSP (circumsporozoite protein) (cp), CA 02293692 1999-12-06 ^
TRAP (thrombospondin-related adhesive protein) (tr), LSA-3 (liver stage antigen 3) (Ia) and Exp-1 (exported protein 1) (ex). Helper epitopes are from the P. falciparum CS protein, the M. tuberculosis 38Kd antigen and Tetanus Toxoid. NANP is the antibody epitope from CS and AM is the 5 adhesion motif from P. falciparum TRAP (Muller et al 1993). The length of the complete string is 229 amino acids as shown in the table 1 legend, with the amino acid sequence:-MINAYLDKLISKYEDEISYIPSAEKIGSKPNDKSLYKPKDELDYKPIVQYDN
FGSASKNKEKALIIGIAGGLALLMNPNDPNRNVGSHLGNVKYLVKSLYDE
io HILLMDCSGSIGSDPNANPNVDPNANPNVQVHFQPLPPAWKLQFIKANS
KFIGITEGSYLNKIQNSLMEKLKELEKATSVLAGLGSNANPNANPNANPNA
NPDEWSPCSVTCGKGTRSRKREGSGK [SEQ ID NO: 41].
The HIV epitope string was also synthesised by annealing oligonucleotides. Finally the HIV and malaria epitope strings were fused 1s by joining the BamHl site at the 3' end of the HIV epitopes to the Bglll site at the 5' end of cassettes CAB to form the HM string (Table 2) Table 2 CTL epitopes of the HIV/SIV epitope string Epitope Restriction Origin YLKDQQLL A24, B8 HIV-1 gp4l ERYLKDQQL B14 HIV-1 gp4l EITPIGLAP Mamu-B'01 SIV env PPIPVGEIY B35 HIV-1 p24 GEIYKRWII B8 HIV-1 p24 KRWIILGLNK B*2705 HIV-1 p24 IILGLNKIVR A33 HIV-1 p24 LGLNKIVRMY Bw62 HIV-1 p24 YNLTMKCR Mamu-A"`02 SIV env RGPGRAFVTI A2, H-2Dd HIV-1 gp120 GRAFVTIGK B*2705 HIV-1 gp120 TPYDINQML B53 HIV-2 gag CTPYDINQM Mamu-A`01 SIV gag *
RPQVPLRPMTY B51 HIV-1 nef QVPLRPMTYK A"0301, All HIV-1 nef VPLRPMTY 835 HIV-1 nef AVDLSHFLK All HIV-1 nef DLSHFLKEK A*0301 HIV-1 nef FLKEKGGL B8 HIV-1 nef ILKEPVHGV A*0201 HIV-1 pol ILKEPVHGVY Bw62 HIV-1 pol HPDIVIYQY B35 HIV-1 pol VIYQYMDDL A"0201 HIV-1 pol Table 2 Sequences of epitopes from HIV or SIV contained in the H
epitope string and assembled as shown in figure 2. The amino acids in the table have SEQ ID NOS: 42 to 64 in the order in which they appear.
Figure 2 shows a schematic outline of the H, M and HM
proteins. The bar patterns on the schematic representations of the polyepitope proteins indicate the origin of the sequences (see tables 1 and 2). The positions of individual epitopes and their MHC restrictions are depicted above and below the proteins. Pb is the only epitope derived from the protein of P. berghei. All other epitopes in the M protein originate from proteins of P. falciparum: cs - circumsporozoite protein, st - STARP, Is -LSA-1 and tr - TRAP. BCG - 38 kDa protein of M. tuberculosis; TT -tetanus toxin.
For the anti-tumour vaccine an epitope string containing CTL
epitopes was generated, similar to the malaria and HIV epitope string. In this tumour epitope string published murine CTL epitopes were fused together to create the tumour epitope string with the amino acid sequence:
MLPYLGWLVF-AQHPNAELL-KHYLFRNL-SPSYVYHQF-IPNPLLGLD
[SEQ ID NO: 65]. CTL epitopes shown here were fused together. The first amino acid methionine was introduced to initiate translation.
CA 02293692 1999-12-06 ^
Ty virus-like particles (VLPs).
The epitope string containing cassette CABDH was introduced into a yeast expression vector to make a C-terminal in-frame fusion to the TyA protein. When TyA or TyA fusion proteins are expressed in yeast from this vector, the protein spontaneously forms virus like particles which can be purified from the cytoplasm of the yeast by sucrose gradient centrifugation. Recombinant Ty-VLPs were prepared in this manner and dialysed against PBS to remove the sucrose before injection (c.f. Layton et al. 1996).
Adenoviruses Replication-defective recombinant Adenovirus with a deletion of the El genes was used in this study (McGrory et al, 1988). The Adenovirus expressed E. coli P-galactosidase under the control of a CMV
IE promoter. For immunisations, 10' pfu of virus were administered intradermally into the ear lobe.
Peptides Peptides were purchased from Research Genetics (USA), 2o dissolved at 10 mg/ml in DMSO (Sigma) and further diluted in PBS to 1 mg/mi. Peptides comprising CTL epitopes that were used in the experiments described herein are listed in table 3 Table 3 Sequence of CTL peptide epitopes sequence Antigen MHC
restriction LPYLGWLVF P1A tumour antigen Ld SYIPSAEKI P. berghei CSP Kd RGPGRAFVTI HIV gag Dd . ......T....... . .._..._.. . .W...-..._._,.._ .... ... . ~._.
TPHPARIGL E. coli 0-galactosidase L
TYQRTRALV Influenza A virus NP K
SDYEGRLI Influenza A virus NP Kk ASNENMETM Influenza A virus NP Db INVAFNRFL P. falciparum TRAP Kb The amino acid sequences in Table 3 have SEQ ID NOS: 66 to 73, in the order in which they appear in the Table.
> Plasmid DNA constructs A number of different vectors were used for constructing DNA
vaccines. Plasmid pTH contains the CMV IE promoter with intron A, followed by a polylinker to allow the introduction of antigen coding sequences and the bovine growth hormone transcription termination I o sequence. The plasmid carries the ampicillin resistance gene and is capable of replication in E. coli but not mammalian cells. This was used to make DNA vaccines expressing each of the following antigens: P. berghei TRAP, P. berghei CS, P. falciparum TRAP, P. falciparum LSA-1 (278 amino acids of the C terminus only), the epitope string containing cassettes is CABDH and the HM epitope string (HIV epitopes followed by cassettes CAB). Plasmid pSG2 is similar to pTH except for the antibiotic resistance gene. In pSG2 the ampicillin resistance gene of pTH has been replaced by a kanamycin resistance gene. pSG2 was used to to make DNA vaccines expressing the following antigens: P. berghei PbCSP, a mouse tumour 2o epitope string, the epitope string containing cassettes CABDH and the HM
epitope string. Plasmid V1J-NP expresses influenza nucleoprotein under the control of a CMV IE promoter. Plasmids CMV-TRAP and CMV-LSA-1 are similar to pTH.TRAP and pTH. LSA-1 but do not contain intron A of the CMV promoter. Plasmids RSV.TRAP and RSV.LSA-1 contain the RSV
25 promoter, SV40 transcription termination sequence and are tetracycline CA 02293692 1999-12-06 ^
resistant. For induction of 0-galactosidase-specific CTL plasmid pcDNA3/His/LacZ (Invitrogen) was used. AII DNA vaccines were prepared from E. coli strain DH5cx using Qiagen plasmid purification columns.
; Generation of recombinant vaccinia viruses Recombinant MVAs were made by first cloning the antigen sequence into a shuttle vector with a viral promoter such as the plasmid pSC11 (Chakrabarti et al. 1985; Morrison et al. 1989). P. berghei CS and P. falciparum TRAP, influenza nucleoprotein and the HM and mouse io tumour epitope polyepitope string were each expressed using the P7.5 promoter (Mackett et al. 1984), and P. berghei TRAP was expressed using the strong synthetic promoter (SSP; Carroll et al. 1995). The shuttle vectors, pSC1 1 or pMCO3 were then used to transform cells infected with wild-type MVA so that viral sequences flanking the promoter, antigen i> coding sequence and marker gene could recombine with the MVA and produce recombinants. Recombinant viruses express the marker gene ((~
glucuronidase or P galactosidase) allowing identification of plaques containing recombinant virus. Recombinants were repeatedly plaque purified before use in immunisations. The recombinant NYVAC-PbCSP
20 vaccinia was previously described (Lanar et aI. 1996). The wild type or Western Reserve (WR) strain of recombinant vaccinia encoding PbCSP
was described previously (Satchidanandam et al. 1991).
Cells and culture medium 2s Murine cells and Epstein-Barr virus transformed chimpanzee and macaque B cells (BCL) were cultured in RPMI supplemented with 10%
heat inactivated fetal calf serum (FCS). Splenocytes were restimulated with the peptides indicated (final concentration 1 g/ml) in MEM medium with 10% FCS, 2mM glutarnine, 50U/ml penicillin, 50 M 2-30 mercaptoethanol and 10mM Hepes pH7.2 (Gibco, UK).
Animals Mice of the strains indicated, 6-8 weeks old were purchased from Harlan Olac (Shaws Farm, Blackthorn, UK). Chimpanzees H1 and 5 H2 were studied at the Biomedical Primate Research Centre at Rijswick, The Netherlands. Macaques were studied at the University of Oxford.
Immunisations Plasmid DNA immunisations of mice were performed by 10 intramuscular immunisation of the DNA into the musculus tibialis under anaesthesia. Mouse muscle was sometimes pre-treated with 50 l of 1 mM
cardiotoxin (Latoxan, France) 5-9 days prior to immunisation as described by Davis et al (1993), but the presence or absence of such pre-treatment was not found to have any significant effect on immunogenicity or 15 protective efficacy. MVA immunisation of mice was performed by either intramuscular (i.m.), intravenous (into the lateral tail vein) (i.v.), intradermal (i.d.), intraperitoneal (i.p.) or subcutaneous (s.c.) immunisation.
Plasmid DNA and MVA immunisation of the chimpanzees H1 and H2 was performed under anaesthesia by intramuscular immunisation of leg 20 muscles. For these chimpanzee immunisations the plasmid DNA was co-administered with 15 micrograms of human GM-CSF as an adjuvant.
Recombinant MVA administration to the chimpanzees was by intramuscular immunisation under veterinary supervision. Recombinant human GM-CSF was purchased from Sandoz (Camberley, UK). For 2-5 plasmid DNA immunisations using a gene gun, DNA was precipitated onto gold particles. For intradermal delivery, two different types of gene guns were used, the Acell and the Oxford Bioscience device (PowderJect Pharmaceuticals, Oxford, UK).
CA 02293692 1999-12-06 ^
ELISPOT assays CD8+ T cells were quantified in the spleens of immunised mice without in vitro restimulation using the peptide epitopes indicated and the ELISPOT assay as described by Miyahara et al (1993). Briefly, 96-well nitrocellulose plates (Miliscreen MAHA, Millipore, Bedford UK) were coated with 15 g/ml of the anti-mouse interferon-y monoclonal antibody R4 (EACC) in 50 [LI of phosphate-buffered saline (PBS). After overnight incubation at 4 C the wells were washed once with PBS and blocked for 1 hour at room temperature with 100 l RPMI with 10% FCS. Splenocytes i o from immunised mice were resuspended to 1 x 10' cells/ml and placed in duplicate in the antibody coated wells and serially diluted. Peptide was added to each well to a final concentration of 1 g/ml. Additional wells without peptide were used as a control for peptide-dependence of interferon-y secretion. After incubation at 37 C in 5%CO2 for 12-18 hours the plates were washed 6 times with PBS and water. The wells were then incubated for 3 hours at room temperature with a solution of 1 g/mI of biotinylated anti-mouse interferon-y monoclonai antibody XMG1.2 (Pharmingen, CA, USA) in PBS. After further washes with PBS, 50 l of a 1 g/mI solution of streptavidin-aikaline-phosphatase polymer (Sigma) was added for 2 hours at room temperature. The spots were developed by adding 50 i of an alkaline phosphatase conjugate substrate solution (Biorad, Hercules, CA, USA). After the appearance of spots the reaction was stopped by washing with water. The number of spots was determined with the aid of a stereomicroscope.
ELISPOT assays on the chimpanzee peripheral blood lymphocytes were performed using a very similar method employing the assay and reagents developed to detect human CD8 T cells (Mabtech, Stockholm).
.
CTL assays CTL assays were performed using chromium labelled target cells as indicated and cultured mouse spleen cells as effector cells as described by Allsopp et al. (1996). CTL assays using chimpanzee or s macaque cells were performed as described for the detection of human CTL by Hill et al. (1992) using EBV-transformed autologous chimpanzee chimpanzee or macaque B cell lines as target cells.
P. berghei challenge to Mice were challenged with 2000 (BALB/c) or 200 (C57BL/6) sporozoites of the P. bergheiANKA strain in 200 l RPMI by intravenous inoculation as described (Lanar et al. 1996). These sporozoites were dissected from the salivary glands of Anopheles stephensi mosquitoes maintained at 18 C for 20-25 days after feeding on infected mice. Blood-1-5 stage malaria infection, indicating a failure of the immunisation, was detected by observing the appearance of ring forms of P. berghei in Giemsa-stained blood smears taken at 5-12 days post-challenge.
P. falciparum challenge 20 The chimpanzees were challenged with 20,000 P. falciparum sporozoites of the NF54 strain dissected from the salivary glands of Ariopheles gambiae mosquitoes, by intravenous inoculation under anaesthesia. Blood samples from these chimpanzees were examined daily from day 5 after challenge by microscopy and parasite culture, in 25 order to detect the appearance of low levels of P. falciparum parasites in the peripheral blood.
P815 tumour challenges Mice were challenged with 1 x 105 P815 cells in 200 l of 30 PBS by intravenous inoculation. Animals were monitored for survival.
CA 02293692 1999-12-06 =
Influenza virus challenges Mice were challenged with 100 haemagglutinating units (HA) of influenza virus A/PR/8/34 by intranasal inoculation. Following challenge the animals were weighed daily and monitored for survival.
Determining peptide specific CTL using tetramers Tetrameric complexes consisting of Mamu-A*01-heavy chain and [32-microglobulin were made as described by Ogg et al (1998). DNA
coding for the leaderless extracellular portion of the Mamu-A*01 MHC
class I heavy chain was PCR-amplified from cDNA using 5'primer MamuNdel: 5'-CCT GAC TCA GAC CAT ATG GGC TCT CAC TCC ATG
[SEQ ID NO: 74] and 3' primer: 5'-GTG ATA AGC TTA ACG ATG ATT
CCA CAC CAT TTT CTG TGC ATC CAG AAT ATG ATG CAG GGA TCC
~5 CTC CCA TCT CAG GGT GAG GGG C [SEQ ID NO: 75]. The former primer contained a Nde/ restriction site, the latter included a Hind/// site and encoded for the bioinylation enzyme BirA substrate peptide. PCR
products were digested with Nde/ and Hindlll and ligated into the same sites of the polylinker of bacterial expression vector pGMT7. The rhesus monkey gene encoding a leaderless [32-microglobulin was PCR amplifed from a cDNA clone using primers B2MBACK: 5'-TCA GAC CAT ATG TCT
CGC TCC GTG GCC [SEQ ID NO: 76] and B2MFOR: 5'-TCA GAC AAG
CTT TTA CAT GTC TCG ATC CCA C [SEQ ID NO: 77] and likewise cloned into the Nde/ and Hindlll sites of pGMT7. Both chains were expressed in E. coli strain BL-21, purified from inclusion bodies, refolded in the presence of peptide CTPYDINQM [SEQ ID NO: 54], biotinylated using the BirA enzyme (Avidity) and purified with FPLC and monoQ ion exchange columns. The amount of biotinylated refolded MHC-peptide complexes was estimated in an ELISA assay, whereby monomeric complexes were first captured by conformation sensitive monoclonal . .. .. T. ... ..... . ...... ._.._..._,.._ _..... . . .... . ... . . . . ...
. . . T..
antibody W6/32 and detected by alkaline phosphatase (AP) -conjugated streptavidin (Sigma) followed by colorimetric substrate for AP. The formation of tetrameric complexes was induced by addition of phycoerythrin (PE)-conjugated streptavidin (ExtrAvidin; Sigma) to the refolded biotinylated monomers at a molar ratio of MHC-peptide : PE-streptavidin of 4: 1. The complexes were stored in the dark at 4 C. These tetramers were used to analyse the frequency of Mamu-A*01/gag-specific CD8+ T cells in peripherial blood lymphocytes (PBL) of immunised macaques.
ImmunogenicitYStudies in Mice Previous studies of the induction of CTL against epitopes in the circumsporozoite (CS) protein of Plasmodium berghei and Plasmodium yoelii have shown variable levels of CTL induction with different delivery systems. Partial protection has been reported with plasmid DNA (Sedegah et al. 1994), influenza virus boosted by replicating vaccinia virus (Li et al.
1991), adenovirus (Rodrigues et al 1997) and particle delivery systems (Schodel et al. 1994). Immunisation of mice intramuscularly with 50 micrograms of a plasmid encoding the CS protein produced moderate levels of CD8+ cells and CTL activity in the spleens of these mice after a single injection (Figures 3, 4).
For comparison groups of BALB/c mice (n = 5) were injected intravenously with 106 ffu/pfu of recombinant vaccinia viruses of different strains (WR, NYVAC and MVA) all expressing P. berghei CSP. The frequencies of peptide-specific CD8+ T cells were measured 10 days later in an ELISPOT assay. MVA.PbCSP induced 181 +/- 48, NYVAC 221+/- 27 and WR 94+/- 19 (mean +/- standard deviation) peptide-specific CD8+ T
cells per million spienocytes. These results show that surprisingly replication-impaired vaccinia viruses are superior to replicating strains in CA 02293692 1999-12-06 ^
priming a CD8+ T cell response. We then attempted to boost these moderate CD8+ T cell responses induced by priming with either plasmid DNA or MVA using homologous or heterologous vectors. A low level of CD8+ T cells was observed after two immunisations with CS recombinant s DNA vaccine alone, the recombinant MVA vaccine alone or the recombinant MVA followed by recombinant DNA (Figure 3). A very much higher level of CD8+ T cells was observed by boosting the DNA-primed immune response with recombinant MVA. In a second experiment using ten mice per group the enhanced immunogenicity of the DNA/MVA
10 sequence was confirmed: DNA/MVA 856 +/- 201; MVA/DNA 168 +/- 72;
MVA/MVA 345+/- 90; DNA/DNA 92 +/- 46. Therefore the sequence of a first immunisation with a recombinant plasmid encoding the CS protein followed by a second immunisation with the recombinant MVA virus yielded the highest levels of CD8+ T lymphocyte response after immunisation.
15 Figure 3 shows malaria CD8 T cell ELISPOT data following different immunisation regimes. Results are shown as the number of peptide-specific T cells per million splenocytes. Mice were immunised either with the PbCSP-plasmid DNA or the PbCSP-MVA virus or combinations of the two as shown on the X axis, at two week intervals and 20 the number of splenocytes specific for the pb9 malaria epitope assayed two weeks after the last immunisation. Each point represents the number of spot-forming cells (SFCs) measured in an individual mouse. The highest level of CD8+ T cells was induced by priming with the plasmid DNA
and boosting with the recombinant MVA virus. This was more 25 immunogenic than the reverse order of immunisation (MVA/DNA), two DNA immunisations (DNA/DNA) or two MVA immunisations (MVA/MVA). It was also more immunogenic than the DNA and MVA immunisations given simultaneously (DNA + MVA 2w), than one DNA immunisation (DNA 4w) or one MVA immunisation given at the earlier or later time point (MVA 2w and 30 MVA 4w).
Figure 4 shows that malaria CD8 T cell ELISPOT and CTL
levels are substantially boosted by a recombinant MVA immunisation following priming with a plasmid DNA encoding the same antigen. A and C. CD8+ T cell responses were measured in BALB/c mice using the y-s interferon ELISPOT assay on fresh splenocytes incubated for 18 h with the Kd restricted peptide SYIPSAEKI [SEQ ID NO: 67] from P. berghei CSP
and the Ld restricted peptide TPHPARIGL [SEQ ID NO: 69] from E. coli R-galactosidase. Note that the ELISPOT counts are presented on a logarithmic scale. B and D. Splenocytes from the same mice were also assayed in conventional StCr-release assays at an effector: target ration of 100:1 after 6 days of in vitro restimulation with the same peptides (1 g/ml).
The mice were immunised with plasmid DNA expressing either P. berghei CSP and TRAP, PbCSP alone, the malaria epitope cassette including the P. berghei CTL epitope (labelled pTH.M), or R-galactosidase. ELISPOT and CTL levels measured in mice 23 days after one DNA immunisation are shown in A and B respectively. The same assays were performed with animals that received additionally lx 10' ffu of recombinant MVA expressing the same antigen(s) two weeks after the primary immunisation. The ELISPOT and CTL levels in these animals are shown in C and D respectively. Each bar represents data from an individual animal.
Studies were also undertaken of the immunogenicity of the epitope string HM comprising both HIV and malaria epitopes in tandem.
Using this epitope string again the highest levels of CD8+ T cells and CTL
were generated in the spleen when using an immunisation with DNA
vaccine followed by an immunisation with a recombinant MVA vaccine (Table 4, Figure 5).
CA 02293692 1999-12-06 ^
Table 4 Immunogenicity of various DNA/MVA combinations as determined by ELISPOT assays Immunisation 1 lmmunisation 2 HIV epitope Malaria epitope None DNA-HM 70 60 100 10 None MVA-HM 422 128 212 94 Table 4 shows the results of ELISPOT assays performed to measure the levels of specific CD8+ T cells to HIV and malaria epitopes following different immunisation regimes of plasmid DNA and MVA as indicated. The numbers are spot-forming cells per million splenocytes. The HM epitope string is illustrated in figure 2. BALB/c mice were used in all cases. The malaria epitope was pb9 as in figures 2 and 3. The HIV
epitope was RGPGRAFVTI [SEQ ID NO: 51]. The immunisation doses were 50 g of plasmid DNA or 10' focus-forming units (ffu) of recombinant MVA. All immunisations were intramuscular. The interval between immunisations 1 and 2 was from 14-21 days in all cases.
Figure 5 shows the CTL responses induced in BALB/c mice to malaria and H1V epitopes by various immunisation regimes employing plasmid DNA and recombinant MVA. Mice were immunised intramuscularly as described in the legend to table 3 and in methods. High levels of CTL (>30% specific lysis at effector/target ration of 25:1) were observed to both the malaria and HIV epitopes only after priming with r _ _ _ ~
plasmid DNA and boosting with the recombinant MVA. The antigen used in this experiment is the HIV-malaria epitope string. The recombinant MVA
is denoted MVA.HM and the plasmid DNA expressing this epitope string is denoted pTH.HM. Levels of specific lysis at various effector to target ratios are shown. These were determined after 5 days in vitro restimulation of spienocytes with the two peptides pb9 and RGPGRAFVTI [SEQ ID NO:
51].
Comparison of numerous delivery systems for the induction of CTL was reported by Allsopp et al. (1996). Recombinant Ty-virus like i o particles (Ty-VLPs) and lipid-tailed malaria peptides both gave good CTL
induction but Ty-VLPs were better in that they required only a single immunising dose for good CTL induction. However, as shown here even two doses of Ty particles fail to induce significant protection against sporozoite challenge (Table 7, line 1). lmmunisation with a recombinant modified vaccinia Ankara virus encoding the circumsporozoite protein of P.
berghei also generates good levels of CTL. However, a much higher level of CD8+ T cell response is achieved by a first immunisation with the Ty-VI-P followed by a second immunisation with the MVA CS vaccine (Table 5).
Table 5 lmmunogenicity of various Ty-VLP/MVA combinations as determined by ELISPOT and CTL assays Immunisation I Immunisation 2 ELISPOT No %Specific Lysis Ty-CABDH Ty- CABDH 75 15 MVA.PbCSP MVA.PbCSP 38 35 Ty-CABDH MVA.PbCSP 225 42 Ty- CABDH MVA.HM 1930 nd CA 02293692 1999-12-06 ^
Table 5 Results of ELISPOT and CTL assays performed to measure the levels of specific CD8+ T cells to the malaria epitope pb9 following different immunisation regimes of Ty-VLPs and recombinant MVA virus as indicated. The CTL and ELISPOT data are from different experiments.
The ELISPOT levels (spots per million splenocytes) are measured on un-restimulated cells and the CTL activity, indicated as specific lysis at an effector to target ratio of 40:1, on cells restimulated with pb9 peptide in vitro for 5-7 days. Both represent mean levels of three mice. BALB/c mice were used in all cases. The immunisation doses were 50 g of Ty-VLP or 10' ffu (foci forming units) of recombinant MVA. All immunisations were intramuscular. The interval between immunisations 1 and 2 was from 14-21 days. MVA.HM includes cassettes CAB.
Priming of an immune response with DNA delivered by a gene gun and boosting with recombinant MVA
Immunogenicity and challenge.
The use of a gene gun to deliver plasmid DNA intradermally and thereby prime an immune response that could be boosted with recombinant MVA was investigated. Groups of BALB/c mice were immunised with the following regimen:
I) Three gene gun immunisations with pTH.PbCSP (4 mg per immunisation) at two week intervals II) Two gene gun immunisations followed by MVA i.v. two weeks later III) One intramuscular DNA immunisation followed by MVA i.v. two weeks later.
The immunogenicity of the three immunisation regimens was analysed using ELISPOT assays. The highest frequency of specific T cells was observed with two gene gun immunisations followed by an MVA i.v.
T =
boost and the intramuscular DNA injection followed an MVA i.v. boost (Figure 6).
Figure 6 shows the results of ELISPOT assays performed to measure the levels of specific CD8+ T cells to the malaria epitope pb9 s following different immunisation regimes. Groups of BALB/c mice (n= 3) were immunised as indicated (g.g. = gene gun). The time between all immunisations was 14 days. ELISPOT assays were done two weeks after the last immunisation.
10 CTL induction to the same antigen in different mouse strains To address the question whether the boosting effect described above in BALB/c mice with two CTL epitopes SYIPSAEKI [SEQ ID NO: 67]
derived from P. berghei CSP and RGPGRAFVTI [SEQ ID NO: 68] derived from HIV) is a universal phenomenon, two sets of experiments were is carried out. CTL responses to the influenza nucleoprotein were studied in five inbred mouse strains. In a first experiment three published murine CTL
epitopes derived from the influenza nucleoprotein were studied (see Table 3). Mice of three different H-2 haplotypes, BALB/c and DBA/2 (H-2d), C57BL/6 and 129 (H-2b); CBA/J (H-2k), were used. One set of animals was 20 immunised twice at two week intervals with the plasmid V1 J-NP encoding the influenza nucleoprotein. Another set of identical animals was primed with V1J-NP and two weeks later boosted intravenously with 106 ffu of MVA.NP, expressing influenza virus NP. The levels of CTL in individual mice were determined in a 51Cr-release assay with peptide re-stimulated 25 spienocytes. As shown in Figure 7, the DNA priming/MVA boosting immunisation regimen induced higher levels of lysis in all the mouse strains analysed and is superior to two DNA injections.
Figure 7 shows the CTL responses against influenza NP in different mouse strains. Mice of different strains were immunised twice two 30 weeks apart with a DNA vaccine V1 J-NP encoding for the influenza CA 02293692 1999-12-06 ^
nucleoprotein (open circles) or primed with the same DNA vaccine and two weeks later boosted with recombinant MVA expressing influenza virus nucleoprotein (closed circles). Two weeks after the last immunisation spienocytes were restimulated in vitro with the respective peptides (Table 3). The CTL activity was determined in a standard 51Cr-release assay with MHC class I-matched target cells.
CTL induction to different antigens in different mouse strains The effect of MVA boosting on plasmid DNA-primed immune to responses was further investigated using different antigens and different inbred mouse strains. Mice of different strains were immunised with different antigens using two DNA immunisations and compared with DNA/MVA immunisations. The antigens used were E. coli -galactosidase, the malaria/HIV epitope string, a murine tumour epitope string and P.
1s falciparum TRAP. Compared with two DNA immunisations the DNA-priming/MVA-boosting regimen induced higher levels of CTL in all the different mouse strains and antigen combinations tested (Figure 8).
Figure 8 shows CTL responses against different antigens induced in different inbred mouse strains. Mice were immunised with two 20 DNA vaccine immunisations two weeks apart (open circies) or primed with a DNA vaccine and two weeks later boosted with a recombinant MVA
expressing the same antigen (closed circles). The strains and antigens were: C57BL/6; P. falciparum TRAP in A. DBA/2; E.coli (3-galactosidase in B. BALB/c; HM epitope string CTL activity against malaria peptide (pb9) in C. DBA/2; HM epitope string CTL activity against pb9 in D. BALB/c; HM
epitope string CTL activity against HIV peptide in E. DBA/2; HM epitope string CTL activity against HIV peptide in F. BALB/c; tumour epitope string CTL activity against P1A-derived peptide in G. DBA/2; tumour epitope string CTL activity against P1A-derived peptide in H. Sequences of peptide 30 epitopes are shown in table 3. Each curve shows the data for an individual mouse.
T
Sporozoites can efficiently prime an immune response that is boostable by MVA
Humans living in malaria endemic areas are continuously exposed to sporozoite inoculations. Malaria-specific CTL are found in these naturally exposed individuals at low levels. To address the question whether low levels of sporozoite induced CTL responses can be boosted by MVA, BALB/c mice were immunised with irradiated (to prevent malaria infection) P. berghei sporozoites and boosted with MVA. Two weeks after the last immunisation splenocytes were re-stimulated and tested for lytic activity. Two injections with 50 or 300 + 500 sporozoites induced very low or undetectable levels of lysis. Boosting with MVA induced high levels of peptide specific CTL. MVA alone induced only moderate levels of lysis (Figure 9).
Figure 9 shows sporozoite-primed CTL responses are substantially boosted by MVA. Mice were immunised with two low doses (50 + 50) of irradiated sporozoites in A. two high doses (300 +500) of sporozoites in B; mice were boosted with MVA.PbCSP following low-dose sporozoite priming in D; high dose sporozoite priming in E. CTL responses following immunisation with MVA.PbCSP are shown in C.
Recombinant adenoviruses as priming agent The prime-boost immunisation regimen has been exemplified using plasmid DNA and recombinant Ty-VLP as priming agent. Here an example using non-replicating adenoviruses as the priming agent is provided. Replication-deficient recombinant Adenovirus expressing E. coli (3-galactosidase (Adeno-GAL) was used. Groups of BALB/c mice were immunised with plasmid DNA followed by MVA or with Adenovirus followed by MVA. All antigen delivery systems used encoded E. coli R-galactosidase. Priming a CTL response with plasmid DNA or Adenovirus and boosting with MVA induces similar levels of CTL (Figure 10).
CA 02293692 1999-12-06 ^
Figure 10 shows CTL responses primed by plasmid DNA or recombinant Adenovirus and boosted with MVA . Groups of BALB/c mice (n=3) were primed with plasmid DNA A or recombinant Adenovirus expressing R-galactosidase B. Plasmid DNA was administered intramuscularly, MVA intravenously and Adenovirus intradermally.
Spienocytes were restimulated with peptide TPHPARIGL [SEQ ID NO: 69]
two weeks after the last immunisation. CTL activity was tested with peptide-pulsed P815 cells.
Immunogenicity of the DNA prime vaccinia boost regimen depends on the replication competence of the strain of vaccinia virus used The prime boosting strategy was tested using different strains of recombinant vaccina viruses to determine whether the different strains with strains differing in their replication competence may differ in their is ability to boost a DNA-primed CTL response. Boosting with replication-defective recombinant vaccinia viruses such as MVA and NYVAC resulted in the induction of stronger CTL responses compared to CTL responses following boosting with the same dose of replication competent WR
vaccinia virus (Figure 11).
Figure 11 shows CTL responses in BALB/c mice primed with plasmid DNA followed by boosting with different recombinant vaccinia viruses. Animals were primed with pTH.PbCSP 50 g/mouse i.m. and two weeks later boosted with different strains of recombinant vaccina viruses (106 pfu per mouse i.v.) expressing PbCSP. The different recombinant 2-5 vaccinia virus strains were MVA in A; NYVAC in B and WR in C. The superiority of replication-impaired vaccinia strains over replicating strains was found in a further experiment. Groups of BALB/c mice (n = 6) were primed with 50 g/animal of pSG2.PbCSP (i.m.) and 10 days later boosted i.v. with 106 ffu/pfu of recombinant MVA, NYVAC and WR expressing PbCSP. The frequencies of peptide-specific CD8+ T cells were determined using the ELISPOT assay. The frequencies were: MVA 1103 .__..._. ..T. _ +/- 438, NYVAC 826 +/- 249 and WR 468 +/- 135. Thus using both CTL
assays and ELISPOT assays as a measure of CD8 T celf immunogenicity a surprising substantially greater immunogenicity of the replication-impaired vaccinia strains was observed compared to the replication competent strain.
The use of recombinant canary or fowl pox viruses for boosting CD8+
T ce11 responses Recombinant canary pox virus (rCPV) or fowl pox virus (rFVP) are made using shuttle vectors described previously (Taylor et al.
Virology 1992, 187: 321-328 and Taylor et al. Vaccine 1988, 6: 504-508).
The strategy for these shuttle vectors is to insert the gene encoding the protein of interest preceded by a vaccinia-specific promoter between two flanking regions comprised of sequences derived from the CPV or FPV
is genome. These flanking sequences are chosen to avoid insertion into essential viral genes. Recombinant CPV or FPV are generated by in vivo recombination in permissive avian cell lines i.e. primary chicken embryo fibroblasts. Any protein sequence of antigens or epitope strings can be expressed using fowl pox or canary pox virus. Recombinant CPV or FPV
is characterised for expression of the protein of interest using antigen-specific antibodies or including an antibody epitope into the recombinant gene. Recombinant viruses are grown on primary CEF. An immune response is primed using plasmid DNA as described in Materials and Methods. This plasmid DNA primed immune response is boosted using 10' ffu/pfu of rCPV or rFPV inoculated intravenously, intradermally or intramuscularly. CD8+ T cell responses are monitored and challenges are performed as described herein.
CA 02293692 1999-12-06 ^
Malaria Challenge Studies in Mice To assess the protective efficacy of the induced levels of CD8+ T cell response immunised BALB/c or C57BL/6 mice were 5 challenged by intravenous injection with 2000 or 200 P. berghei sporozoites. This leads to infection of liver cells by the sporozoites.
However, in the presence of a sufficiently strong T lymphocyte response against the intrahepatic parasite no viable parasite will leave the liver and no blood-stage parasites will be detectable. Blood films from challenged 10 mice were therefore assessed for parasites by microscopy 5-12 days following challenge.
BALB/c mice immunised twice with a mixture of two plasmid DNAs encoding the CS protein and the TRAP antigen, respectively, of P.
berghei were not protected against sporozoite challenge. Mice immunised 15 twice with a mixture of recombinant MVA viruses encoding the same two antigens were not protected against sporozoite challenge. Mice immunised first with the two recombinant MVAs and secondly with the two recombinant plasmids were also not protected against sporozoite challenge. However, all 15 mice immunised first with the two plasmid 2o DNAs and secondly with the two recombinant MVA viruses were completely resistant to sporozoite challenge (Table 6 A and B).
To assess whether the observed protection was due to an immune response to the CS antigen or to TRAP or to both, groups of mice were then immunised with each antigen separately (Table 6 B). All 10 25 mice immunised first with the CS plasmid DNA and secondly with the CS
MVA virus were completely protected against sporozoite challenge.
Fourteen out of 16 mice immunised first with the TRAP plasmid DNA
vaccine and secondly with the TRAP MVA virus were protected against sporozoite challenge. Therefore the CS antigen alone is fully protective when the above immunisation regime is employed and the TRAP antigen is substantially protective with the same regime.
The good correlation between the induced level of CD8+ T
lymphocyte response and the degree of protection observed strongly > suggests that the CD8+ response is responsible for the observed protection. In previous adoptive transfer experiments it has been demonstrated that CD8+ T lymphocyte clones against the major CD8+ T
cell epitope in the P. berghei CS protein can protect against sporozoite challenge. To determine whether the induced protection was indeed mediated by CDB+ T cells to this epitope we then employed a plasmid DNA and a recombinant MVA encoding only this nine amino acid sequence from P. berghei as a part of a string of epitopes (Table 6 B). (All the other epitopes were from micro-organisms other than P. berghei).
Immunisation of 10 mice first with a plasmid encoding such an epitope t~ string and secondly with a recombinant MVA also encoding an epitope string with the P. berghei CTL epitope led to complete protection from sporozoite challenge (Table 6 B). Hence the induced protective immune response must be the CTL response that targets this nonamer peptide sequence.
CA 02293692 1999-12-06 =
Table 6 Results of mouse challenge experiments using different combinations of DNA and MVA vaccine Immunisation 1 Immunisation 2 No. Infected/ %Protection No. challenged A. Antigens used: PbCSP + PbTRAP
DNA DNA 5/5 0%
MVA MVA 9/10 10%
DNA MVA 0/5 100%
MVA DNA 5/5 0%
Control mice immunised with p-galactosidase DNA DNA 5/5 0%
MVA MVA 5/5 0%
DNA MVA 5/5 0%
MVA DNA 5/5 0%
B.
DNA (CSP +TRAP) MVA (CSP +TRAP) 0/10 100%
DNA (CSP) MVA (CSP) 0/10 100%
DNA (TRAP) MVA (TRAP) 2/16 88%
DNA (epitope) MVA (epitope) 0/11 100%
DNA (beta-gal) MVA (beta-gal) 6/7 14%
none none 9/10 10%
Table 6 Results of two challenge experiments (A and B) using different immunisation regimes of plasmid DNA and MVA as indicated.
BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 ffu of recombinant MVA. The interval between 3o immunisations 1 and 2 was from 14-21 days in all cases. Challenges were performed at 18-29 days after the last immunisation by i.v. injection of 2000 P. berghei sporozoites and blood films assessed at 5, 8 and 10 days post challenge. CSP and TRAP indicate the entire P. berghei antigen and epitope' indicates the cassettes of epitopes shown in table 1 containing T
only a single P. berghei K~-restricted nonamer CTL epitope. Note that in experiment B immunisation with the epitope string alone yields 100%
protection Mice immunised twice with recombinant Ty-VLPs encoding pb9 were fully susceptible to infection. Similarly mice immunised twice with the recombinant MVA encoding the full CS protein were fully susceptible to infection. However, the mice immunised once with the Ty-VLP and subsequently once with the recombinant MVA showed an 85% reduction in malaria incidence when boosted with MVA expressing the full length CS
protein, and 95% when MVA expressing the HM epitope string which includes pb9 was used to boost (Table 7).
Table 7 Results of challenge experiments using different immunisation regimes of Ty-VLPs and MVA
Imrnunisation I Immunisation 2 No. Infected/No.challenged %Protection Ty-CABDHFE Ty- CABDHFE 7/8 13%
Ty-CABDH MVA.PbCSP 2/13 85%
Ty- CABDHFE MVA-NP 5/5 0%
MVA.PbCSP MVA.PbCSP 6/6 0%
MVA.HM Ty- CABDHFE 14/14 0%
Ty=- CABDHFE MVA.HM 1/21 95%
none MVA.HM 8/8 0%
none none 11/12 9%
Table 7 Results of challenge experiments using different immunisation regimes of Ty-VLPs and MVA as indicated. BALB/c mice were used in all cases. Immunisations were of 50 g of Ty-VLP or 10' ffu of recombinant MVA administered intravenously. The interval between immunisations 1 and 2 was from 14-21 days in all cases. Challenges were performed at 18-29 days after the last immunisation by i.v. injection of CA 02293692 1999-12-06 ^
2000 P. berghei sporozoites and blood films assessed at 5, 8 and 10 days post challenge. CSP indicates the entire P. berghei antigen. Ty-VLPs carried epitope cassettes CABDH or CABDHFE as described in table 1.
MVA.HM includes cassettes CAB.
s To determine whether the enhanced immunogenicity and protective efficacy observed by boosting with a recombinant MVA is unique to this particular vaccinia virus strain or is shared by other recombinant vaccinias the following experiment was performed. Mice were immunised with the DNA vaccine encoding P. berghei CS protein and boosted with either (i) recombinant MVA encoding this antigen; (ii) recombinant wild-type vaccinia virus (Western Reserve strain) encoding the same antigen (Satchidanandam et al. 1991), or (iii) recombinant NYVAC (COPAK) virus (Lanar et al. 1996) encoding the same malaria antigen. The highest degree of protection was observed with boosting by the MVA recombinant, 1s 80% (Table 8). A very low level of protection (10%) was observed by boosting with the wild-type recombinant vaccinia virus and a significant level of protection, 60%, by boosting with the NYVAC recombinant. Hence the prime-boost regime we describe induces protective efficacy with any non-replicating vaccinia virus strain. Both the MVA recombinant and 2o NYVAC were significantly (P <0.05 for each) better than the WR strain recombinant.
Table 8 Challenge data results for DNA boosted with various vaccinia strain recombinants.
Immunisation 1 Immunisation 2 No. Infected/No. challenged %Protection DNA-beta gal. MVA.NP 8/8 0%
DNA-CSP MVA-CSP 2/10 80%
DNA-CSP WR-CSP 9/10 10%
DNA-CSP NYVAC-CSP 4/10 60%
7_ lff' Table 8 Results of a challenge experiment using different immunisation regimes of plasmid DNA and various vaccinia recombinants as indicated. BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 ffu/pfu of recombinant MVA or s 10 ffu/pfu of recombinant wild type (WR) vaccinia or 106 ffu/pfu of recombinant NYVAC. Because the WR strain will replicate in the host and the other strains will not, in this experiment a lower dose of WR was used.
The interval between immunisations 1 and 2 was 23 days. Challenges were performed at 28 days after the last immunisation by i.v. injection of t o 2000 P. berghei sporozoites and blood films assessed at 7, 9 and 11 days post challenge. pbCSP indicates the entire P. berghei antigen and NP the nucleoprotein antigen of influenza virus (used as a control antigen). The first immunisation of group A mice was with the plasmid DNA vector expressing beta galactosidase but no malaria antigen.
>> In a further experiment shown in Table 8, mice were immunised with the DNA vaccine encoding P. berghei CS protein and boosted with either (i) recombinant MVA encoding this antigen; (ii) recombinant WR vaccinia virus encoding the same antigen or (iii) recombinant NYVAC (COPAK) virus encoding the same malaria antigen, 2o all at 106 ffu/pfu. A high and statistically significant degree of protection was observed with boosting with recombinant NYVAC (80%) or recombinant MVA (66%). A low and non-significant level of protection (26%) was observed by boosting with the WR recombinant vaccinia virus (Table 9). MVA and NYVAC boosting each gave significantly more 2> protection than WR boosting (P = 0.03 and P = 0.001 respectively). These data re-emphasise that non-replicating pox virus strains are better boosting agents for inducing high levels of protection.
CA 02293692 1999-12-06 =
Table 9 Influence of different recombinant vaccinia strains on protection.
Immunisation 1 Immunisation No. inf./ o DNA 2 No. chall. protection CSP MVA.PbCSP 5/15 66 CSP NYVAC.PbCSP 2/15 80 CSP WR.PbCSP 11/15 26 galactosidase MVA.NP 8/8 0 Table 9 Results of challenge experiments using different immunisation regimes of plasmid DNA and replication incompetent vaccinia recombinants as boosting immunisation. BALB/c mice were used in all cases. The immunisation doses were 50 g of plasmid DNA or 106 -o ffu/pfu of recombinant MVA or recombinant wild type (WR) vaccinia or recombinant NYVAC. The interval between immunisations 1 and 2 was 23 days. Challenges were performed at 28 days after the last immunisation by i.v. injection of 2000 P. berghei sporozoites and blood films assessed at 7, 9 and 11 days post challenge. PbCSP indicates the entire P. berghei antigen and NP the nucleoprotein antigen of influenza virus (used as a control antigen). The control immunisation was with a plasmid DNA vector expressing P-gatactosidase followed by MVA.NP.
Alternative routes for boosting immune responses with recombinant MVA
Intravenous injection of recombinant MVA is not a preferred route for immunising humans and not feasible in mass immunisations.
T _ T
Therefore different routes of MVA boosting were tested for their immunogenicity and protective efficacy.
Mice were primed with plasmid DNA i.m. Two weeks later they were boosted with MVA administered via the following routes: intravenous (i.v.), s subcutaneous (s.c.), intraperitoneal (i.p.), intramuscular (i.p.) and intradermal (i.d.). Two weeks after this boost peptide-specific CD8+ T cells were determined in an ELISPOT assay. The most effective route which induced the highest levels were i.v. and i.d inoculation of MVA. The other routes gave moderate to poor responses (Figure 12).
io Figure 12 shows frequencies of peptide-specific CD8+ T cells following different routes of MVA boosting. Results are shown as the number of spot-forming cells (SFC) per one million splenocytes. Mice were primed with plasmid DNA and two weeks later boosted with MVA via the indicated routes. The number of splenocytes specific for the SYIPSAEKI
15 [SEQ ID NO: 671 peptide was determined in INF-y ELISPOT assays two weeks after the last immunisation. Each bar represents the mean number of SFCs from three mice assayed individually.
Boosting via the i.v. route was compared with the i.d. and i.m route in a challenge experiment. The i.d route gave high levels of 20 protection (80% protection). In the group of animals that were boosted via the i.m. route, 50% of the animals were protected. Complete protection was achieved with MVA boost administered i.v. (Table 10) Table 10 Influence of the route of MVA administration on protective 25 efficacy Irnmunisation Immunisation No. infected/ %
1 2 No. protection DNA MVA challenged CSP CSP i.v. *0/20 100 CSP CSP i.d 2/10 80 CSP CSP i.m. 5/10 50 CA 02293692 1999-12-06 ^
Epitope epitope i.v. 1/10 90 NP NP i.v. 10/10 0 ' culminative data from two independent experiments Table 10 Results from challenge experiments using different routes of MVA boosting immunisation. Animals were primed by intramuscular plasmid DNA injection and two weeks later boosted with the indicated recombinant MVA (106 ffu/mouse) administered via the routes indicated.
The mice were challenged 16 days after the last immunisation with 2000 P.
berghei sporozoites and screened for blood stage parasitemia at day 8 and post challenge. Epitope indicates the polypeptide string HM.
Alternative routes of DNA priming: The use of a gene gun to prime peptide specific CD8+ T cells Gene gun deiivery is described in detail in for example in Eisenbraun et al. DNA Cell Biol. 1993, 12: 791-797 and Degano et al.
1-5 Vaccine 1998, 16: 394-398.
The mouse malaria challenge experiments described so far using plasmid DNA to prime an immune response used intramuscular injection of plasmid DNA. Intradermal delivery of plasmid DNA using a biolistic device is another route to prime specific CTL responses. Plasmid DNA is coated onto gold particles and delivered intradermally with a gene gun. Groups of mice (n=10) were immunised three times at two weeks intervals with the gene gun alone (4 g/immunisation), immunised two times with the gene gun followed by an intravenous MVA.PbCSP boost or immunised intramuscularly with 50 g of pTH.PbCSP and two weeks later boosted with MVA.PbCSP intravenously. Two weeks after the last immunisation the animals were challenged with 2000 sporozoites to assess protective efficacy of each immunisation regimen. In the group that received the intravenous MVA boost following two gene gun immunisations T =
one out of ten animals developed blood stage parasitemia (90%
protection). Complete protection was observed with intramuscular DNA
priming followed by MVA i.v boosting. Seven out of 10 animals that were immunised three times with the gene gun were infected. (30% protection) (Table 11).
lnununisation I lmmunisation 2 Immunisation 3 No. inf./ %
DNA No. protection chall.
gene gun DNA ~ene gun DNA gene gtni DNA 7/10 30 gene gun DNA gene gun DNA MVA.PbCSP 1/10 90 DNA i.m MVA.PbCSP 0/10 100 Na'ive 10/10 0 Table 11 Results of challenge experiments comparing different routes io of DNA priming (intradermally by gene gun versus intramuscular needle injection). Groups of BALB/c mice (n=10) were immunised as indicated.
Each gene gun immunisation delivered 4 g of plasmid DNA
intraepidermally. For i.m. immunisations 50 g of plasmid DNA were injected. Twenty days after the last immunisation mice were challenged as described previously.
Highly susceptible C57BU6 mice are protected C57BL/6 mice are very susceptible to P. berghei sporozoite challenge.
C57BL/6 mice were immunised using the DNA-MVA prime boost regime with both pre-erythrocytic antigens PbCSP and PbTRAP, and challenged with either 200 or 1000 infectious sporozoites per mouse. (Two hundred sporozoites corresponds to more than twice the dose required to induce infection in this strain). All ten mice challenged with 200 sporozoites showed sterile immunity. Even the group challenged with 1000 CA 02293692 1999-12-06 ^
sporozoites, 60% of the mice were protected (Table 12). All the naive C57BL/6 mice were infected after challenge.
Table 12 Protection of C57BL/6 mice from sporozoite challenge 5 No. animals inf./ %
No. challenged protection 1000 sporozoites DNA followed by MVA 4/10 60 Naive 5/5 0 io 200 sporozoites DNA followed by MVA 0/10 100 Na'ive 5/5 0 15 Table 12 Results of a challenge experiment using C57BL/6 mice.
Animals were immunised with PbCSP and PbTRAP using the DNA
followed by MVA prime boost regime. Fourteen days later the mice were challenged with P. berghei sporozoites as indicated.
2o EXAMPLE 4 Protective efficacy of the DNA-priming/MVA-boosting regimen in two further disease models in mice Following immunogenicity studies, the protective efficacy of the DNA-priming MVA-boosting regimen was tested in two additional murine 25 challenge models. The two challenge models were the P815 tumour model and the influenza A virus challenge model. In both model systems CTL
have been shown to mediate protection.
P815 tumour challenges:
3o Groups (n = 10) of DBA/2 mice were immunised with a combination of DNA
followed by MVA expressing a tumour epitope string or the HM epitope r _ string. Two weeks after the last immunisation the mice were challenged intravenously with 105 P815 cells. Following this challenge the mice were monitored regularly for the development of tumour-related signs and survival.
Figure 13 shows the survival rate of the two groups of mice.
Sixty days after challenge eight out of ten mice were alive in the group immunised with the tumour epitopes string. In the group immunised with the HM epitope string only 2 animals survived. This result is statistically significant: 2/10 vs 8/10 chi-squared = 7.2. P = 0.007. The onset of death in the groups of animals immunised with the tumour epitope string is delayed compared to the groups immunised with the HM epitope string.
Influenza virus challenges:
Groups of BALB/c mice were immunised with three gene gun immunisations with plasmid DNA, two intramuscular plasmid DNA
injections, one i.m. DNA injection followed by one MVA.NP boost i.v. or two gene gun immunisations followed by one MVA.NP boost i.v. Plasmid DNA
and recombinant MVA expressed the influenza virus nucleoprotein. Two weeks after the last immunisation the mice were challenged intranasally with 100 HA of influenza A/PRI8/34 virus. The animals were monitored for survival daily after challenge.
Complete protection was observed in the following groups of animals = two DNA gene gun immunisations followed by one MVA.NP boost i.v., = one i.m. DNA injection followed by one MVA.NP boost i.v.
= two i.m. DNA injections.
In the group of animals immunised three times with the gene gun 71 % of the animals survived (5/7) and this difference from the control group was not significant statistically (P > 0.05). In the naive group 25% of the animals survived (Figure 14) and this group differed significantly (P <
0.05) for the two completely protected groups.
CA 02293692 1999-12-06 =
Figure 14 shows results of an influenza virus challenge experiment. BALB/c mice were immunised as indicated. GG = gene gun immunisations, im = intramuscular injection, iv = intravenous injection.
Survival of the animals was monitored daily after challenge.
In a second experiment groups of 10 BALB/c mice were immunised with MVA.NP i.v. alone, three times with the gene gun, two times with the gene gun followed by one MVA.NP boost i.v. and two i.m injections of V1J-NP followed by one MVA.NP boost. Two weeks after the last immunisation the mice were challenged with 100 HA units of influenza A/PR/8/34 virus.
Complete and statistically significant protection was observed in the following groups of animals:
= two gene gun immunisations followed by one MVA.NP boost, = two i.m injections of V1J-NP followed by one MVA.NP boost.
25 In the group receiving one MVA.NP i.v., 30% (3 out of 10) of animals survived. In the group immunised with a DNA vaccine delivered by the gene gun three times, 70% of the animals were protected but this protection was not significantly different from the na'ive controls. In this challenge experiment 40% (4 out of 10) of the naive animals survived the challenge.
Immunogenicity studies in non-human primates 2> lmmunogenicity and protective efficacy of the prime boost regimen in non-human primates.
In order to show that the strong immunogenicity of the DNA
priming/MVA boosting regime observed in mice translates into strong immunogenicity in primates, the regimen was tested in macaques. The vaccine consisted of a string of CTL epitopes derived from HIV and SIV
sequences (Figure 2), in plasmid DNA or MVA, denoted DNA.H and MVA.H respectively. The use of defined CTL epitopes in a polyepitope string allows testing for SIV specific CTL in macaques. Due to the MHC
class I restriction of the antigenic peptides, macaques were screened for their MHC class I haplotype and Mamu-A*01-positive animals were selected for the experiments described.
Three animals (CYD, Di and DORIS) were immunised following this immunisation regimen:
week 0 DNA (8 g, i.d., gene gun) io week 8 DNA (8 g, i.d., gene gun) week 17 MVA (5 x 10$ pfu, i.d.) week 22 MVA (5 x 108 pfu, i.d.) Blood from each animal was drawn at weeks 0, 2, 5, 8, 10, 11, 17, 18, 19, 21, 22, 23, 24 and 25 of the experiment. The animals were monitored for induction of CTL using two different methods. PBMC isolated from each bleed were re-stimulated in vitro with a peptide encoded in the epitope string and tested for their ability to recognise autologous peptide-loaded target cells in a chromium release cytotoxicity assay. Additionally, freshly isolated PBMC were stained for antigen specific CD8+ T cells using tetramers.
Following two gene gun immunisations very low levels of CTL
were detected using tetramer staining (Figure 15). Two weeks after the first MVA boosting, all three animals developed peptide specific CTL as 2~ detected by tetramer staining (Figure 15). This was reflected by the detection of moderate CTL responses following in vitro restimulation (Figure 16, week 19). The second boost with MVA.H induced very high levels of CD8+, antigen specific T cells (Figure 15) and also very high levels of peptide specific cytotoxic T cells (Figure 16, week 23).
Figure 15 shows detection of SIV-specific MHC class I-restricted CD8+ T cells using tetramers. Three Mamu-A"`A01-positive CA 02293692 1999-12-06 ^
macaques were immunised with plasmid DNA (gene gun) followed by MVA
boosting as indicated. Frequencies of Mamu-A*A01/CD8 double-positive T
cells were identified following FACS analysis. Each bar represents the percentage of CD8+ T cells specific for the Mamu-A*01/gag epitope at the s indicated time point. One percent of CD8 T cells corresponds to about 5000/106 peripheral blood lymphocytes. Thus the levels of epitope-specific CD8 T cells in the peripheral blood of these macaques are at least as high as the levels obvserved in the spleens of immunised and protected mice in the malaria studies.
Figure 16 shows CTL induction in macaques following DNA/MVA immunisation. PBMC from three different macaques (CYD, DI
and DORIS) were isolated at week 18, 19 and 23 and were restimulated with peptide CTPYDINQM [SEQ ID NO: 54] in vitro. After two restimulations with peptide CTPYDINQM [SEQ ID NO: 54] the cultures were tested for their lytic activity on peptide-pulsed autologous target cells.
Strong CTL activity was observed.
lmmunogenicity and Challenge Studies in Chimpanzees To show that a similar regime of initial immunisation with plasmid DNA and subsequent immunisation with recombinant MVA can be effective against Plasmodium falciparum malaria in higher primates an immunisation and challenge study was performed with two chimpanzees.
Chimp H1 received an initial immunisation with 500 g of a plasmid expressing Plasmodium faiciparum TRAP from the CMV promoter without intron A, CMV-TRAP. Chimp H2 received the same dose of CMV-LSA-1, which expresses the C-terminal portion of the LSA-1 gene of P. falciparum.
Both chimps received three more immunisations over the next 2 months, but with three plasmids at each immunisation. H1 received CMV-TRAP as before, plus pTH-TRAP, which expresses TRAP using the CMV promoter T _,._... _....._...__. _ _ with intron A, leading to a higher expression level. H1 also received RSV-LSA-1, which expresses the C-terminal portion of LSA-1 from the RSV
promoter. H2 received CMV-LSA-1, pTH-LSA-1 and RSV-TRAP at the second, third and fourth immunisations. The dose was always 500 FLg of 5 each plasmid.
It was subsequently discovered that the RSV plasmids did not express the antigens contained within them, so H1 was only immunised with plasmids expressing TRAP, and H2 with plasmids expressing LSA-1.
10 Between and following these DNA immunisations assays of cellular immune responses were performed at several time points, the last assay being performed at three months following the fourth DNA
immunisation, but no malaria-specific T cells were detectable in either ELISPOT assays or CTL assays for CD8+ T cells.
15 Both animals were subsequently immunised with three doses of 108 ffu of a recombinant MVA virus encoding the P. falciparum TRAP
antigen over a 6 week period. Just before and also following the third recombinant MVA immunisation T cell responses to the TRAP antigen were detectable in both chimpanzees using an ELISPOT assay to whole 2o TRAP protein bound to latex beads. This assay detects both CD4+ and CD8+ T cell responses. Specific CD8+ T responses were searched for with a series of short 8-11 amino acid peptides in both immunised chimpanzees. Such analysis for CD8+ T cell responses indicated that CD8+ T cells were detectabie only in the chimpanzee H1. The target 25 epitope of these CD8+ T lymphocytes was an 11 amino acid peptide from TRAP, tr57, of sequence KTASCGVWDEW [SEQ ID NO: 781. These CD8+ T cells from H1 had lytic activity against autologous target cells pulsed with the tr57 peptide and against autologous target cells infected with the recombinant PfTRAP-MVA virus. A high precursor frequency of 30 these specific CD8+ T cells of about 1 per 500 lymphocytes was detected CA 02293692 1999-12-06 ^
in the peripheral blood of this chimpanzee H1 using an ELISPOT assay two months following the final MVA immunisation. No specific CD8+ T cell response was clearly detected in the chimpanzee H2, which was not primed with a plasmid DNA expressing TRAP.
Two months after the third PfTRAP-MVA immunisation challenge of H1 and H2 was performed with 20,000 sporozoites, a number that has previously been found to yield reliably detectable blood stage infection in chimpanzees 7 days after challenge (Thomas et al. 1994 and unpublished data). The challenge was performed with the NF54 strain of Plasmodium falciparum. This is of importance because the TRAP
sequence in the plasmid DNA and in the recombinant MVA is from the T9/96 strain of P. falciparum which has numerous amino acid differences to the NF54 TRAP allele (Robson et al. 1990). Thus, this sporozoite challenge was performed with a heterologous rather than homologous strain of parasite. In the chimpanzee H2 parasites were detectable in peripheral blood as expected 7 days after sporozoite challenge using in v i t r o parasite culture detection. However, in H 1 the appearance of blood stage parasites in culture from the day 7 blood samples was delayed by three days consistent with some immune protective effect against the liver-stage infection. In studies of previous candidate malaria vaccines in humans a delay in the appearance of parasites in the peripheral blood has been estimated to correspond to a substantial reduction in parasite density in the liver (Davis et al. 1989). Thus the chimpanzee HI, immunised first with P. falciparum TRAP plasmid DNA and subsequently with the same antigen expressed by a recombinant MVA virus showed a strong CD8+ T
lymphocyte response and evidence of some protection from heterologous sporozoite challenge.
i DISCUSSION
These examples demonstrate a novel regime for immunisation against malaria which induces high levels of protective CD8+
T cells in rodent models of human malaria infection. Also demonstrated is ~ an unprecedented complete protection against sporozoite challenge using subunit vaccines (36 out of 36 mice protected in Table 6 using DNA
priming and MVA boosting with the CS epitope containing vaccines).
Induction of protective immune responses using the DNA priming/MVA
boosting regimen was demonstrated in two additional mouse models of io viral infection influenza A model and cancer (P815 tumour model). More importantly for vaccines for use in humans this immunisation regimen is also highly immunogenic for CD8+ T cells in primates. Strong SIV-gag-specific CTL were induced in 3 out of 3 macaques with plasmid DNA and MVA expressing epitope strings. The levels induced are comparable to t 5 those found in SIV-infected animals. The data from the chimpanzee studies indicate that the same immunisation regime can induce a strong CD8+ T lymphocyte response against P. falciparum in higher primates with some evidence of protection against P. falciparum sporozoite challenge.
Ty-VLPs have previously been reported to induce good levels 20 of CD8+ T cell responses against the P. berghei rodent malaria (Allsopp et al. 1995) but alone this construct is not protective. It has now been found that subsequent immunisation with recombinant MVA boosts the CD8+ T
cell response very substantially and generates a high level of protection (Table 7).
25 Recombinant MVA viruses have not been assessed for efficacy as malaria vaccines previously. Recombinant MVA alone was not significantly protective, nor was priming with recombinant MVA followed by a second immunisation with recombinant plasmid DNA. However, a second immunisation with the recombinant MVA following an initial 30 immunisation with either Ty-VLPs or plasmid DNA yielded impressive CA 02293692 1999-12-06 =
levels of protection. Non-recombinant MVA virus has been safely used to vaccinate thousands of human against smallpox and appears to have an excellent safety profile. The molecular basis of the increased safety and immunogenicity of this strain of vaccinia virus is being elucidated by detailed molecular studies (Meyer et al. 1991; Sutter at al. 1994).
Plasmid DNA has previously been tested as a malaria vaccine for the P. yoelii rodent malaria. High levels of, but not complete, protection is seen in some strains but in other strains of mice little or no protection was observed even after multiple immunisations (Doolan et al.
1996). Although plasmid DNA has been proposed as a method of immunisation against P. falciparum, success has not previously been achieved. The evidence provided here is the first evidence to show that plasmid DNA may be used in an immunisation regime to induce protective immunity against the human malaria parasite P. falciparum.
A similar regime of immunisation to the regime demonstrated herein can be expected to induce useful protective immunity against P.
falciparum in humans. It should be noted that five of the vaccine constructs employed in these studies to induce protective immunity in rodents or chimpanzees contain P. falciparum sequences and could therefore be used for human immunisation against P. falciparum. These are: 1. The P. falciparum TRAP plasmid DNA vaccine. 2. The P.
falciparum TRAP recombinant MVA virus. 3. The Ty-VLP encoding an epitope string of numerous P falciparum epitopes, as well as the single P.
berghei CTL epitope. 4. The plasmid DNA encoding the same epitope string as 3. 5. The recombinant MVA encoding the longer HM epitope string including many of the malaria epitopes in 3 and 4. Similarly the plasmid DNAs and MVA encoding HIV epitopes for human class I
molecules could be used in either prophylactic or therapeutic immunisation against HIV infection.
T ._..._. .. .... _._.._.._~-...._a_....----..... ... ... ....... .. r These studies have provided clear evidence that a novel sequential immunisation regime employing a non-replicating or replication-impaired pox virus as a boost is capable of inducing a strong protective CD8+ T cell response against the malaria parasite. The examples demonstrate clearly a surprising and substantial enhancement of CD8+ T
cell responses and protection compared to replicating strains of pox viruses. Because there is no reason to believe that the immunogenicity of CD8+ T cell epitopes from the malaria parasite should differ substantially from CD8+ T cell epitopes in other antigens it is expected that the immunisation regime described herein will prove effective at generating CD8+ T cell responses of value against other diseases. The critical step in this immunisation regimen is the use of non-replicating or replication-impaired recombinant poxviruses to boost a pre-existing CTL response.
We have shown that CTL responses can be primed using different antigen delivery systems such as a DNA vaccine i.d. and i.m, a recombinant Ty-VLP, a recombinant adenovirus and irradiated sporozoites. This is supported by the data presented on the generation of a CD8+ T cell response against HIV, influenza virus and tumours. Amongst several known examples of other diseases against which a CD8+ T cell immune response is important are the following: infection and disease caused by the viruses HIV, herpes simplex, herpes zoster, hepatitis C, hepatitis B, influenza, Epstein-Barr virus, measles, dengue and HTLV-1; by the bacteria Mycobacterium tuberculosis and Listeria sp.; and by the protozoan parasites Toxoplasma and Trypanosoma. Induction of protective CTL
responses against influenza A virus has been demonstrated in Figure 14.
Furthermore, the immunisation regime described herein is expected to be of value in immunising against forms of cancer where CD8+ T cell responses plays a protective role. The induction of protective CTL
responses using the DNA prime MVA boost regime against tumours is CA 02293692 1999-12-06 ^
shown in Figure 13. Specific examples in humans include melanoma, cancer of the breast and cancer of the colon.
References s 1. Nardin EH & Nussenzweig RS. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annual Review of Immunology (1993) 11: 687-727.
io 2. Hill AVS, Allsopp, CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM. (1991) Common West African HLA antigens are associated with protection from severe malaria. Nature 352: 595-600 3. Aidoo M, Lafvani A, Allsopp CEM, et al. Identification of conserved 1s antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. The Lancet. (1995) 345: 1003-1007.
4. Wizel B, Houghten RA, Parker KC, Coligan JE, Church P, Gordon DM, Ballou WR, Hoffman SL. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two 20 overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J. Exp Med. (1995) 182: 1435-45.
5. Lalvani A, Aidoo M, Allsopp CE, Plebanski M, Whittle HC, Hill AV. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. Research in Immunology (1994) 25 145: 461-8.
6. Seguin MC, Klotz FW, Schneider I, Weir JP, Goodbary M, Slayter M, Raney JJ, Aniagolu JU, Green SJ. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and 30 CD8+ T cells. J. Exp. Med. (1994) 180: 353-8.
T i 7. Thomas AW, Slierendregt B, Mons B, Druilhe P. Chimpanzees and supporting models in the study of malaria pre-erythrocytic stages.
Mem. Inst. Oswaldo Cruz. (1994) 89 Suppl 2: 111-4.
8. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl. Acad. Sci USA. (1994) 91:
9. Li S, Rodrigues M, Rodriguez D, Rodriguez JR, Esteban M, Palese P, Nussenzweig RS, Zavala F. Priming with recombinant influenza io virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.
Proc. Natl. Acad. Sci. USA. (1993) 90: 5214-8.
10. Lanar DE, Tine JA, de-Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and Immunity (1996) 64: 1666-71.
11.Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo et al.
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 279: 2103-6 12. Ada G. Do cytotoxic T lymphocytes clear some HIV/SIV infections?
Journal of Medical Primatology (1996) 25: 158-62.
13. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, 2 5 Silvera P, Dennis M, Corcoran T, Stott J et-al Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine (1995) 1: 1167-73.
14. Mayr A, Hochstein-Mintzel V, Sticki H. Infection (1975) 33: 6-14.
15. Mayr A, Zentralbl Veterinarmed B (1976) 23: 417-30.
CA 02293692 1999-12-06 =
16. Mayr A, Stickl H., Muller HK, Danner K, Singer H. Zentralbl Bakteriol B.
(1978) 167: 375- 90.
17. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. Dtsch Med Wochenschr. (1974) 99: 23866-922.
> 18. Mahnel H, Mayr A. Berl Munch Tierarztl Wochenschr (1994) 107: 253-6.
19. Meyer H, Sutter G, Mayr A. J Gen Virol. (1991) 72: 1031-8.
20. Altenburger W, Suter CP, Altenburger J. Arch Virol. (1989) 105: 15-27.
21. Sutter G, Ramsey-Ewing A, Rosales R, Moss B. J. Virol. (1994) 68:
4109-16.
22. Sutter G, Moss B. Proc Natl Acad Sci U S A (1992) 89: 10847-51.
23. Sutter GW, Wyatt LS, Foley PL, Bennink JR, Moss B. Vaccine (1994).
12: 1032-40.
24. Hirsch VM, Goldstein S, Channock R, et al. Channock R. ed Vaccines 95. Cold Spring Harbor Laboratory Press, (1995) 195-200.
25. Hirsch VM, Fuerst TR, Sutter G, et al. J. Virol. (1996) 70: 3741-52.
26. Moss B, Carroll MW, Wyatt L, et al. In: Anonymous, ed. Vaccines:
Novel strategies in design and production. Plenum Pres (1995).
27. Symons JA, Alcami A, Smith GL. Cell. (1995) 81: 551-60.
28. Alcami A, Smith GL. J. Virol. (1995) 69: 4633-9.
29. Alcami A, Smith GL. Cell. (1992) 71: 153-67.
30. Graham KA et al. Virology (1997) 229: 12-24.
31. Alcami A, Smith GL. Proc. Natl. Acad. Sci. USA (1996) 93:11029-34.
32. Blanchard TJ, Rowland-Jones S, Gotch F, McMichael AJ, Smith GL.
Lancet (1997) 348: 1741 33. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC. J. Infect. Dis. (1994) 170(5): 1100-9.
34. Davis NL, Brown KW, Johnston RE, J. Virol, (1996) 70(6): 3781-7.
35. Layton GT, Harris SJ, Myhan J, West D, Gotch F, Hill-Perkins M, Cole JS, Meyers N, Woodrow S, French TJ, Adams SE, Kingsman AJ.
. .. .. T.. ._......_ ___.._.___._ ...._ . .. . .... .. .... . . . i Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology (1996) 87: 171-8.
36. McGrory-WJ; Bautista-DS; Graham-FL A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology (1988) 163: 614-7 37. Rodrigues EG, Zavala F, Eichinger D, Wifson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. Journal io of Immunology (1997) 158: 1268-74.
38. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Molecular Genetics (1993) 2: 1847-51.
39. Miyahira Y, Murata K, Rodriguez D et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J lmmunol Methods (1995) 18: 45-54.
40. Allsopp CEM, Plebanski M, Gilbert S et al. (1996) Comparison of numerous delivery systems for the induction of cytotoxic T
lymphocytes. European Journal of Immunology (1996) 26:1951-1959.
41. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+
T cell-mediated protective immunity against malaria. J. Immunol.
(1997) 158: 1268-74.
42. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, Milich D.
immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med. (1994) 180:
1037-46.
CA 02293692 1999-12-06 =
43. Satchidanandam V, Zavala F, Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol. Biochem. Parasitol. (1991) 48: 89-99.
44. Davis JR; Murphy JR; Baqar S; Clyde DF; Herrington DA; Levine MM.
s Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Transactions of the Royal Society for Tropical Medicine and Hygiene. (1989) 83: 748-50.
45. Meyer, H., Sutter, G. and Mayr, A. (1991). Mapping of deletions in the io genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-38.
46. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice 1s to influenza virus. Vaccine (1994) 12: 1032-40.
47. Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman, SL Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med. (1996) 20 183:1739-46.
48. Muller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. Thrombospondin related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells suggesting a role for 25 this molecule in sporozoite invasion of hepatocytes. EMBO-J. (1993) 12: 2881-9.
49. Chakrabarti S et al. Mol. Cell. Biol. (1995) 5: 3403-9.
50. Morrison HG, Bauer SP, Lange JV, Esposito JJ, McCormick JB, Auperin DD Protection of guinea pigs from Lassa fever by vaccinia r i virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology. (1989) 171: 179-88.
51. Mackett M et al. J. Virol. (1984) 49: 857-864.
52. Carroll MW and Moss BE, Biotechnology (1995) 19: 352-4.
----- - -- -- -- --INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis) A. 'ilte indications made below relate to the microorganism referred to in the description on page 12 , line 1 0 - 13 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet 0 Name of depositary institution European Collection of Animal Cell Cultures (CAMR) Address of depositary institution (including postal code and country) Salisbury Wiltshire United Kingdom Date of deposit Accession Number June 1997 V97060511 C. ADDTTIONAL INDICATIONS (leave blank ijnot applicable) This information is continued on an additional sheet Q
In respect of all designated States to which such action is possibl and to the extent that it is legally permissible under the law of the designated State, it is requested that a sample of the deposited microorganism be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. EPC Rule 28(4), UK Patent Rules 1995, Schedule 2, Paragraph 3, Australian Regulation 3.25(3), Danish D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not jor all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) TheindieationslistedbelowwillbesubmittedtotheInternationalBureaulater(specifyt/
tegeneralnatureoftheindicationse.g., Accession Number ofDeposit) For receiving Office use only For Intemational Bureau use only ~ This sheet was received with the international application This sheet was received by the International Bureau on:
0? SEP'iQO
Authorized officer Authorized ofCicer Form PC'T/RO/134 (July 1992) ~', INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
C. ADDITIONAL INDICATIONS (continued) Patents Act Sections 22 and 33(3), Icelandic Patents Act Sections 22 and 33(3), Norwegian Patents Act Sections 22 and 33(3) and generally similar provisions mutatis mutandis for any other designated State.
SEQUENCE LISTING
GENERAL INFORMATION
APPLICANT: OXXON PHARMACCINES LIMITED
TITLE: METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A
NUMBER OF SEQUENCES: 78 CORRESPONDENCE ADDRESS: KIRBY EADES GALE BAKER
OTTAWA, ON
CANADA, K1P 6N9 COMPUTER-READABLE FORM
MEDIUM TYPE: Floppy disk COMPUTER: IBM TYPE PC
OPERATING SYSTEM: WINDOWS 95 SOFTWARE: PATENTIN V. 2.1 CURRENT APPLICATION DATA
APPLICATION NUMBER: 2,293,692 FILING DATE: 1988-06-09 CLASSIFICATION:
PRIOR APPLICATION DATA
APPLICATION NUMBER: GB 9711957.2 FILING DATE: 1997-06-09 CLASSIFICATION:
PATENT AGENT INFORMATION
NAME: EDWIN J. GALE
REFERENCE NUMBER: 44072-NP
INFORMATION FOR SEQ ID NO: 1 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 1 aag ccg aac gac aag tcc ttg tat 24 Lys Pro Asn Asp Lys Ser Leu Tyr INFORMATION FOR SEQ ID NO: 2 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 2 Lys Pro Asn Asp Lys Ser Leu Tyr INFORMATION FOR SEQ ID NO: 3 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 3 aaa cct aag gac gaa ttg gac tac 24 Lys Pro Lys Asp Glu Leu Asp Tyr INFORMATION FOR SEQ ID NO: 4 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 4 Lys Pro Lys Asp Glu Leu Asp Tyr INFORMATION FOR SEQ ID NO: 5 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 5 aag cca atc gtt caa tac gac aac ttc 27 Lys Pro Ile Val Gln Tyr Asp Asn Phe INFORMATION FOR SEQ ID NO: 6 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 6 Lys Pro Ile Val Gln Tyr Asp Asn Phe INFORMATION FOR SEQ ID NO: 7 SEQUENCE CHARACTERISTICS
LENGTH: 33 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(33) SEQUENCE DESCRIPTION: SEQ ID NO: 7 gcc tcc aag aac aag gaa aag gct ttg atc atc 33 Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile INFORMATION FOR SEQ ID NO: 8 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 8 Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile INFORMATION FOR SEQ ID NO: 9 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 9 ggt atc gct ggt ggt ttg gcc ttg ttg 27 Gly Ile Ala Gly Gly Leu Ala Leu Leu INFORMATION FOR SEQ ID NO: 10 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 10 Gly Ile Ala Gly Gly Leu Ala Leu Leu INFORMATION FOR SEQ ID NO: 11 SEQUENCE CHARACTERISTICS
LENGTH: 30 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(30) SEQUENCE DESCRIPTION: SEQ ID NO: 11 atg aac cct aat gac cca aac aga aac gtc 30 Met Asn Pro Asn Asp Pro Asn Arg Asn Val INFORMATION FOR SEQ ID NO: 12 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 12 Met Asn Pro Asn Asp Pro Asn Arg Asn Val INFORMATION FOR SEQ ID NO: 13 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 13 atg atc aac gcc tac ttg gac aag ttg 27 Met Ile Asn Ala Tyr Leu Asp Lys Leu INFORMATION FOR SEQ ID NO: 14 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 14 Met Ile Asn Ala Tyr Leu Asp Lys Leu INFORMATION FOR SEQ ID NO: 15 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 15 atc tcc aag tac gaa gac gaa atc 24 Ile Ser Lys Tyr Glu Asp Glu Ile INFORMATION FOR SEQ ID NO: 16 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 16 Ile Ser Lys Tyr Glu Asp Glu Ile INFORMATION FOR SEQ ID NO: 17 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 17 tcc tac atc cca tct gcc gaa aag atc 27 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 18 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 18 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 19 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 19 cac ttg ggt aac gtt aag tac ttg gtt 27 His Leu Gly Asn Val Lys Tyr Leu Val INFORMATION FOR SEQ ID NO: 20 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 20 His Leu Gly Asn Val Lys Tyr Leu Val INFORMATION FOR SEQ ID NO: 21 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 21 aag tct ttg tac gat gaa cac atc 24 Lys Ser Leu Tyr Asp Glu His Ile INFORMATION FOR SEQ ID NO: 22 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 22 Lys Ser Leu Tyr Asp Glu His Ile INFORMATION FOR SEQ ID NO: 23 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 23 tta ttg atg gac tgt tct ggt tct att 27 Leu Leu Met Asp Cys Ser Gly Ser Ile INFORMATION FOR SEQ ID NO: 24 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 24 Leu Leu Met Asp Cys Ser Gly Ser Ile INFORMATION FOR SEQ ID NO: 25 SEQUENCE CHARACTERISTICS
LENGTH: 48 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(48) SEQUENCE DESCRIPTION: SEQ ID NO: 25 aac gct aat cca aac gca aat ccg aac gcc aat cct aac gcg aat ccc 48 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro INFORMATION FOR SEQ ID NO: 26 SEQUENCE CHARACTERISTICS
LENGTH: 16 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 26 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro INFORMATION FOR SEQ ID NO: 27 SEQUENCE CHARACTERISTICS
LENGTH: 60 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(60) SEQUENCE DESCRIPTION: SEQ ID NO: 27 gac gaa tgg tct cca tgt tct gtc act tgt ggt aag ggt act cgc tct 48 Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser aga aag aga gaa 60 Arg Lys Arg Glu INFORMATION FOR SEQ ID NO: 28 SEQUENCE CHARACTERISTICS
LENGTH: 20 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 28 Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser Arg Lys Arg Glu INFORMATION FOR SEQ ID NO: 29 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 29 tac ttg aac aaa att caa aac tct ttg 27 Tyr Leu Asn Lys Ile Gln Asn Ser Leu INFORMATION FOR SEQ ID NO: 30 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 30 Tyr Leu Asn Lys Ile Gln Asn Ser Leu INFORMATION FOR SEQ ID NO: 31 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(27) SEQUENCE DESCRIPTION: SEQ ID NO: 31 atg gaa aag ttg aaa gaa ttg gaa aag 27 Met Glu Lys Leu Lys Glu Leu Glu Lys INFORMATION FOR SEQ ID NO: 32 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 32 Met Glu Lys Leu Lys Glu Leu Glu Lys INFORMATION FOR SEQ ID NO: 33 SEQUENCE CHARACTERISTICS
LENGTH: 24 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(24) SEQUENCE DESCRIPTION: SEQ ID NO: 33 gct act tct gtc ttg gct ggt ttg 24 Ala Thr Ser Val Leu Ala Gly Leu INFORMATION FOR SEQ ID NO: 34 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 34 Ala Thr Ser Val Leu Ala Gly Leu INFORMATION FOR SEQ ID NO: 35 SEQUENCE CHARACTERISTICS
LENGTH: 48 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(48) SEQUENCE DESCRIPTION: SEQ ID NO: 35 gac cca aac gct aac cca aac gtt gac cca aac gcc aac cca aac gtc 48 Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val INFORMATION FOR SEQ ID NO: 36 SEQUENCE CHARACTERISTICS
LENGTH: 16 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 36 Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val INFORMATION FOR SEQ ID NO: 37 SEQUENCE CHARACTERISTICS
LENGTH: 42 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(42) SEQUENCE DESCRIPTION: SEQ ID NO: 37 caa gtt cac ttc caa cca ttg cct ccg gcc gtt gtc aag ttg 42 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu INFORMATION FOR SEQ ID NO: 38 SEQUENCE CHARACTERISTICS
LENGTH: 14 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 38 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu INFORMATION FOR SEQ ID NO: 39 SEQUENCE CHARACTERISTICS
LENGTH: 42 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope FEATURE
NAME/KEY: CDS
LOCATION: (1)..(42) SEQUENCE DESCRIPTION: SEQ ID NO: 39 caa ttc atc aag gcc aac tct aag ttc atc ggt atc acc gaa 42 Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu INFORMATION FOR SEQ ID NO: 40 SEQUENCE CHARACTERISTICS
LENGTH: 14 TYPE: PRT
ORGANISM: Artificial Sequence OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
encoding epitope SEQUENCE DESCRIPTION: SEQ ID NO: 40 Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu INFORMATION FOR SEQ ID NO: 41 SEQUENCE CHARACTERISTICS
LENGTH: 229 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 41 Met Ile Asn Ala Tyr Leu Asp Lys Leu Ile Ser Lys Tyr Glu Asp Glu Ile Ser Tyr Ile Pro Ser Ala Glu Lys Ile Gly Ser Lys Pro Asn Asp Lys Ser Leu Tyr Lys Pro Lys Asp Glu Leu Asp Tyr Lys Pro Ile Val Gln Tyr Asp Asn Phe Gly Ser Ala Ser Lys Asn Lys Glu Lys Ala Leu Ile Ile Gly Ile Ala Gly Gly Leu Ala Leu Leu Met Asn Pro Asn Asp Pro Asn Arg Asn Val Gly Ser His Leu Gly Asn Val Lys Tyr Leu Val Lys Ser Leu Tyr Asp Glu His Ile Leu Leu Met Asp Cys Ser Gly Ser Ile Gly Ser Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn Val Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu Gln Phe Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Gly Ser Tyr Leu Asn Lys Ile Gln Asn Ser Leu Met Glu Lys Leu Lys Glu Leu Glu Lys Ala Thr Ser Val Leu Ala Gly Leu Gly Ser Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asp Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Lys Gly Thr Arg Ser Arg Lys Arg Glu Gly Ser Gly Lys INFORMATION FOR SEQ ID NO: 42 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 42 Tyr Leu Lys Asp Gln Gln Leu Leu INFORMATION FOR SEQ ID NO: 43 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 43 Glu Arg Tyr Leu Lys Asp Gln Gln Leu INFORMATION FOR SEQ ID NO: 44 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 44 Glu Ile Thr Pro Ile Gly Leu Ala Pro INFORMATION FOR SEQ ID NO: 45 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 45 Pro Pro Ile Pro Val Gly Glu Ile Tyr INFORMATION FOR SEQ ID NO: 46 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 46 Gly Glu Ile Tyr Lys Arg Trp Ile Ile INFORMATION FOR SEQ ID NO: 47 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 47 Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys INFORMATION FOR SEQ ID NO: 48 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 48 Ile Ile Leu Gly Leu Asn Lys Ile Val Arg INFORMATION FOR SEQ ID NO: 49 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 49 Leu Gly Leu Asn Lys Ile Val Arg Met Tyr INFORMATION FOR SEQ ID NO: 50 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 50 Tyr Asn Leu Thr Met Lys Cys Arg INFORMATION FOR SEQ ID NO: 51 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 51 Arg Gly Pro Gly Arg Ala Phe Val Thr Ile INFORMATION FOR SEQ ID NO: 52 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 52 Gly Arg Ala Phe Val Thr Ile Gly Lys INFORMATION FOR SEQ ID NO: 53 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 53 Thr Pro Tyr Asp Ile Asn Gln Met Leu Pro INFORMATION FOR SEQ ID NO: 54 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 54 Cys Thr Pro Tyr Asp Ile Asn Gln Met INFORMATION FOR SEQ ID NO: 55 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 55 Arg Pro Gln Val Pro Leu Arg Pro Met Thr Tyr INFORMATION FOR SEQ ID NO: 56 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 56 Gln Val Pro Leu Arg Pro Met Thr Tyr Lys INFORMATION FOR SEQ ID NO: 57 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 57 Val Pro Leu Arg Pro Met Thr Tyr INFORMATION FOR SEQ ID NO: 58 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 58 Ala Val Asp Leu Ser His Phe Leu Lys INFORMATION FOR SEQ ID NO: 59 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 59 Asp Leu Ser His Phe Leu Lys Glu Lys INFORMATION FOR SEQ ID NO: 60 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 60 Phe Leu Lys Glu Lys Gly Gly Leu INFORMATION FOR SEQ ID NO: 61 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 61 Ile Leu Lys Glu Pro Val His Gly Val INFORMATION FOR SEQ ID NO: 62 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 62 Ile Leu Lys Glu Pro Val His Gly Val Tyr INFORMATION FOR SEQ ID NO: 63 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 63 His Pro Asp Ile Val Ile Tyr Gln Tyr INFORMATION FOR SEQ ID NO: 64 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 64 Val Ile Tyr Gln Tyr Met Asp Asp Leu INFORMATION FOR SEQ ID NO: 65 SEQUENCE CHARACTERISTICS
LENGTH: 45 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 65 Met Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Gln His Pro Asn Ala Glu Leu Leu Lys His Tyr Leu Phe Arg Asn Leu Ser Pro Ser Tyr Val Tyr His Gln Phe Ile Pro Asn Pro Leu Leu Gly Leu Asp INFORMATION FOR SEQ ID NO: 66 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 66 Leu Pro Tyr Leu Gly Trp Leu Val Phe INFORMATION FOR SEQ ID NO: 67 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 67 Ser Tyr Ile Pro Ser Ala Glu Lys Ile INFORMATION FOR SEQ ID NO: 68 SEQUENCE CHARACTERISTICS
LENGTH: 10 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 68 Arg Gly Pro Gly Arg Ala Phe Val Thr Ile INFORMATION FOR SEQ ID NO: 69 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 69 Thr Pro His Pro Ala Arg Ile Gly Leu INFORMATION FOR SEQ ID NO: 70 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 70 Thr Tyr Gln Arg Thr Arg Ala Leu Val INFORMATION FOR SEQ ID NO: 71 SEQUENCE CHARACTERISTICS
LENGTH: 8 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 71 Ser Asp Tyr Glu Gly Arg Leu Ile INFORMATION FOR SEQ ID NO: 72 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 72 Ala Ser Asn Glu Asn Met Glu Thr Met INFORMATION FOR SEQ ID NO: 73 SEQUENCE CHARACTERISTICS
LENGTH: 9 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence:peptide SEQUENCE DESCRIPTION: SEQ ID NO: 73 Ile Asn Val Ala Phe Asn Arg Phe Leu INFORMATION FOR SEQ ID NO: 74 SEQUENCE CHARACTERISTICS
LENGTH: 33 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 74 cctgactcag accatatggg ctctcactcc atg 33 INFORMATION FOR SEQ ID NO: 75 SEQUENCE CHARACTERISTICS
LENGTH: 85 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 75 gtgataagct taacgatgat tccacaccat tttctgtgca tccagaatat gatgcaggga 60 tccctcccat ctcagggtga ggggc 85 INFORMATION FOR SEQ ID NO: 76 SEQUENCE CHARACTERISTICS
LENGTH: 27 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 76 tcagaccata tgtctcgctc cgtggcc 27 INFORMATION FOR SEQ ID NO: 77 SEQUENCE CHARACTERISTICS
LENGTH: 31 TYPE: DNA
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
primer SEQUENCE DESCRIPTION: SEQ ID NO: 77 tcagacaagc ttttacatgt ctcgatccca c 31 INFORMATION FOR SEQ ID NO: 78 SEQUENCE CHARACTERISTICS
LENGTH: 11 TYPE: PRT
ORGANISM: Artificial Sequence FEATURE
OTHER INFORMATION: Description of Artificial Sequence: peptide SEQUENCE DESCRIPTION: SEQ ID NO: 78 Lys Thr Ala Ser Cys Gly Val Trp Asp Glu Trp
Claims (89)
1. A kit for generating a protective CD8+ T cell immune response against at least one target antigen, which kit comprises:
(i) a priming composition comprising a source of one or more CD8+ T
cell epitopes of the target antigen, wherein the source of CD8+ T
cell epitopes in (i) is a non-viral vector or a non-replicating or replication-impaired viral vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T
cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier;
with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
(i) a priming composition comprising a source of one or more CD8+ T
cell epitopes of the target antigen, wherein the source of CD8+ T
cell epitopes in (i) is a non-viral vector or a non-replicating or replication-impaired viral vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T
cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is a non-replicating or replication-impaired recombinant poxvirus vector, together with a pharmaceutically acceptable carrier;
with the proviso that if the source of epitopes in (i) is a viral vector, the viral vector in (ii) is derived from a different virus.
2. The kit according to claim 1, with the proviso that the source of CD8+ T cell epitopes in (i) is other than a poxvirus vector.
3. The kit according to claim 1 or claim 2, wherein the source of CD8+ T cell epitopes in (i) is DNA or RNA.
4. The kit according to claim 3, wherein the source of epitopes in (i) is a recombinant DNA plasmid.
5. The kit according to claim 3 or claim 4, further comprising GM-CSF as an adjuvant for (i).
6. The kit according to any one of claims 1 to 5, wherein the source of CD8+ T cell epitopes in (i) encodes or comprises the target antigen.
7. The kit according to any one of claims 3 to 5, wherein the source of epitopes in (i) encodes a single CD8+ T cell epitope or a recombinant string of two or more CD8+ T cell epitopes.
8. The kit according to claim 1 or claim 2, wherein the source of epitopes in (i) is a peptide, polypeptide, protein, polyprotein or particle comprising two or more CD8+ T cell epitopes, present in a recombinant string of CD8+ T cell epitopes or in a target antigen.
9. The kit according to claim 8, wherein the source of CD8+ T cell epitopes in (i) is a recombinant protein particle.
10. The kit according to claim 1 or claim 2, wherein the source of epitopes in (i) is a recombinant adenovirus vector.
11. The kit according to any one of claims 1 to 10, wherein the source of CD8+ T cell epitopes in (ii) is a recombinant vaccinia virus vector.
12. The kit according to claim 11, wherein the recombinant vaccinia virus vector is of the vaccinia virus strain Modified Virus Ankara (MVA), or a strain derived therefrom.
13. The kit according to claim 11, wherein the recombinant vaccinia virus vector is of the strain NYVAC or a strain derived therefrom.
14. The kit according to any one of claims 1 to 10, wherein the source of CD8+ T cell epitopes in (ii) is a recombinant avipox vector.
15. The kit according to any one of claims 1 to 14, for generating a protective immune response against a pathogen or cancer comprising the target antigen.
16. The kit according to claim 15, for generating a protective immune response against a malaria pathogen.
17. The kit according to claim 16, wherein the CD8+ T cell epitopes in or encoded by (i) include one or more malaria epitopes from the following list KPNDKSLY; KPKDELDY; KPIVQYDNF; ASKNKEKALII; GIAGGLALL;
MNPNDPNRNV; MINAYLDKL; ISKYEDEI; SYIPSAEKI; HLGNVKYLV;
KSLYDEHI; LLMDCSGSI; YLNKIQNSL; MEKLKELEK; ATSVLAGL.
MNPNDPNRNV; MINAYLDKL; ISKYEDEI; SYIPSAEKI; HLGNVKYLV;
KSLYDEHI; LLMDCSGSI; YLNKIQNSL; MEKLKELEK; ATSVLAGL.
18. The kit according to claim 17, wherein the CD8+ T cell epitopes in (i) include all of the following epitopes KPNDKSLY; KPKDELDY;
KPIVQYDNF; ASKNKEKALII; GIAGGLALL; MNPNDPNRNV; MINAYLDKL;
ISKYEDEI; SYIPSAEKI; HLGNVKYLV; KSLYDEHI; LLMDCSGSI;
YLNKIQNSL; MEKLKELEK; ATSVLAGL.
KPIVQYDNF; ASKNKEKALII; GIAGGLALL; MNPNDPNRNV; MINAYLDKL;
ISKYEDEI; SYIPSAEKI; HLGNVKYLV; KSLYDEHI; LLMDCSGSI;
YLNKIQNSL; MEKLKELEK; ATSVLAGL.
19. The kit according to claim 15, for generating an immune response against HIV.
20. The kit according to claim 19, wherein the CD8+ T cell epitopes in or encoded by (i) include one or more HIV epitopes from the following list YLKDQQLL; ERYLKDQQL; EITPIGLAP; PPIPVGEIY; GEIYKRWII;
KRWIILGLNK; IILGLNKIVR; LGLNKIVRMY; YNLTMKCR; RGPGRAFVTI;
GRAFVTIGK; TPYDINQML; CTPYDINQM; RPQVPLRPMTY;
QVPLRPMTYK; VPLRPMTY; AVDLSHFLK; DLSHFLKEK; FLKEKGGL;
ILKEPVHGV; ILKEPVHGVY; HPDIVIYQY; VIYQYMDDL.
KRWIILGLNK; IILGLNKIVR; LGLNKIVRMY; YNLTMKCR; RGPGRAFVTI;
GRAFVTIGK; TPYDINQML; CTPYDINQM; RPQVPLRPMTY;
QVPLRPMTYK; VPLRPMTY; AVDLSHFLK; DLSHFLKEK; FLKEKGGL;
ILKEPVHGV; ILKEPVHGVY; HPDIVIYQY; VIYQYMDDL.
21. The kit according to claim 19, wherein the CD8+ T cell epitopes in or encoded by (i) include all of the following epitopes YLKDQQLL;
ERYLKDQQL; EITPIGLAP; PPIPVGEIY; GEIYKRWII; KRWIILGLNK;
IILGLNKIVR; LGLNKIVRMY; YNLTMKCR; RGPGRAFVTI; GRAFVTIGK;
TPYDINQML; CTPYDINQM; RPQVPLRPMTY; QVPLRPMTYK; VPLRPMTY;
AVDLSHFLK; DLSHFLKEK; FLKEKGGL; ILKEPVHGV; ILKEPVHGVY;
HPDIVIYQY; VIYQYMDDL.
ERYLKDQQL; EITPIGLAP; PPIPVGEIY; GEIYKRWII; KRWIILGLNK;
IILGLNKIVR; LGLNKIVRMY; YNLTMKCR; RGPGRAFVTI; GRAFVTIGK;
TPYDINQML; CTPYDINQM; RPQVPLRPMTY; QVPLRPMTYK; VPLRPMTY;
AVDLSHFLK; DLSHFLKEK; FLKEKGGL; ILKEPVHGV; ILKEPVHGVY;
HPDIVIYQY; VIYQYMDDL.
22. The kit according to any one of claims 1 to 21, wherein the priming composition and/or the boosting composition is in particulate form suitable for delivery by means of a gene gun.
23. Use of at least one dose of (i) and at least one dose of (ii) of the kit according to any one of claims 1 to 22, in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the at least one target antigen, wherein component (ii) is to be administered following component (i).
24. Use of at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or cancer, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant DNA plasmid.
25. The use according to claim 24, wherein the recombinant replication impaired poxvirus is a recombinant MVA vector.
26. Use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or cancer, and at least one dose of a recombinant MVA vector encoding the same epitope or antigen in the manufacture of a medicament for generation of a protective CD8+ T cell immune response against the pathogen or cancer, wherein the recombinant non-replicating or replication-impaired poxvirus is to be administered following the recombinant protein or particle.
27. The use according to any one of claims 24 to 26, for generation of a protective CD8+ T cell immune response against malaria.
28. The use according to any one of claims 24 to 26, for generation of a protective CD8+ T cell immune response against HIV.
29. The use according to claim 23, wherein (ii) is in a form for delivery intravenously, intraepidermally or intradermally.
30. A medicament for boosting a primed CD8+ T cell response against at least one target antigen, comprising a source of one or more CD8+
T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
31. The medicament according to claim 30, wherein the vector is a vaccinia virus vector.
32. The medicament according to claim 30 or claim 31, for boosting a naturally primed CD8+ T cell response against malaria.
33. Use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
34. The use of an MVA vector as a source of one or more CD8+ T
cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
cell epitopes of a target antigen in the manufacture of a medicament for use in generation of a boost in a CD8+ T cell immune response against the target antigen.
35. The kit according to claim 9, wherein the recombinant protein particle is a Ty-virus-like particle.
36. The kit according to claim 14, wherein the recombinant avipox vector is canarypox or fowlpox or a strain derived therefrom.
37. The kit according to claim 36, wherein the recombinant avipox vector is ALVAC.
38. The kit according to claim 16, wherein the malaria pathogen is Plasmodium falciparum.
39. The use according to claim 27, wherein the malaria is Plasmodium falciparum malaria.
40. The use according to claim 24 or claim 25, wherein the recombinant replication impaired poxvirus is in a form for delivery intravenously, intraepidermally or intradermally.
41. The use according to claim 26, wherein the recombinant MVA
vector is in a form for delivery intravenously, intraepidermally or intradermally.
vector is in a form for delivery intravenously, intraepidermally or intradermally.
42. The medicament according to claim 31, wherein the vaccinia virus vector is MVA.
43. Use of at least one dose of (i) followed by at least one dose of (ii) of the kit according to any one of claims 1 to 22, for generation of a protective CD8+ T cell immune response against the at least one target antigen.
44. Use of at least one dose of a recombinant DNA plasmid encoding at least one CD8+ T cell epitope or antigen of a pathogen or cancer, followed by at least one dose of a recombinant non-replicating or replication-impaired poxvirus encoding the same epitope or antigen, for generation of a protective CD8+ T cell immune response against the pathogen or cancer.
45. The use according to claim 44, wherein the recombinant replication impaired poxvirus is a recombinant MVA vector.
46. The use of at least one dose of a recombinant protein or particle comprising at least one epitope or antigen of a pathogen or cancer, followed by at least one dose of a recombinant MVA vector encoding the same epitope or antigen for generation of a protective CD8+ T cell immune response against the pathogen or cancer.
47. The use according to any one of claims 44 to 46, for generation of a protective CD8+ T cell immune response against malaria.
48. The use according to claim 47, wherein the malaria is Plasmodium falciparum malaria.
49. The use according to any one of claims 44 to 46, for generation of a protective CD8+ T cell immune response against HIV.
50. The use according to claim 43, wherein (ii) is in a form for delivery intravenously, intraepidermally or intradermally.
51. The use according to claim 44 or claim 45, wherein the recombinant replication impaired poxvirus is in a form for delivery intravenously, intraepidermally or intradermally.
52. The use according to claim 46, wherein the recombinant MVA
vector is in a form for delivery intravenously, intraepidermally or intradermally.
vector is in a form for delivery intravenously, intraepidermally or intradermally.
53. The use of a recombinant non-replicating or replication-impaired poxvirus vector as a source of one or more CD8+ T cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
54. The use of an MVA vector as a source of one or more CD8+ T
cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
cell epitopes of a target antigen for generation of a boost in a CD8+ T cell immune response against the target antigen.
55. A kit comprising:
(i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is DNA, a Ty-virus-like particle comprising two or more CD8+ T cell epitopes present in a recombinant string of CD8+ T cell epitopes, or a non-replicating recombinant adenovirus vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is the vaccinia virus strain Modified Virus Ankara (MVA), or a strain derived therefrom;
for use as a therapeutic or prophylactic vaccine.
(i) a priming composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is DNA, a Ty-virus-like particle comprising two or more CD8+ T cell epitopes present in a recombinant string of CD8+ T cell epitopes, or a non-replicating recombinant adenovirus vector, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a source of one or more CD8+ T cell epitopes of the target antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, wherein the source of CD8+ T cell epitopes is the vaccinia virus strain Modified Virus Ankara (MVA), or a strain derived therefrom;
for use as a therapeutic or prophylactic vaccine.
56. The kit according to claim 55, wherein the source of epitopes in the priming composition is a recombinant DNA plasmid.
57. The kit according to claim 56, further comprising GM-CSF as an adjuvant for the priming composition.
58. The kit according to any one of claims 55 to 57, wherein the source of CD8+ T cell epitopes in the priming composition encodes the target antigen.
59. The kit according to any one of claims 55 to 57, wherein the source of epitopes in the priming composition encodes a single CD8+ T cell epitope or a recombinant string of two or more CD8+ T cell epitopes.
60. The kit according to any one of claims 55 to 59, for generating a protective immune response against a malaria pathogen.
61. A kit according to claim 60, wherein the CD8+ T cell epitopes in or encoded by the priming composition include one or more malaria epitopes selected from the amino acid sequences of SEQ ID Nos 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 32 and 34.
62. The kit according to claim 61, wherein the CD8+ T cell epitopes in the priming composition include all of said malaria epitopes.
63. The kit according to any one of claims 55 to 59, for generating an immune response against HIV.
64. The kit according to claim 63, wherein the CD8+ T cell epitopes in or encoded by the priming composition include one or more HIV epitopes selected from the amino acid sequences of SEQ ID NO 42 to 64.
65. The kit according to claim 64, wherein the CD8+ T cell epitopes in or encoded by the priming composition include all of said HIV epitopes.
66. The kit according to any one of claims 55 to 65, wherein the priming composition and/or the boosting composition is in particulate form suitable for delivery by means of a gene gun.
67. The kit according to any one of claims 55 to 66, wherein the boosting composition is in a form suitable for delivery intravenously, intraepidermally or intradermally.
68. A kit comprising:
(i) a priming composition comprising a DNA plasmid encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a Modified Virus Ankara (MVA) vector encoding a source of CD8+ T cell epitopes from the target hepatitis B or hepatitis C antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
(i) a priming composition comprising a DNA plasmid encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising a Modified Virus Ankara (MVA) vector encoding a source of CD8+ T cell epitopes from the target hepatitis B or hepatitis C antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
69. The kit according to claim 68, further comprising GM-CSF as an adjuvant for the priming composition.
70. The kit according to claim 68 or claim 69, wherein the priming composition and/or the boosting composition is in particulate form suitable for delivery by means of a gene gun.
71. The kit according to any one of claims 68 to 70, wherein the boosting composition is in a form suitable for delivery intravenously or intradermally.
72. Use of a priming composition and a boosting composition as defined in any one of claims 68 to 71 for the production of a vaccine against hepatitis B or hepatitis C.
73. The use of an MVA vector encoding a source of CD8+ T cell epitopes from a target hepatitis B or hepatitis C antigen in the manufacture of a medicament for boosting a differently primed CD8+ T cell immune response against the hepatitis B or hepatitis C antigen.
74. A kit comprising:
(i) a priming composition comprising as a source of CD8+ T cell epitopes, DNA encoding a recombinant string of CD8+ T cell epitopes from a target melanoma antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising as a source of CD8+ T cell epitopes a Modified Virus Ankara (MVA) vector encoding a recombinant string of CD8+ T cell epitopes from the target melanoma antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
(i) a priming composition comprising as a source of CD8+ T cell epitopes, DNA encoding a recombinant string of CD8+ T cell epitopes from a target melanoma antigen, together with a pharmaceutically acceptable carrier; and (ii) a boosting composition comprising as a source of CD8+ T cell epitopes a Modified Virus Ankara (MVA) vector encoding a recombinant string of CD8+ T cell epitopes from the target melanoma antigen, including at least one CD8+ T cell epitope which is the same as a CD8+ T cell epitope of the priming composition, together with a pharmaceutically acceptable carrier, for use as a therapeutic or prophylactic vaccine.
75. The kit according to claim 74, further comprising GM-CSF as an adjuvant for the priming composition.
76. The kit according to claim 74 or claim 75, wherein the priming composition and/or the boosting composition is in particulate form suitable for delivery by means of a gene gun.
77. The kit according to any one of claims 74 to 76, wherein the boosting composition is in a form suitable for delivery intravenously or intradermally.
78. Use of a priming and a boosting composition as defined in any one of claims 74 to 77 for the production of a vaccine against melanoma.
79. The use of an MVA vector comprising as a source of CD8+ T
cell epitopes a recombinant string of two or more CD8+ T cell epitopes from a target melanoma antigen in the manufacture of a medicament for boosting a differently primed CD8+ T cell immune response against the target melanoma antigen.
cell epitopes a recombinant string of two or more CD8+ T cell epitopes from a target melanoma antigen in the manufacture of a medicament for boosting a differently primed CD8+ T cell immune response against the target melanoma antigen.
80. A medicament for boosting a naturally primed CD8+ T cell response against at least one target antigen in an individual naturally exposed to the target antigen, comprising a source of one or more CD8+ T cell epitopes of the target antigen, wherein the source of CD8+ T cell epitopes is a non-replicating or a replication-impaired recombinant poxvirus vector, and a pharmaceutically acceptable carrier.
81. The medicament according to claim 80, wherein the vector is an avipox virus vector.
82. The medicament according to claim 81, wherein the vector is a fowlpox virus vector.
83. The medicament according to claim 80, wherein the vector is a vaccinia virus vector such as MVA.
84. The medicament according to any one of claims 80 to 83, wherein the target antigen is a malaria antigen.
85. The medicament according to any one of claims 80 to 84, wherein the individual is a primate.
86. The use of a recombinant non-replicating or replication-impaired pox virus vector encoding one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament according to any one of claims 80 to 85.
87. The use of an MVA encoding one or more CD8+ T cell epitopes of a target antigen in the manufacture of a medicament for boosting a naturally primed CD8+ T cell immune response against the target antigen.
88. The use according to claim 86 or claim 87, wherein the CD8+ T
cell immune response is a primate CD8+ T cell immune response.
cell immune response is a primate CD8+ T cell immune response.
89. The medicament according to claim 83, wherein the vaccinia virus vector is MVA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711957.2A GB9711957D0 (en) | 1997-06-09 | 1997-06-09 | Methods and reagents for vaccination |
GB9711957.2 | 1997-06-09 | ||
PCT/GB1998/001681 WO1998056919A2 (en) | 1997-06-09 | 1998-06-09 | Methods and reagents for vaccination which generate a cd8 t cell immune response |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2293692A1 CA2293692A1 (en) | 1998-12-17 |
CA2293692C true CA2293692C (en) | 2010-04-27 |
Family
ID=10813841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2293692A Expired - Lifetime CA2293692C (en) | 1997-06-09 | 1998-06-09 | Methods and reagents for vaccination which generate a cd8 t cell immune response |
Country Status (12)
Country | Link |
---|---|
US (10) | US6663871B1 (en) |
EP (5) | EP1616954B1 (en) |
JP (2) | JP4282095B2 (en) |
CN (1) | CN100379865C (en) |
AT (4) | ATE391784T1 (en) |
AU (1) | AU737780B2 (en) |
CA (1) | CA2293692C (en) |
DE (4) | DE69839405T2 (en) |
DK (2) | DK0979284T4 (en) |
ES (1) | ES2189185T5 (en) |
GB (1) | GB9711957D0 (en) |
WO (1) | WO1998056919A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB0023203D0 (en) * | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
EP1502602A3 (en) * | 1998-10-05 | 2006-05-17 | Pharmexa A/S | Methods for therapeutic vaccination |
HUP0103976A3 (en) | 1998-10-05 | 2008-04-28 | Pharmexa As | Novel methods for therapeutic vaccination |
US7148035B1 (en) | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
US6783762B1 (en) * | 1999-01-28 | 2004-08-31 | Stichting Biomedical Primate Research Centre | Product and method for obtaining specific immunization with one or more antigens |
CA2372709C (en) | 1999-05-28 | 2011-10-25 | Stefan Wintersperger | Vector for integration of heterologous sequences into poxviral genomes |
WO2001002607A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
EP1227837B1 (en) | 1999-10-22 | 2008-05-21 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
ATE457996T1 (en) * | 1999-12-23 | 2010-03-15 | Medical Res Council | IMPROVEMENTS IN OR RELATING TO IMMUNE RESPONSES TO HIV |
AU780064B2 (en) * | 1999-12-28 | 2005-02-24 | Epimmune, Inc. | Optimized minigenes and peptides encoded thereby |
EP2388015A1 (en) | 2000-03-02 | 2011-11-23 | Emory University | DNA expression vectors and methods of use |
US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
CA2407303A1 (en) * | 2000-04-28 | 2001-11-08 | Genoveffa Franchini | Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
US7241742B2 (en) | 2000-10-31 | 2007-07-10 | Mgi Pharma Biologics, Inc. | CYP1B1 nucleic acids and methods of use |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
SI1335987T2 (en) | 2000-11-23 | 2016-10-28 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
ATE445411T1 (en) | 2001-03-08 | 2009-10-15 | Us Gov Health & Human Serv | MVA-EXPRESSING MODIFIED HIV ENVELOPE, GAG AND POL GENES |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
JP2005517639A (en) * | 2001-11-30 | 2005-06-16 | イシス イノベーション リミテッド | vaccine |
WO2003066833A2 (en) * | 2002-02-08 | 2003-08-14 | New York University | Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies |
AU2003213839A1 (en) * | 2002-03-13 | 2003-09-22 | Merck & Co., Inc. | Method of inducing an enhanced immune response against hiv |
PT1420822E (en) † | 2002-04-19 | 2007-09-04 | Bavarian Nordic As | Modified vaccinia virus ankara for the vaccination of neonates |
JP4654026B2 (en) * | 2002-05-20 | 2011-03-16 | 独立行政法人科学技術振興機構 | BCG vaccine and its use |
DE60320520T3 (en) | 2002-09-05 | 2019-05-09 | Bavarian Nordic A/S | METHOD FOR THE AMPLIFICATION OF A POXVIRUS IN SERUM-FREE CONDITIONS |
EP1583500A4 (en) * | 2002-11-13 | 2008-02-13 | Us Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
WO2004056391A1 (en) * | 2002-12-20 | 2004-07-08 | The University Of New South Wales | A method of immunisation and agents useful for same |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
US20050287068A1 (en) * | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
GB2421025A (en) * | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
EP1890724A2 (en) * | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
WO2007004231A1 (en) * | 2005-07-04 | 2007-01-11 | Pradeep Seth | Hiv-1 vaccinogens with immunomodulators |
FR2893254B1 (en) | 2005-11-14 | 2007-12-21 | Biomerieux Sa | COMPOSITION COMPRISING A BIORESORBABLE COLLOIDAL SYNTHETIC VECTOR AND A VIRAL VECTOR AND ITS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC USE. |
TWI477602B (en) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
WO2007102326A1 (en) * | 2006-03-07 | 2007-09-13 | Yokohama City University | Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
EP2462930B1 (en) * | 2006-11-09 | 2017-05-31 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
WO2009127666A2 (en) * | 2008-04-15 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Method and compositions |
US8691502B2 (en) * | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
US20110274723A1 (en) | 2009-10-23 | 2011-11-10 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
CA2793772A1 (en) * | 2010-03-26 | 2011-09-29 | Emergent Product Development Gaithersburg Inc. | Ectodomains of influenza matrix 2 protein, expression system, and uses thereof |
GB201007207D0 (en) | 2010-04-29 | 2010-06-16 | Univ Cork | Method |
WO2012023033A2 (en) | 2010-08-18 | 2012-02-23 | Purdue Pharma L.P. | Improved peptide immunogens |
GB201018480D0 (en) | 2010-11-02 | 2010-12-15 | Oxford Biomedica Ltd | Factors |
US9044420B2 (en) * | 2011-04-08 | 2015-06-02 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
KR102135818B1 (en) * | 2012-10-28 | 2020-07-22 | 버베리안 노딕 에이/에스 | Pr13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES |
GB201221133D0 (en) | 2012-11-23 | 2013-01-09 | Epiontis Gmbh | Epigenetic method for the identification of subpopulations of CD8 and T lympocytes, in particular CD8 alpha and beta T lymphocytes |
WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
US10576143B2 (en) * | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
JP6664338B2 (en) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Immunogenic combination |
US20190381158A1 (en) * | 2016-02-04 | 2019-12-19 | Duke University | Cell-based vaccine compositions and methods of use |
US11065320B2 (en) * | 2016-04-12 | 2021-07-20 | Oxford University Innovation Limited | Prime target |
CA3056542A1 (en) | 2017-03-15 | 2018-09-20 | Oxford Biomedica (Uk) Limited | Method |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US175365A (en) * | 1876-03-28 | Improvement in sheet-metal-straightening machines | ||
US171272A (en) * | 1875-12-21 | Improvement in school-desks | ||
US138454A (en) * | 1873-04-29 | Improvement in card-racks | ||
US131594A (en) * | 1872-09-24 | Improvement in pulley-blocks | ||
US197349A (en) * | 1877-11-20 | Improvement in ore-mills | ||
ZA754725B (en) * | 1974-08-01 | 1976-06-30 | H Stickl | Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
GB8405530D0 (en) * | 1984-03-02 | 1984-04-04 | Lysons R J | Vaccine for swine dysentery |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
CH682669A5 (en) | 1989-03-08 | 1993-10-29 | Health Research Inc | recombinant virus engineered to express a gene product in a host, corresponding methods and vaccine. |
US5462734A (en) * | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
BE1004877A3 (en) | 1991-05-27 | 1993-02-16 | Solvay | RECOMBINANT AVIPOX VIRUS, CULTURE OF CELLS INFECTED WITH THIS VIRUS AND POULTRY VACCINES DERIVED FROM THIS VIRUS. |
CA2110489A1 (en) | 1991-06-14 | 1992-12-23 | Enzo Paoletti | Immunodeficiency virus recombinant poxvirus vaccine |
AU670538B2 (en) | 1991-07-26 | 1996-07-25 | Virogenetics Corporation | Infectious bursal disease virus recombinant poxvirus vaccine |
ATE181108T1 (en) * | 1991-08-26 | 1999-06-15 | Immuno Ag | DIRECT MOLECULAR CLONING OF A MODIFIED GENOME OF A CHORDOPOX VIRUS |
US5972351A (en) * | 1992-04-03 | 1999-10-26 | Isis Innovation Limited | Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens |
ES2196018T3 (en) | 1993-08-11 | 2003-12-16 | Wyeth Corp | RECOMBINANT ADENOVIRUS VACCINES. |
DE4341770A1 (en) * | 1993-12-08 | 1995-06-14 | Basf Ag | Process for the production of lactic acid esters |
WO1996003144A1 (en) * | 1994-07-27 | 1996-02-08 | The Council Of The Queensland Institute Of Medical Research | Polyepitope vaccines |
FR2724945B1 (en) * | 1994-09-27 | 1996-12-27 | Centre Nat Rech Scient | VIRAL VECTORS AND USE IN GENE THERAPY |
US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
WO1996039178A1 (en) * | 1995-06-05 | 1996-12-12 | The Wistar Institute Of Anatomy And Biology | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US20010036928A1 (en) * | 1996-04-22 | 2001-11-01 | Chamberlain Ronald S. | Heterologous boosting immunizations |
CA2252406A1 (en) * | 1996-04-22 | 1997-10-30 | Nicholas P. Restifo | Heterologous boosting immunizations |
CA2261990A1 (en) * | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
US6355252B1 (en) * | 1997-02-21 | 2002-03-12 | Isis Innovation Ltd. | Soluble vaccinia virus protein that binds chemokines |
GB0023203D0 (en) * | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
US20010036929A1 (en) * | 1998-09-25 | 2001-11-01 | Arch Development Corporation. | Xrcc3 is required for assembly of Rad51-complexes in vivo |
WO2001002607A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
DE60016765T2 (en) | 1999-08-25 | 2005-11-24 | Merck & Co., Inc. | SYNTHETIC PAPILLOMA GENES WHICH ARE OPTIMIZED FOR EXPRESSION IN HUMAN CELLS |
GB9922361D0 (en) | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
ES2276788T3 (en) | 2000-05-10 | 2007-07-01 | Sanofi Pasteur Limited | IMMUNOGEN POLIPEPTIDES CODED BY MAGE MINIGENS AND THEIR USES. |
CU23235A1 (en) | 2001-02-28 | 2007-09-26 | Ct Ingenieria Genetica Biotech | RECOMBINANT POXVIRUS FOR CHEMICAL PROTEINS OF THE HUMAN IMMUNODEFICIENCY VIRUS AND ITS APPLICATION IN THERAPEUTICS AND AIDS PREVENTION |
JP2002271316A (en) * | 2001-03-13 | 2002-09-20 | Sanyo Electric Co Ltd | Reproducing equipment |
CN1164331C (en) | 2001-05-23 | 2004-09-01 | 中国人民解放军第二军医大学 | Human hepatitis B nucleic acid vaccine |
JP2005517639A (en) * | 2001-11-30 | 2005-06-16 | イシス イノベーション リミテッド | vaccine |
US20040171272A1 (en) * | 2003-02-28 | 2004-09-02 | Applied Materials, Inc. | Method of etching metallic materials to form a tapered profile |
US6942373B2 (en) * | 2003-03-14 | 2005-09-13 | Fiberstars Incorporated | Fiberoptic lighting system with shaped collector for efficiency |
JP2007503834A (en) | 2003-09-05 | 2007-03-01 | サノフィ パストゥール リミテッド | Multi-antigen vector for melanoma |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
EP1682666B1 (en) | 2003-09-24 | 2008-12-31 | Oxxon Therapeutics Limited | HIV Pharmaceutical vaccines |
GB2421025A (en) | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
EP1890724A2 (en) | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
-
1997
- 1997-06-09 GB GBGB9711957.2A patent/GB9711957D0/en active Pending
-
1998
- 1998-06-09 JP JP50189099A patent/JP4282095B2/en not_active Expired - Lifetime
- 1998-06-09 DE DE69839405T patent/DE69839405T2/en not_active Expired - Lifetime
- 1998-06-09 AT AT04029353T patent/ATE391784T1/en active
- 1998-06-09 WO PCT/GB1998/001681 patent/WO1998056919A2/en active IP Right Grant
- 1998-06-09 EP EP04029353A patent/EP1616954B1/en not_active Expired - Lifetime
- 1998-06-09 DE DE69810459T patent/DE69810459T3/en not_active Expired - Lifetime
- 1998-06-09 CN CNB98808063XA patent/CN100379865C/en not_active Expired - Lifetime
- 1998-06-09 CA CA2293692A patent/CA2293692C/en not_active Expired - Lifetime
- 1998-06-09 EP EP98928434A patent/EP0979284B2/en not_active Expired - Lifetime
- 1998-06-09 DK DK98928434.4T patent/DK0979284T4/en active
- 1998-06-09 AU AU80266/98A patent/AU737780B2/en not_active Expired
- 1998-06-09 EP EP08006920A patent/EP2058399A1/en not_active Withdrawn
- 1998-06-09 ES ES98928434T patent/ES2189185T5/en not_active Expired - Lifetime
- 1998-06-09 AT AT04029354T patent/ATE391783T1/en active
- 1998-06-09 EP EP02079736A patent/EP1335023B1/en not_active Expired - Lifetime
- 1998-06-09 AT AT02079736T patent/ATE393225T1/en active
- 1998-06-09 EP EP04029354A patent/EP1589108B1/en not_active Expired - Lifetime
- 1998-06-09 DE DE69839357T patent/DE69839357T2/en not_active Expired - Lifetime
- 1998-06-09 AT AT98928434T patent/ATE230437T1/en active
- 1998-06-09 DE DE69839359T patent/DE69839359T2/en not_active Expired - Lifetime
- 1998-06-09 DK DK02079736T patent/DK1335023T3/en active
-
1999
- 1999-12-09 US US09/454,204 patent/US6663871B1/en not_active Expired - Lifetime
-
2003
- 2003-09-02 US US10/653,624 patent/US20040131594A1/en not_active Abandoned
- 2003-10-16 US US10/686,943 patent/US20040213799A1/en not_active Abandoned
-
2004
- 2004-04-28 US US10/833,745 patent/US20040191272A1/en not_active Abandoned
- 2004-04-28 US US10/833,439 patent/US7514087B2/en not_active Expired - Fee Related
- 2004-04-28 US US10/833,744 patent/US7407661B2/en not_active Expired - Fee Related
-
2006
- 2006-08-14 JP JP2006221144A patent/JP2007023044A/en active Pending
-
2008
- 2008-08-04 US US12/221,498 patent/US20090191237A1/en not_active Abandoned
-
2009
- 2009-05-15 US US12/454,385 patent/US20090324632A1/en not_active Abandoned
- 2009-06-19 US US12/456,699 patent/US20100119551A1/en not_active Abandoned
-
2010
- 2010-11-05 US US12/940,627 patent/US20110159034A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2293692C (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
AU2001286109B2 (en) | Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen | |
US20030138454A1 (en) | Vaccination method | |
AU2001286109A1 (en) | Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen | |
Gilbert et al. | Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations | |
US20060127413A1 (en) | Recombinant mva strains as potential vaccines against p. falciparum malaria | |
AU2004203141B2 (en) | Methods and reagents for vaccination which generate CD8 T cell immune response | |
AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20180611 |